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Figure 1.1 Diagram comparing the tissues in a healthy (a) and a rheumatoid arthritic (b) knee joint.
The healthy joint has a thin smooth synovial lining whereas the synovium in the arthritic joint is
inflamed and thickened due to the infiltration of inflammatory cells. Bone and cartilage loss are also
evident in the arthritic joint. (Adaptedfrom the National Institutes ofHealth, 2005) 9
Figure 1.2 Descartes model ofpain sensation showing the hypothesised link between the peripheral
tissues and the brain in sensing painful stimuli such as noxious heat. This cartoon, adaptedfrom the
original published by Descartes in his 1606 work entitled L'Homme, is considered to be one ofthe
earliest systematic representations of the organization whereby a noxious stimulus activates systems
that travel through the nerves to the spinal cord and then to the brain 12
Figure 1.3 (a) Basic structure and components ofa primary afferent neurone. The peripheral
terminal innervates the target tissue, the axon conducts action potentials and the central terminal
transfers the signal to central processes. The cell body controls the identity of the nerve and produces
the proteins the receptors and channels that can be transported to the peripheral or central terminal.
Schematics showing (b) a selection of ion channels involved in the depolarisation of the peripheral
terminal and (c) neurotransmitters released from the central terminal. Diagram modified from (Woolf
and Ma 2007) 15
Figure 1.4 Sensitisation ofpain responses from external stimuli. The normal response shown by the
right hand curve (green) is shifted to the left following inflammation (red). A stimulus that is normally
not noxious will now become so, a term described as allodynia, and a normally noxious stimulus will
result in a higher intensity ofpain sensation a term known as hyperalgesia, (illustration redrawn from
(Gottschalk and Smith 2001) 21
Figure 2.1 Photograph ofthe rat incapacitance tester used to assess the weight distribution of rats.
An identical device but with a smaller Perspex holding box and smallerforce transducers was used
for measurements in murine studies 49
Figure 2.2 Photograph of the PAM device used to assess the limb withdrawal threshold of rats when
a localised pressure was manually applied across the knee joint. The same base unit was used but
with a smaller (in diameter) force transducer connected when assessing the limb withdrawal
threshold ofmice 50
Figure 2.3 Photograph of the digital micrometer used to measure the knee joint diameter ofboth rats
and mice 51
Figure 2.4 Photograph ofan anaesthetised rat in a typical experimental setup for recording the
neuronal activity of the afferents of the MAN innervating the rat knee joint. The left hind-paw was
fixed to a solid brass platform using plaster ofParis to enable a stable recording to be taken 53
Figure 2.5 A schematic diagram showing how the raw neuronal signal from the MAN was collected,
processed, digitised and then stored on a PC 54
Figure 2.6 Screenshotfrom Spike2 ofa raw filtered neuronal trace from the MAN and the responses
during a typical set ofmechanical stimulations using the lg, 7g and 21g von Frey filaments.
Spontaneous activity was measuredfor a 10s period before each individual hair was appliedfor 10s.
The identification of individual units is shown in Figure 2.7. 55
Figure 2.7 Screenshots from Spike V.5.01 software analysis on one mechanical application ofthe
VFF for a period ofapproximately 10 seconds, a) The original neuronal trace (lower trace, in green)
had a trigger level set to differentiate the action potentials from the background noise (top trace, in
black), b) In this example two waveform templates were createdfrom the two different units firing in
xi
response to the VFF application. Template 01 shows the waveform ofa unit which fires 1551 times
during this experiment (blue). The original neuronal trace was then re-scanned and the units
corresponding to the different waveform templates were highlighted in different colours and
separated into two individual traces c) 58
Figure 2.8 Summary diagram illustrating an example ofhow an AUC value was calculated using the
Microsoft Excel macro. The daily assessments of the behavioural readoutfor an individual animal (0)
were plotted during the dosing period (day 11-15). The pre-treatment value prior to dosing on day 11
was used as a baseline value and the macro calculated the areas above (red lines) as positive values,
and the areas underneath (blue lines) as negative values. The individual areas were then summed to
give the total AUC valuefor that animal in response to that drug 64
Figure 3.1 The proportion of electrophysiology experiments yielding successful recordings. Of 164
experiments started, 70% (115/164) were successful in achieving a positive neural recording from the
MAN. 71
Figure 3.2 (a) The mean body weights measured on the day of the electrophysiological recording of
naive rats (n=76) and rats injected with FCA (n=88) 14-28 days prior to the recording. There was no
significant difference in the mean body weights ofnaive or FCA-injected animals on the day of
recording (P>0.05, unpaired t-test) and (b) FCA animals maintained an appropriate, gradual,
increase in weightfollowing injection ofFCA indicating the animals are not experiencing any
hindrance to their normal behaviours and are not in severe pain 72
Figure 3.3 (a) Knee joint diameters ofnaive (n=76) and FCA-injected (n=88) animals (red bar
indicates the mean value) and (b) box and whiskers plots showing the range and median knee joint
diameter ratios on the day of the electrophysiology recordings. Measurements showed that the knee
joint diameter of the FCA-injected limb (left) was significantly greater than the un-injected limb (***
P<0.001, paired t-test), and therefore the FCA-injected animals had a significantly higher KD ratio
than naive animals (*** P<0.001, Mann-Whitney t-test) 72
Figure 3.4 Number offibres inner\>ating the naive (n=34, number offibres—93) and FCA-injected
(n=50, number offibres=130) knee joint that were capsaicin -positive or -negative. There was no
significant difference in the proportion offibres expressing the TRPV1 receptor as both naive and
FCA-injected animals 75% responded to capsaicin (P>0.05, Fisher's exact test) 73
Figure 3.5 Proportions of (a) naive (n=52, number offibres =118) and (b) FCA-injected knee (n=63,
number offibres=163) joint afferent nerve fibres showing spontaneous neural activity in the ten
minutes prior to any mechanical or chemical stimulation of the joint. There was a significantly
greater proportions ofspontaneously active fibres in the MAN ofFCA-injected joints than naive joints
(P<0.05, Fishers exact test) 74
Figure 3.6 The mean spontaneous discharge frequency offibres innervating the naive (n=76, number
offibres =117) and FCA-injected knee (n=88, number offibres=148) in 600s before any other tests
were performed. There was significantly more spontaneous activity observed in FCA-injected knee
joint afferents than there was in naive joint ajferents (P>0.05, unpaired t-test) 75
Figure 3.7 Capsaicin evoked neural discharge offibres innervating the naive (open rectangles) and
FCA-injected (filled rectangles) knee joints. There was no significant difference between the naive
and FCA-injected animals when examining (a) the duration of response, (b) the change in discharge
frequency and (c) the change in absolute number ofaction potentials evoked by the injection lpg
capsaicin (P>0.05, unpaired t-test). (d) A screenshot ofa typical response of the MANfollowing
injection of lpg capsaicin into an FCA-injected animal at day 18 post-FCA. The arrow indicates the
time at which the drug was injected. 76
Figure 3.8 The change in frequency ofneural discharge from baseline in the fibres innervating the
naive and FCA-injected knee joint evoked by (a) 1, (b) 7 and (c) 21g von Frey filaments. There is a
significant increase in the response to the 7 and 21g von Frey filament in the FCA-injected joints
xii
compared to naive (P<0.05, P<0.01, unpaired t-test). No change in frequency offiring was observed
between naive and FCA-injected animals evoked by the lg filament. Typical responses of the nerve to
stimulation by the von Frey filaments taken are shown in d-f recordings taken from an FCA-injected
animal (18 days post-FCA) 77
Figure 3.9 Quantitative analysis showing the percentage ofFB cells in ipsilateral L3-L5 DRG which
expressed the TRPV1 receptor, measured at various time points following injection of2% FB (10pi,
control) or FB + FCA (150pl, lmg.ml'1, FCA) into the left knee joint. Control animals are defined as
those receiving only FB. There was no significant difference in the percentage ofFB cells expressing
TRPV1 in control or FCA-injected animals at any time point (P>0.05, two-way ANOVA) 78
Figure 4.1 Figure illustrating the protocol for the morphine behavioural study. Intra-articular
injection ofFCA or morphine (1, 3 or lOmg.ml'1) was administered as indicated by the red and blue
arrows respectively. The days highlighted in red are the days on which behavioural measurements
were made 87
Figure 4.2 A schematic diagram illustrating the protocol for the endomorphin behavioural study.
Intra-articular injection ofFCA (red arrow) or endomorphin (blue arrow, 1, 3 or lOmg.ml'1) was
administered on the days indicated by the arrows. The days highlighted in red are the days on which
behavioural measurements were made 88
Figure 4.3 Schematic of the test protocol used in the capsaicin-evoked neural discharge experiments.
The times that the close arterial injections ofcapsaicin (red arrows) and EMI or morphine (blue
arrow) were given are shown 90
Figure 4.4 Schematic showing the test protocol showing the times ofmechanical stimulation (red
arrows) and the time when either EMI or morphine were delivered (blue arrow). Pre-treatment with
naloxone (500pg) in certain experiments occurred 3 minutes before the test drug was delivered. 91
Figure 4.5 Figure illustrating (a) the pooled mean body weights for all rats (n=32, days 0-11) and (b)
the same set ofanimals shown in their designated dosing groups for morphine (n=8, days 14-21)
following injection ofFCA on day 0. Animals gained weight daily over the duration of the study
period. Intra-articular injection ofmorphine (0.1, 0.3 and lmg) on day 14 had no effect on the weight
gain of the animals and consequently there was no significant difference in the group mean body
weights on days 14 to 21 (P>0.05, two-way ANOVA, n=32) 94
Figure 4.6 Figure illustrating (a) pooled body weights ofall animals (n=32, days 0-11) and (b) the
same animals in their designated dosing groups for EMI (n=8, days 14-23) following injection of
FCA on day 0. Despite a statistically insignificant decrease in weightfrom day 0 to day 1 (P>0.05,
paired t-test, n=32), animals gained weight daily over the duration of the study period. Intra-articular
injection ofEMI on days 14, 16 and 18 (indicated by the grey arrows) had no effect on the weight
gain of the animals and consequently there was no significant difference in the group mean body
weights on days 14 to 23 (P>0.05, two-way ANOVA, n=32). The consistent weight gain provides
evidence that the animals were not in severe pain or discomfort throughout the studies and were able
to continue normal behaviours such as feeding and drinking. The shaded area indicates the drug
treatment period 95
Figure 4.7 Graphs showing the effect of intra-articular FCA and morphine (1 -lOmg.ml ) on the
distribution of the animals' body weight between their hind limbs, (a) FCA resulted in a significant
decrease in WD ratio on days 4, 7 and 11 post-FCA when compared to day 0 (*** represents
P<0.001, one-way ANOVA, n=32). (b) The WD ratio on day 14, immediately before morphine
treatment began, was significantly lower than the pre-FCA value. The mean WD ratios of the
morphine 0.1-lmg and vehicle- treated animals on (c) day 14 following the intra-articular
administration of the drug and (e) days 14-21 post-FCA. The groups ofanimals dosed with 0.3 and
lmg morphine had statistically higher WD ratio values than the vehicle treated group on day 18, 4
days after treatment f* P<0.05, two-way ANOVA, n=8) (d) The WD ratio AUC values during the 3
hours post-morpliine on day 14 calculatedfrom the baseline pre-morphine values were analysed to
compare the drug-treated groups to the vehicle-treated group. *** represents statistical significance
(P<0.001) using a one-way ANOVA followed by a Dunn's post-hoc test 96
Figure 4.8 Graphs showing that (a) FCA resulted in a significant decrease in WD ratio on days 3, 7,
9 and 11 post-FCA as compared to day 0 values (*** represents P<0.001, one-way ANOVA, n=32).
(b) The WD ratio on day 11 was significantly lower than the day 0 value (*** P<0.001, 0.31 ± 0.02
vs. 1.00 ±0.02, Wilcoxon t-test, n=32). (c) The mean WD ratios of the EMI and vehicle- treated
animals on day 11-23 post-FCA. The 30pg group mean WD ratio was significantly higher than the
vehicle group on days 21 and 23 post-FCA. (d) The WD ratio AUC values for the dosing period (day
14-18 post-FCA) were calculated from the basal day 11 values and were analysed to compare the
drug-treated groups to the vehicle-treated group. EMI at 10 and 30pg were significantly larger than
the vehicle treated group ofanimals (* P<0.05, ** P<0.01, one-way ANOVA, n=8) 99
Figure 4.9 Capsaicin evoked neural discharge offibres innervating (a) the naive (n=5, fibres=18)
and (b) the FCA-injected (n=6, fibres=12) knee joint before and after vehicle (saline) administration.
There was no significant difference in the neural discharge frequency at any time pointfollowing
repeat capsaicin injections (P>0.05, one-way ANOVA) 103
Figure 4.10 Graphs showing capsaicin (lpg) evoked neural discharge offibres innervating (a) naive
(n=5, fibres=12) and (b) FCA-injected (n-6, fibres=12) knee joint in two tests prior to and three tests
following injection of300pg morphine, (a) There was no significant difference in the neural discharge
frequency at any time point in naive animals (P>0.05, one-way ANOVA). (b) Morphine (300pg)
caused a significant reduction in the capsaicin evoked neural discharge at 200 minutes when
compared to 0 minutes (P<0.01, one-way ANOVA) 104
Figure 4.11 Capsaicin (lpg) evoked neural discharge offibres innervating (a) naive (n=6, fibres=15)
and (b) FCA-injected (n=5, fibres=17) knee joint before and after administration of lOOpg ofEMI.
There was no significant difference in the neural discharge frequency at any time pointfollowing
repeat capsaicin injections (P>0.05, one-way ANOVA) 104
Figure 4.12 Graphs showing the mean change in the frequency ofneural discharge above basal
activity in (a) and (b) naive and (c) and (d) FCA-injected animals evoked by a 10s stimulation with a
1, 7 and 21g von Frey filament, (a) and (c) Repeat applications of the 1, 7 and 21g filaments 20
minutes apart produced consistent mean discharge frequencies over the course of the experiment.
There was no significant difference in the mean discharge frequencies of the 1, 7 and 21g filaments
over time when analysing the filaments individually (P>0.05, one-way ANOVA). Moreover the angle
of the linear regression slope for each filament, in both naive and FCA-injected animals, is not
significantly different from zero (P>0.05, linear regression). Injection ofsaline at 95 minutes had no
effect on the neural discharge frequency evoked by the von Frey filaments in both (b) naive and (d)
FCA-injected animals. There was no significant difference in the mean change in discharge frequency
evoked when comparing the pre-saline 1, 7 and 21g values with the corresponding post-saline values
(P>0.05, one-way ANOVA) 106
Figure 4.13 Graphs showing the effect ofmorphine (300pg) and EMI (lOOpg) on von Frey filament
evoked firing in (a) and (b) naive and (c) and (d) FCA-injected animals. The mean change in the
frequency ofneural discharge from background activity in naive animals evoked by application of the
1, 7 and 21g von Frey filament before and after injection of(a) morphine (n=6, fibres=14) and (b)
EMI (n=6, fibres=13). In naive animals morphine had no effect on the neural discharge frequency
evoked by the 1 and 7g von Frey filaments, but significantly reduced the mean discharge frequency
evoked by the 21g filament compared to the pre-morphine value (P<0.05, one-way ANOVA, n=6). In
naive animals injection ofEMI had no effect on the change in mean discharge frequency evoked by
any of thefilaments pre- and post-EMl (P>0.05, one-way ANOVA, n-6). The mean neural discharge
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Joint inflammation during arthritis occurs initially as a result of damaged cells
activating or releasing pro-inflammatory mediators. The subsequent infiltration of numerous
inflammatory cells into the area of tissue damage further exacerbates the condition. The
underlying pathophysiology of chronic inflammatory joint disease results in peripheral
sensitisation of nerves at the site of the damaged tissue, together with central sensitisation of
the spinal processes connected to that tissue, which leads to the pain that is a common
distressing symptom of arthritis.
Most arthritis is chronic by the time a patient presents in the clinic, so a rodent
model of chronic inflammatory joint pain was used to investigate the mechanisms which
contribute to pain in human joints. Freund's complete adjuvant (FCA)-induced unilateral
arthritis of the rat knee joint is a well established model of arthritis, mimicking the
histopathology, hyperalgesia and swelling of the joint as seen in the clinic. In vivo
electrophysiology, behaviour and immunohistochemistry techniques were used to elucidate
the role played by opioid receptors and their endogenous ligands, and also the voltage-gated
sodium channels (VGSCs), in chronic inflammatory joint hypersensitivity.
Exogenous opioids such as morphine have long been used in the management of
pain as they exhibit powerful analgesic properties, which are generally attributed to centrally
mediated actions. The peripheral effect of the recently discovered endogenous opioid peptide
endomorphin-1 (EMI) and morphine was assessed using behavioural and electrophysiology
techniques during the "chronic" inflammatory phase (14-28 days post-FCA) of the rat model
of unilateral arthritis.
The effect of administering these opioid receptor agonists directly into the knee joint
on behavioural measures of hyperalgesia was investigated to determine whether they provide
analgesia when restricted to the periphery. Both EMI and morphine significantly reduced
joint hypersensitivity in a dose-dependent manner, as measured using an established readout
of "pain", based on how the conscious animals distribute their weight between the inflamed
and non-inflamed hind limbs.
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The antinociceptive properties of EMI and morphine were studied in rats
anaesthetized with pentobarbital by recording the neuronal discharge patterns of primary
afferent nerves innervating the rat knee joint evoked by mechanical and chemical
stimulation. In arthritic animals both morphine and EMI decreased neuronal firing evoked
by mechanical (von Frey filament) stimulation of the inflamed knee, an effect that was
abolished by pre-treatment with the opioid antagonist naloxone. In contrast, only morphine
decreased the neuronal discharge evoked by capsaicin in both naive and arthritic animals.
The VGSCs are crucial for transmitting information concerning environmental
stimuli from the periphery to the central nervous system, and hence play an integral role in
regulating the excitability of nociceptive primary afferent neurones. The expression levels of
the VGSC's Nav1.7, Nav1.8 and Nav1.9, predominantly found in nociceptive primary
afferents, were investigated in the cell bodies of the knee joint afferent population using
immunohistochemical techniques. Expression was measured in naive animals and also on
days 7, 14, 21 and 28 days during the progression of the adjuvant-induced arthritis. Nav1.9
expression was upregulated at days 14, 21 and 28 post-FCA, with Nav1.7 and Nav1.8
showing increased channel expression at days 14 and 28 post-FCA in comparison with time
matched control animals.
Throughout the studies the effect of FCA and test compounds on the behavioural
hypersensitivity and swelling of the knee joints was measured. A new device, designed to
assess knee joint hypersensitivity directly across the knee joint of rodents, was developed
and validated to help align pre-clinical measures with those used in the clinic with the view
to help successfully correlate animal studies to human. The pressure application
measurement (PAM) device consists of a recording base unit with digital display that is
connected to a force transducer embedded in a moulded plastic thumb unit. A gradually
increasing squeeze is applied across the knee joint between the thumb unit and forefinger
and at the point the force applied across the knee became noxious, the animal withdraws its
leg indicating the test endpoint. PAM recorded a joint hypersensitivity as shown by a
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decrease in limb withdrawal threshold in FCA-injected animals. Equally PAM measurements
showed the expected analgesic effect of prednisolone in both species, and also the
attenuation of FCA-induced hypersensitivity in rats dosed with morphine or celecoxib. PAM
is therefore a novel behavioural tool for detecting localised primary mechanical
hypersensitivity in a model of chronic inflammatory joint pain in rodents.
In summary, results from the in vivo electrophysiology studies show that during the
chronic phase of FCA-induced joint hypersensitivity there are functional opioid receptors
present in the periphery and agonists at these receptors are able to attenuate nociceptive
firing evoked by noxious mechanical von Frey filaments. Furthermore EMI and morphine
administered directly into the knee joint attenuate the FCA-induced joint hypersensitivity by
activating opioid receptors located in the periphery. Immunohistochemical results showed
that the number of primary afferent neurons expressing the VGSCs was upregulated during
FCA-induced inflammation, which could account in some part for the increased neuronal
hypersensitivity observed in chronic inflammatory joint pain. Future novel analgesics
targeting opioid receptors and VGSCs in the periphery may facilitate the breakthrough of a
novel potent analgesic drug without undesirable centrally mediated side-effects.
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Chapter 1: General Introduction
The work presented in this thesis concerns the role that the opioid receptors and the
VGSCs play in generating the chronic pain associated with inflammatory arthritis in the knee
joint. By using behavioural; in vivo electrophysiological and immunohistochemical staining
techniques, in a rat model of inflammatory knee joint monoarthritis, the mechanisms
involved in the sensitisation of peripheral nociceptors were investigated.
This chapter provides an overview of the historical background and more recent
understanding of the subject matter investigated throughout the thesis. The peripheral and
central mechanisms involved in joint inflammation and nociception and how these processes
commonly present themselves in the clinic in arthritic joint disease, along with commonly
used experimental animal models of joint pain will be discussed. In addition the role of
various inflammatory mediators, receptors and channels involved in these processes, along
with potential pharmacological therapeutic agents will be considered, with particular
emphasis on the opioid receptors and their endogenous ligands, and the VGSCs.
1.1 Clinical presentation of chronic pain
1.1.1 Introduction
Chronic pain is a major health problem that affects 19% of European adults in a
moderate or severe form (Breivik et al. 2006), and is often presented in association with
diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA). Chronic pain is ranked by
the World Health Organisation (WHO) as one of the major reasons for health related work
absence (Garcia and Altman 1997; Gureje et al. 1998). Pain is categorised as being chronic
when symptoms are still present even after the resolution of the initial injury, or in
degenerative diseases such as OA where the condition will never heal. It is not the duration
that makes a pain chronic, but the inability of the body to return its physiological functions to
normal. Chronic pain can lead to a severe reduction in the sufferers' quality of life caused by
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psychological and social problems as a result of sleep disturbance, anxiety, depression and
decreased functional capacity (Ashburn and Staats 1999).
There is great demand for the improved management of pain, but despite our
increased understanding of the mechanisms involved in pain processing and the
pathophysiology of diseases such as OA and RA, many patients still receive inadequate
treatment. Pharmacological management has scarcely progressed in over a century, with
unvarying reliance on cyclo-oxygenase (COX) inhibitors and the opioid analgesics (Rasor
and Harris 2007). The recent withdrawal of Merck's COX-2 inhibitor, rofecoxib (Vioxx) due
to several deaths from cardiovascular complications has eliminated one of the most effective
and popular treatments available to patients (Fitzgerald 2002; Dieppe et al. 2004; Fitzgerald
2004). This has left a huge gap in the market and the race is on to find a novel analgesic
without detrimental side effects (Mount and Featherstone 2005).
1.1.2 Arthritis
Arthritis is a term used for over 100 different conditions, with the most commonly
occurring being OA and RA, each of which is considered below. The Centres for Disease
Control report that in the US alone there are currently 46 million adults diagnosed with
arthritis, with the prediction that this value will increase to 67 million by 2030. Arthritis is
one of the most common conditions that gives rise to chronic pain (Fitzcharles et al. 2004).
The tissue damage and inflammatory processes commonly involved in these two diseases
result in the associated pain being described as both chronic and inflammatory.
1.1.2.1 Rheumatoid arthritis
RA is a prevalent, hostile autoimmune disease with unknown aetiology characterised
by persistent synovitis and progressive deterioration of the articular joints. The incidence
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rates in the UK are 1.16% in women and 0.44% in men, with women three times more
susceptible to the condition than men (Symmons et al. 2002). It is thought that a combination
of genetic factors, infectious agents and sex hormones trigger the autoimmune pathogenic
pathway leading to articular cartilage loss and erosion of articular bone (Oilier et al. 2001).
Increased understanding of the immune system means that the pathogenesis of RA has
recently become clearer. A large amount of published evidence suggests that T lymphocytes,
cytokines and macrophages play a critical role in the initiation and perpetuation of synovial
inflammation (see Firestein 2003, for review), with these processes leading to joint pain, a
loss in the range of movement and deformity in the limbs. RA a systemic disease often
affecting tissues other than the joints, commonly including; the skin, lungs and muscles
(Scott 2006). At the time of first diagnosis it is usual for just one joint to be affected with the
disease commonly spreading to the corresponding contralateral joint as the disease
progresses. Patients suffering from RA rate reducing the joint pain associated with their
condition as being the most desirable outcome of their treatment (Heiberg and Kvien 2002;
Heiberg et al. 2005).
1.1.2.2 Osteoarthritis
OA is the most common form of arthritis and results from the wear and tear of the
joint rather than the autoimmune response attributed to RA (Felson and Zhang 1998). It is
diagnosed by swollen stiff joints and a reduction in functionality. Commonly found in load
bearing joints the condition involves cartilage loss, increased bone density in the subchondral
region, cysts and formation of new bone and cartilage at the joint margin (Swagerty and
Hellinger 2001). In well advanced cases of OA the cartilage can be completely missing
causing the two ends of the bone to make contact and rub against each other. A single joint
can be involved, but more commonly several joints including the knees, hips, hands and
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spine are involved (Dieppe and Lohmander 2005). As with RA, pain is the dominant
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Figure 1.1 Diagram comparing the tissues in a healthy (a) and a rheumatoid arthritic (b) knee joint.
The healthy joint has a thin smooth synovial lining whereas the synovium in the arthritic joint is
inflamed and thickened due to the infiltration of inflammatory cells. Bone and cartilage loss are also
evident in the arthritic joint. (Adapted from the National Institutes of Health, 2005).
1.1.3 Treatments currently available for chronic joint pain
Mild to moderate pain associated with RA and OA is usually treated with non¬
steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, diclofenac and lbuprofen which
reduce pain and inflammation (Morgan et al. 1993). These drugs work by inhibiting the
action of COX, thereby preventing the metabolism of arachadonic acid and consequently the
production of the eicosanoids (Vane 1971). The eicosanoids play an integral role in the
bodies inflammatory response, with prostaglandin E2 (PGE2) in particular being an important
sensitising agent and mediator of pain (Katori 1989). The prolonged use of these drugs has
been shown to have undesirable side effects such as reducing renal function (Lifschitz 1983)
and causing gastrointestinal ulceration and bleeding (Goodwin 1987). The development of
selective COX-2 inhibitors such as rofecoxib, celecoxib and etoricoxib potentially removed
these side-effects which are mediated by inhibition of the COX-1 enzyme (Lipsky and
Isakson 1997; Hawkey 1999; Riendeau et al. 2001). As mentioned above the COX-2
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inhibitor rofecoxib has been cited in causing an increased risk of heart attack and stroke,
which lead to the withdrawal of the drug in 2004. Rofecoxib was one of the most widely
used drugs ever to be withdrawn from the international market and in 2003, before its
withdrawal, Merck reported that sales of the drug amounted to 2.5 billion US dollars (New
York Times, 07/12/2004).
Opioids such as morphine and oxycodone are potent analgesics that provide
excellent relief in cases of severe acute and chronic pain (Dellemijn 2001; Przewlocki and
Przewlocka 2001). Their long-term use is compromised by various unwanted side effects
such as tolerance, addiction, constipation, nausea, respiratory depression and euphoria
meaning that prescription of these drugs is often restricted (Nicholson 2003). These side
effects appear to be mediated through centrally located opioid receptors and consequently
there is great interest in opioids that selectively target receptors expressed in the periphery
(Stein et al. 1989).
Recent clinical advances in the pharmacological treatment of pain have included the
use of the anticonvulsant drug gabapentin. Gabapentin was originally introduced for the
treatment of epilepsy (Crawford et al. 1987), but is now widely used in the treatment of post¬
operative and chronic pain (Guindon et al. 2007). Several hypotheses have been put forward
suggesting its mechanism of action, but it is predominantly thought that its binding to a
subunit of the voltage gated N-type calcium channel plays a key role in its analgesic
properties (Cheng and Chiou 2006).
1.2 Pain and Nociception
1.2.1 Overview of pain
Pain is defined by the International Association for the Study of Pain (IASP) as; an
unpleasant sensory and emotional experience associated with actual or potential tissue
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damage, or described in terms of such damage. The sensation of pain is the body's first line
of defence against any potentially threatening or damaging environmental stimuli. The pain
sensation is essential for maintaining the health of the human body, with its two main
functions being to recognise harmful stimuli and generate the reflex required to avoid tissue
damage and to provide a means of sensing when damage has occurred enabling protection
and repair of that damage.
1.2.2 The discovery of nociceptors
Rene Descartes is regarded as the first philosopher to hypothesize correctly that pain
results from peripheral nerves transmitting information to the higher centres in the brain (see
Figure 1.2). Early scientists accepted that pain was a sensation in its own right, but did not
appreciate that it was detected by its own special sense organs (Perl 1996). This was first
described by the Austrian physiologist Max von Frey who revealed that the skin was
comprised of an intricate mosaic of minute sensory areas relating to touch, coldness, warmth
and pain, all mediated by specific sensory organs (von Frey 1894; 1922). From this he
deduced the morphological type of specialized afferent nerve terminals related to each type
of sensation, and he attributed pain to fine unspecialised free nerve endings.
In 1903 Charles Sherrington further described how different kinds of nerve endings
exist in the skin of dogs, with one of his perceptive remarks being "There is considerable
evidence that the skin is provided with a set of nerve-endings whose specific office it is to be
amenable to stimuli that do the skin injury, stimuli that in continuing to act would injure it
still further.", he further went on to infer that "the species of nerve-ending excited in these
cases may preferably be termed nocicipient" (Sherrington 1903). Sherrington's work on
mammalian neuronal function, summarised in his book, The Integrative action of the
nervous system, greatly developed the understanding of nervous function and pain sensation
(Sherrington 1906). Sherrington argued that pain is a specific sensation with its own sensory
11
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machinery which he named 'noci-receptors'. First published over 100 years ago, this work
provided a framework for subsequent research that led to our modern day understanding of
the mechanisms involved in synaptic transmission and pain (Burke 2007; Levine 2007).
Figure 1.2 Descartes model of pain sensation showing the hypothesised link between the peripheral
tissues and the brain in sensing painful stimuli such as noxious heat. This cartoon, adapted from the
original published by Descartes in his 1606 work entitled L'Homme, is considered to be one of the
earliest systematic representations of the organization whereby a noxious stimulus activates systems
that travel through the nerves to the spinal cord and then to the brain.
The introduction of electrophysiology studies capable of recording the compound
action potentials of electrical nerve signals (Adrian 1926a; b; Adrian and Zotterman 1926)
showed that peripheral nerves were composed of groups of fibres conducting at different
velocities (Erlanger and Gasser 1937). Groups of fibres were named in the order in which
their signal appeared on the oscilloscope screen after a brief single electrical impulse given
to the nerve trunk. Subsequent investigations were undertaken into how the different fibre
types responded to various stimuli (Heinbecker et al. 1932; Zotterman 1933; Clarke et al.
1935). In mammals, AP-fibres are the fast conducting (35-100m.s"'), large diameter (>10pm)
myelinated fibres that respond to light touch and innocuous stimuli. A5-fibres are slower
conducting (5-30m.s"') medium diameter (2-5pm) myelinated fibres and C-fibres are the
slow conducting (0.05-2m.s_1), small diameter (0.2-1.5pm) unmyelinated fibres. A8- and C-
fibres both respond to noxious stimuli. The development of a micropipette recording
12
Chapter 1: General Introduction
technique in 1965 allowed characterisation of 513 cutaneous afferents, recorded in the
anaesthetised cat, to thermal and mechanical stimulation and showed a significant population
of A5-fibres that were activated exclusively by noxious mechanical stimuli (Burgess and Perl
1967). These afferents were named nociceptors, a term derived from Sherrington's earlier
work. In experiments on the skin innervating the hind limb of a cat the unmyelinated C-
fibres were later described as being either low-threshold afferents that were activated by
innocuous mechanical stimuli, or high-threshold nociceptive afferents that were responsive
to noxious mechanical stimuli, high temperatures and chemical stimulation (Bessou and Perl
1969). Of the high-threshold nociceptors approximately one third were responsive to intense
mechanical stimulation only and two-thirds were responsive to all the noxious stimuli. The
former group of nociceptors were named mechanonociceptors and the later were named
polymodal nociceptors.
1.2.3 Current understanding of afferent nerve fibres
The nociceptive primary afferent neurone has four major components; the peripheral
terminal, the axon, the cell body and the central terminal (Figure 1.3a). The normal resting
membrane potential of primary afferents is typically -70mV. The peripheral terminal
transduces the external stimuli into an action potential as a consequence of the terminal
becoming depolarised as a result of various ion channels being activated, which further
trigger the opening of voltage gated sodium channels (VGSCs Figure 1.3b). A wave of
depolarisation occurs as a result of the increased permeability of the cell membrane to
sodium and potassium ions (Hodgkin and Huxley 1952a; b; c). Action potentials are
propagated along the axon to the central terminal in the dorsal horn of the spinal cord which
forms the presynaptic component of the first synapse in the sensory pathway. Calcium ions
enter the central terminal and cause the release of both inhibitory and excitatory
neurotransmitters as summarised schematically in Figure 1.3c.
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The classification of a primary afferent as being either an AP-, A5- or C-fibre is still
determined by conduction velocity and axonal diameter, with only the AS- and C-fibre types
considered to be involved in nociceptive signalling (Dubner 1978; Handwerker and Kobal
1993). Within these groups further subtypes exist, as determined by their sensory profile and
the molecular markers which they express. Activation of AS-fibres evokes sharp acute pain,
a prickling sensation and aching pain. Two sub sets of AS-fibres are apparent; type I and
type II with type I being the most common. Type I fibres typically respond to heat, chemical
and mechanical stimuli whereas type II are mechanically insensitive (Treede et al. 1995;
Lawson 2002). As discussed above, C-fibres can be described as either polymodal or
mechanonociceptors (Bessou and Perl 1969). Another population of C-fibres are the silent or
mechanically insensitive afferents, first described in the knee joints these sensory afferents
are present throughout the periphery (Schaible and Grubb 1993). Silent nociceptors are
normally unresponsive to acute noxious stimuli, but following tissue damage and
inflammation the inflammatory mediators lead to a decrease in the activation threshold of
these nociceptors rendering them active to noxious stimuli (McMahon and Koltzenburg
1990; Cervero et al. 1994).
14
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Figure 1.3 (a) Basic structure and components of a primary afferent neurone. The peripheral terminal
innervates the target tissue, the axon conducts action potentials and the central terminal transfers the
signal to central processes. The cell body controls the identity of the nerve and produces the proteins
the receptors and channels that can be transported to the peripheral or central terminal. Schematics
showing (b) a selection of ion channels involved in the depolarisation of the peripheral terminal and
(c) neurotransmitters released from the central terminal. Diagram modified from (Woolf and Ma
2007).
Neurochemical and electrophysiological studies in both mice and rats have revealed
that two distinct subsets of nociceptive C-fibres exist that are determined by the ion channels
and receptors they express and their central projections in the superficial dorsal horn (Hunt
and Rossi 1985; Stucky and Lewin 1999; Braz et al. 2005). The first subset express the NGF
receptor TrkA and rely on nerve growth factor (NGF) for their survival; these nociceptors
contain the peptides substance P (SP) and calcitonin gene related peptide (CGRP) and are
therefore termed peptidergic (Molliver et al. 1995; Bennett et al. 1996). The peptidergic
nociceptors project to lamina I and the outer layer of lamina II in the dorsal horn (Zylka et al.
2005). The second class of nociceptors are determined by the expression of isolectin B4
(IB4) and do not contain SP or CGRP and are therefore named non-peptidergic or IB4-
positive (Molliver et al. 1997). The non-peptidergic nociceptors project preferentially to the
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non-peptidergic neurones express different patterns of receptors and ion channels, for
example the adenosine triphosphate (ATP) receptor P2X3 is expressed primarily in non-
peptidergic (Vulchanova et al. 1998) whereas the transient receptor potential vanilloid 1
(TRPV1) receptor is expressed equally in both types (Caterina et al. 1997). It is thought that
peptidergic neurones are the main subset involved in generating neurogenic inflammation by
releasing SP from their peripheral terminals in response to pro-inflammatory stimuli (De
Felipe et al. 1998). This process is considered to initiate chronic pain following tissue
damage (Woolf et al. 1998). Non-peptidergic neurones have been implicated in the
generation of chronic pain following nerve damage (Malmberg et al. 1997).
1.2.4 Pain sensation (transduction)
Pressure, light touch, chemical and thermal (hot or cold) stimuli can be transduced
by the peripheral terminal of afferent neurones into an electrical signal (action potential)
which is transmitted to the central nervous system along the nerve axon, as described above.
Stimulation of the skin by chemical irritants produces an acutely painful response, but this is
not a model relevant to chronic inflammatory pain as studied in this thesis. However,
chemical mediators such as SP and histamine do play an important role in neurogenic
inflammation and peripheral sensitisation following tissue injury. The chemical mediators
can be released from the afferents themselves, mast cells, surrounding tissue including the
vasculature and inflammatory cells. These chemical mediators and their role in sensitising
peripheral nerves will be discussed further in section 1.3.2.
1.2.4.1 Mechanical stimuli
Relatively little is known about the mechanisms involved in detecting noxious
mechanical stimuli. Much of our understanding comes from studies into the bacterial
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mechanosensitive ion channels which show both large and small conductance (see Corry and
Martinac 2007 for review). Recent studies have highlighted the role of neurotrophin-3
(Mcllwrath et al. 2007) and endothelin-1 (Namer et al. 2007) in regulating the mechanical
sensitivity of primary afferents. Several ion channels have been implicated in the
mechanosensitivity of mammalian afferents (see Sukharev and Corey 2004 for review). The
acid sensing ion channel (ASIC), transient receptor potential family (TRPA1) and P2Y
receptors have all been suggested to play an important role in sensing mechanical stimuli
(Nakamura and Strittmatter 1996; Corey et al. 2004; Kwan et al. 2006; Lingueglia 2007).
1.2.4.2 Thermal stimuli
Detection of thermal sensation such as heat or cold allows an organism to regulate
their internal environment. In the monkey, temperatures below 15°C and above 43°C illicit
neural discharge and a subsequent thermal sensation (LaMotte and Campbell 1978; Tillman
et al. 1995), and a specific heat gated ion channel was identified in a subset of primary
afferent neurones (Cesare and McNaughton 1996; Reichling and Levine 1997). The cloning
of the TRPV1 receptor in 1997 really progressed our understanding of the ion channels
involved in painful heat sensation (Caterina et al. 1997). Early behavioural studies in rats
were the first to suggest that the burning sensation caused by application of capsaicin to the
skin was mediated through such a receptor (Szolcsanyi and Jancso-Gabor 1975; Szolcsanyi
et al. 1975). Capsaicin, the component of chilli peppers from the genus Capsicum that makes
the pepper 'hot', was identified as an exogenous ligand to these receptors, being able to
evoke neuronal discharge in a population of sensory afferents and cause the release of the
inflammatory mediators SP and CGRP (Szolcsanyi et al. 1988; Szallasi and Blumberg 1999).
The TRPV1 receptor has a threshold of activation of approximately 43°C (Caterina and
Julius 2001). The receptor is not only activated by heat and capsaicin, but also by protons
present in greater concentrations than usual at a pH of <6. To date the cloning of the TRP
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family of receptors has revealed 3 subtypes, the TRPV subtype made up of TRPV1-TRPV6,
the TRPM family comprising TRPM1-8 and the TRPA family formed from the TRPA1
receptor only (Tominaga and Caterina 2004). Of these receptors, activation of TRPV1,
TRPV2, TRPV3 and TRPV4 occurs as a result of warm to hot temperature conditions or
stimuli (Jordt et al. 2003), with TRPM8 and TRPA1 being activated by cold stimuli or
temperatures below 15°C (Campero et al. 1996).







Table 1.1 Members of the TRPV and TRPM family. Red, orange, and blue text indicates the channels
which are activated by high heat (>43°C). warm (>30°C), and cold (<15°C) stimuli respectively.
TRPV1 expression studies have shown the receptor to be most densely expressed in
small diameter cell bodies which give rise to unmyelinated C-fibres, and centrally in lamina I
and II of the dorsal horn where these unmyelinated C-fibres project. Deletion of the TRPV1
receptor in knockout mice caused significant deficits in thermal sensation at both peripheral
and central aspects of the pain pathway but these mice were not completely insensitive to
thermal nociception, suggesting that TRPV1 mediates some but not all thermal sensation
(Caterina et al. 2000). Mediators such as ATP and bradykinin have been shown to lower the
temperature threshold for activation of TRPV 1 receptors to as low as 30°C through protein
kinase mediated phosphorylation of the receptor suggesting that inflammatory pain may
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occur as a result of modulation of this receptor (Reeh and Petho 2000; Numazaki et al.
2002).
The methods involved in the transduction of noxious cold sensation are less well
studied than those involved in noxious heat. The cooling sensations of low temperatures and
menthol were described in the early 1950's (Hensel and Zotterman 1951), with the
sensations later being attributed to a non selective cation cold receptor called TRPM8
(McKemy et al. 2002; Peier et al. 2002). TRPM8 is normally activated by temperatures
lower than 25°C but as described above with TRPV1, modulation of the channel can lead to
sensitisation of the channel, with its activation being seen at temperatures up to 30°C
(McKemy et al. 2002; Peier et al. 2002). Like TRPV1, TRPM8 is expressed in small-
diameter C-fibres, yet the two receptors do not appear to ever be co-expressed on the same
neurones (Nealen et al. 2003).
In addition to TRPM8, the TRPA1 receptor has been shown to be involved in cold
sensation with a lower activation threshold than TRPM8 (Story et al. 2003). The receptor is
activated at temperatures below 17°C and unlike TRPM8 menthol is not a ligand for this
receptor. TRPA1 is expressed exclusively in peptidergic neurones and is often seen co-
expressed with TRPV1. TRPA1 knockout mice appear to be deficient in detecting noxious
cold pain sensations at temperatures less than 0°C, but exhibited normal pain behaviour to
noxious heat, suggesting that the role of TRPA1 may be exclusive to transduction of stimuli
at low temperatures (Kwan et al. 2006).
1.2.5 The pain pathway
As described in section 1.2.3, primary afferent fibres enter the spinal cord and
terminate in specific regions of the grey matter of the dorsal horn within the spinal cord (see
(Millan 1999). The cyto-architectural organization of the spinal cord was first described by
the Swedish neuroscientist Rexed, based on the density and myelination of each of the 10
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lamina (Rexed 1952). The primary afferents synapse onto second order neurones via
chemical excitation by the neurotransmitter glutamate. The second order nociceptive dorsal
horn inter-neurones appear as three main types; nociceptive specific which are mainly found
in lamina I and respond to noxious stimuli only, non-nociceptive specific predominantly
found in lamina II, III and IV and wide dynamic range neurones responding to a range of
intensity of stimuli (Besson and Chaouch 1987; Dubner and Hargreaves 1989; Millan 1999).
Axons from the wide dynamic range and nociceptive specific inter-neurones cross the spinal
cord and typically ascend the spinothalamic tract conveying information to the thalamus.
Other ascending pathways exist such as the spinoreticular, spinohypothalamic and
spinocervicothalamic tracts projecting to different areas of the brain such as the
mesencephalon and diencephalons (Besson 1999). Neurones within the thalamus project to
the somatosensory cortex and anterior cingulate gyrus to allow the localisation and
characterisation of painful stimuli and the perception and emotional response to the pain (see
Willis and Coggeshall 1991).
1.3 Inflammatory joint pain
Inflammation is characterised by four common signs; the calor (heat), dolor (pain),
rubor (redness), and tumor (swelling), caused by local vasodilation, oedema formation as
inflammatory cells infiltrate the area and pain caused by chemical mediators causing
nocicepitve discharge. Pain arising from inflammation can be categorised into two different
types as defined by the IASP committee on taxonomy: hyperalgesia is 'an increased response
to a stimulus that is normally painful' and allodynia is 'pain due to a stimulus which does not
normally provoke pain' (see Figure 1.4).
Primary hyperalgesia can exist at the immediate site of injury with secondary
hyperalgesia in the tissue surrounding the damaged area. In the following sections I will
describe the knee joint anatomy and summarise some of the important processes involved in
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establishing inflammatory joint pain through mechanisms of peripheral and central
sensitisation.
Figure 1.4 Sensitisation of pain responses from external stimuli. The normal response shown by the
right hand curve (green) is shifted to the left following inflammation (red). A stimulus that is normally
not noxious will now become so, a term described as allodynia. and a normally noxious stimulus will
result in a higher intensity of pain sensation a term known as hyperalgesia, (illustration redrawn from
(Gottschalk and Smith 2001).
1.3.1 Knee joint afferent nociceptors and inflammation
Anatomical studies of the feline knee joint provided the first information of the
neurological innervation of the joint (Skoglund 1956; Freeman andWyke 1967; Heppelmann
et al. 1995; Heppelmann 1997). Further studies have described similar morphology in dogs
(O'Connor 1984), rats (Hildebrand et al. 1991) and humans (Halata et al. 1985). Taken
collectively, these studies show that there is very little difference in the neuronal architecture
and types of fibres innervating the knee joint. The most notable inter-species difference was
Pain response in normal uninjured tissue
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the absolute number of afferents innervating the joint based on the overall size of the joint.
Synovial joints are predominantly innervated by AS- and C-fibres which terminate in non-
corpuscular endings with 60% of the afferents innervating the knee joint of the cat being
classed as nociceptive (Heppelmann and Pawlak 1997). These afferents can be classified as
belonging to one of five groups based on their sensitivity to pressure or movement within the
joint (Coggeshall et al. 1983; Schaible and Schmidt 1983a; b; 1988):
• Group I : low threshold units that are weakly activated by innocuous pressure and
movement in the joint
• Group II : high threshold units that are strongly activated by innocuous pressure
and movement in the joint
• Group III : high threshold units that are only activated by noxious pressure and
movement outside the normal range of the joint
• Group IV : units that respond to intense pressure but not movement
• Group V : silent nociceptors
The knee joint of the rat has three primary afferent nerves, namely the medial
(MAN), lateral (LAN) and posterior articular nerves (PAN). The MAN nerve branches from
the saphenous nerve and transverses the antro-medial aspect of the thigh running alongside
the descending genicular artery and vein to the medial aspect of the knee (Freeman and
Wyke 1967). Here the nerve splits into two branches and spreads to innervate various
structures in the knee including: the ligamentum patellae, the fibrous capsule of the knee
joint and the medial collateral ligament. The MAN of the cat contains approximately 630
afferents of which the majority (20% and 70% respectively) fall into either group III or
group IV as described above (Langford and Schmidt 1983). Electrophysiological recordings
made during this thesis were obtained from the MAN in rats. The rat MAN comprises
approximately 400 axons innervating the rat knee joint (Hildebrand et al. 1991), with the
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majority of the cell bodies of these sensory neurones being located in dorsal root ganglia
(DRG) L3-L5 (Salo and Theriault 1997).
Peripheral sensitisation (described in section 1.3.2) during inflammation of the knee
joint has been thoroughly characterised using electrophysiological studies, where pressure
and movement of an inflamed joint lead to enhanced A(3- and AS-fibre responses (Schaible
and Grubb 1993). In addition approximately 80% of A8- and C-fibres in inflamed joints of
cats are spontaneously active, firing at a rate of more than double in inflamed joints
compared to normal joints (Coggeshall et al. 1983; Schaible and Schmidt 1985; 1988).
1.3.2 Peripheral sensitisation
Typically immediate pain results from tissue injury or damage, which causes the
release of local inflammatory mediators from the damaged cells that act directly on terminals
of peripheral nociceptors. Algogens such as 5-hydroxytryptamine (5-HT), K+, H+, ATP,
nitric oxide, histamine, and bradykinin (BK) can all be released from damaged cells, leading
to the classical inflammatory response, pain and the recruitment of cytokine releasing
immune cells to the injury site (Kidd and Urban 2001). Some of these algogens depolarise
the cell membrane immediately by acting through specific ligand-gated ion channels, for
example 5-HT acting on the 5-HT3 receptor, causes an immediate nociceptive neuronal
discharge (Zemlan et al. 1988). Peripheral sensitisation occurs when these inflammatory
mediators bind to G-protein coupled receptors and activate protein kinases (PK) which in
turn phosphorylate the nociceptive receptors and ion channels, reducing the threshold
required for nociceptive activation (Woolf and Salter 2000; Mackey 2004). Additionally,
silent nociceptors that were previously inactive will be activated and add to the peripheral
nociceptive drive, with the overall effect being an increased input to the spinal cord
(Coggeshall et al. 1983; Schaible and Schmidt 1988; Schaible and Grubb 1993).
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1.3.2.1 Bradykinin (BK)
BK is produced by enzyme mediated cleavage of kininogen found in the plasma at
the site of tissue injury, and makes an early contribution to pain and inflammation through
both a direct action on the nociceptors and secondary actions through indirect pathways
(Dray et al. 1992; Dray and Perkins 1993). The direct action of BK is mediated through the
B2 receptors and causes depolarisation of the peripheral nerve terminals and propagation of
an action potential (Beck and Handwerker 1974). Sensitisation of peripheral nerves by BK is
mediated through the BKj receptor which is present in low numbers in normal tissues but
enhanced expression is seen in inflamed tissues (Marceau et al. 1998). Bi activation causes
lowered threshold of activation and altered kinetics of VGSCs, reduced activity of voltage
gated potassium channels (Wang et al. 2006), activation of the arachidonic acid pathway and
increased sensitivity of primary afferents to heat stimuli (Lang et al. 1990). Bj and B2 null
mutant mice demonstrated an attenuated acute inflammatory pain response to intra-plantar
injection of adjuvant highlighting a role of the receptors in peripheral sensitisation (Fox et al.
2003). BK shows multiple complex interactions with other inflammatory mediators which
lead to enhance peripheral sensitisation which are too numerous to discuss at this juncture.
For a comprehensive review see (Perkins 1999).
1.3.2.2 Eicosanoids
COX-1 and COX-2 are induced in peripheral tissues following injury and
inflammation (Dubois et al. 1998). The breakdown of arachidonic by the COX enzymes
leads to the production and release of the prostaglandins and leukotrienes, collectively
known as the eicosanoids, which act as sensitising agents. Such sensitising affects are
mediated through the prostanoid receptor activating PKA which leads to a reduction in the
activation threshold of VGSCs (England et al. 1996) and enhancement of the action of BK
(Grubb et al. 1991). Although the eicosanoids are predominantly thought to act as sensitising
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agents, PGE2 and PGI2 have been shown to directly excite afferent nociceptors through the
EPi_4 receptors (Birrell et al. 1991).
1.3.2.3 TRPV1
The TRPV1 receptor plays an integral role in the transduction of noxious thermal
stimuli into nociceptive neuronal signals as described in section 1.2.4.2. In rats
approximately half of the peptidergic and half of the IB4-positive primary afferent nerves
express TRPV1 (Guo et al. 1999; Michael and Priestley 1999). TRPV1 receptors have been
implicated in playing an important role in primary sensitisation of nociceptors, as during a
model of peripheral inflammation, transport of the receptor mRNA to the periphery was
increased and the proportion of TRPV1-labelled unmyelinated C-fibres was almost doubled
(Carlton and Coggeshall 2001). Additionally, a similar model using carrageenan induced
inflammation of the footpad in rats, showed the sensitivity of central terminals to capsaicin
was increased, as evidenced by the increase in capsaicin-evoked release of glutamate from
the dorsal horn (Tohda et al. 2001). Local inflammation induced by FCA increased TRPV1
protein levels in small and medium diameter DRG neurones (Amaya et al. 2003). A role for
TRPV1 in inflammatory pain sensations was confirmed by use of the receptor antagonist
capsazepine which reversed FCA-induced mechanical hyperalgesia in the Guinea-pig
(Walker et al. 2003). In contrast to these studies it has also been reported that TRPV1
expression is not significantly altered in the acute or chronic stages of antigen-induced
arthritis in the rat (Bar et al. 2004), which suggests that various pre-clinical models of
chronic inflammatory pain may have different underlying pathophysiologies determined by
the mode of action of the inflammatory agent or the species studied. Genetically modified
mice lacking TRPV1 display clear and robust deficits in response to noxious heat stimuli,
measured at the level of the cultured sensory neuron, the primary afferent fibre, and the
spinal cord dorsal horn (Caterina et al. 2000).
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Capsaicin-based tests are regularly used in the clinic to quantify neuronal sensitivity
in patients suffering with RA (Morris et al. 1997). In these tests capsaicin is applied to the
forearm of the patient for 30 minutes leading to the development of a mechanical
hypersensitivity, but in patients suffering from RA this area of hypersensitivity is
substantially larger than in normal patients implying enhanced central mechanisms in this
disease (see section 1.3.3). Administration of capsaicin into the rat knee joint leads to a short
term degeneration of unmyelinated C-fibres with no positive staining for CGRP or SP being
observed in the knee joint up to 7 days after injection (Ferrell et al. 1992; Mapp et al. 1996),
and this may account for the desensitising properties of topically applied creams used in the
treatment of pain.
1.3.2.4 Neurogenic inflammation
Neurogenic inflammation is a term used to describe the contribution of sensory
nerves to the local inflammatory response (Jancso et al. 1967; Foreman 1987a; Just and
Heppelmann 2002). Stimulation of peptidergic fibres causes the release of the neuropeptides
such as neurokinin A and B, SP and CGRP, which have inflammatory roles (Foreman
1987b; Snijdelaar et al. 2000). These neuropeptides lead to an increase in blood flow, vessel
permeability and plasma extravastation first described following the observation that SP
increased the proliferation of T lymphocyte into areas of inflammation (Payan et al. 1983).
Antidromic nerve stimulation can lead to the local axon reflex with nociceptors outside the
immediate area of stimulation releasing neuropeptides (Ferrell and Russell 1986). The
release of neuropeptides causes mast cell degranulation and an increased release or
formation of histamine, cytokines and the eicosanoids which in turn contribute to peripheral
sensitisation (Kidd et al. 1990). The neuropeptides also exhibit numerous actions on
leukocytes and the prostanoids (for review see McGillis and Fernandez 1999).
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1.3.2.5 Cytokines
Pro-inflammatory cytokines such as tumour necrosis factor alpha (TNFa),
interleukin (EL)-ip, IL-6 and IL-8, can be released from mast cells, leukocytes and
synoviocytes and have been shown directly to sensitise nociceptors during inflammation
(Bianchi et al. 1998; Dayer 2002; De Jongh et al. 2003). These cytokines cause the
production and release of prostaglandins from surrounding cells (Dayer et al. 1986), and
upregulate the levels of SP in peptidergic neurones (Jonakait et al. 1990). Furthermore
cytokines regulate the increase in inflammatory cell recruitment, adhesion and activation,
and both EL-1 and TNFa have been shown to play a pivotal role in the tissue destruction seen
in chronic inflammatory diseases such as rheumatoid arthritis (Dayer 2002). An increase in
cytokine levels within the rat knee joint following chronic inflammation has recently been
described (Barton et al. 2007a; b).
Crucially all of these inflammatory mediators act to modify the normal response of
afferent nerve fibres by reducing their activation threshold and increasing their excitability
(Heppelmann and Pawlak 1997). In addition to inflammatory algogens causing peripheral
afferent nociceptor sensitisation, up-regulation of receptors and ion channels such as TRPV1,
the VGSCs, ASICs, opioid receptors and P2X / P2Y receptors have been associated with
neuronal hyper-responsiveness. Of particular interest in this thesis are the opioid receptors
and VGSCs which will be discussed in sections 1.5-1.7.
1.3.3 Central sensitisation
Central sensitisation, in the spinal cord and brain, occurs as a consequence of
sustained or repeated activation of sensory afferent fibres terminating in laminae I, II and V
of the dorsal horn (Woolf 1983; Bolay and Moskowitz 2002). Glutamate released from the
terminals of these afferents normally acts on postsynaptic AMPA receptors to evoke a fast
excitatory potential leading to depolarisation at the spinal level (Mendell 1966). Under the
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physiological condition of inflammation, the release of neuropeptides, such as substance P
and CGRP, leads to both AMPA and NMDA receptors becoming active in the processing of
spinal neural signals and a long term increase in the excitability of the ascending dorsal horn
neurones. NMDA receptors have been shown to play a key role in the development of
central sensitisation in rats as a result of inflammatory pain (Sluka et al. 1994; Zhang et al.
2003). The overall result is that responsiveness of these postsynaptic cells to existing inputs
and normally sub-threshold stimuli is increased and the receptive field size is expanded. This
central sensitisation is responsible for the amplification of peripheral inputs from regions
beyond the inflamed or injured tissue, a phenomena described in both humans and animals as
secondary hyperalgesia (Schaible and Grubb 1993; Woolf and Salter 2000). Central
sensitisation serves a protective purpose by making normally innocuous stimuli evoke pain
responses in areas other than the initial site of injury to spare body parts from further injury
whilst healing occurs (Woolf and Walters 1991). Administration of a local anaesthetic before
pro-inflammatory agents such as capsaicin, blocks C-fibre activation and prevents central
sensitisation in both rodents (Fitzgerald and Woolf 1982) and humans (LaMotte et al. 1992),
proving that the process occurs as a result of repeated primary afferent stimulation. Central
sensitisation can be studied in animals through the phenomenon known as wind up. Wind up
is a frequency-dependent increase in the excitability of spinal cord caused by electrical
stimulation of nociceptive C-fibres (Herrero et al. 2000). Wind-up is very useful in studying
spinal cord physiology in rats, but it is not a process identical to central sensitisation, as it
probably shares only a small component of the processes involved in central sensitisation as
a result of peripheral inflammation (Herrero et al. 2000).
The experiments conducted in this thesis are focussed on the mechanisms involved
in peripheral sensitisation during inflammatory joint pain, and although central sensitisation
is an extremely important process in the overall perception of chronic pain, at this stage the
mechanisms involved will not be explored any further.
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1.4 Animal models of inflammatory pain
Several animal models of inflammatory pain exist that are commonly used to further
the understanding of the underlying mechanisms involved in both acute and chronic pain
states. These models are commonly used as pre-clinical screens for assessment of the
efficacy of potential novel analgesics in the treatment of inflammatory pain. Generally these
models rely on inducing agents to cause an inflammatory response and associated
hypersensitivity (Le Bars et al. 2001).
1.4.1 Adjuvant-induced arthritis
Freund's complete adjuvant is an inflammatory agent first formulated by the
Hungarian born American immunologist Jules Freund after whom the adjuvant was named
(Freund and Lipton 1955; Freund 1956). FCA is a mixture of mineral oils, inactivated and
heat killed Mycobacterium tuberculosis and emulsifying agents. Intradermal injection of
FCA into the tail base of rats induces a polyarthritis (Pearson 1956), with the subsequent
development of joint lesions nearly identical to those seen in human RA (Pearson 1963). The
initial inflammation at the site of injection is followed by severe swelling in multiple joints
approximately 5 days after FCA treatment (Pearson 1956; Glenn and Gray 1965; Pircio et al.
1975). It is thought that the mineral oil along with the peptidoglycans of the cell walls of the
gram positive bacteria Mycobacterium tuberculosis that are present in FCA contribute to the
immunostimulation within the animal, which leads to the development of arthritis
(Whitehouse et al. 1974; Koga et al. 1976). Heat shock proteins have been implicated in the
pathogenesis of human arthritis and a 65kD heat shock protein present in FCA contains a
specific epitope corresponding to an amino acid sequence recognised by rat T cells (van
Eden et al. 1988).
FCA-induced polyarthritis was soon suggested as being a suitable experimental
model of chronic pain (De Castro Costa et al. 1981) as well as being used in studies of anti-
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arthritic drugs (Rainsford 1982). Behaviours such as chronic scratching (Calvino et al. 1987),
a reduced threshold to noxious heat and pressure (Millan et al. 1987) and hyperventilation
(Colpaert 1987) were all observed in rats, validating this as a suitable model of chronic pain.
The induction of polyarthritis using FCA is however associated with systemic disease and
many undesirable side-effects such as severe weight loss, nodular lesions of the ears, feet,
tail and genitals and diarrhoea (Pearson 1956). These side effects made it difficult to attribute
the pain and hypersensitivity observed purely to joint arthritis. Furthermore as the welfare of
laboratory animals is of highest priority, especially during chronic studies, the question of
whether or not this model is ethically acceptable was raised (Casey and Dubner 1989).
Refinement of the polyarthritic model saw the development of a technique where
FCA was injected sub-dermally around the tibio-tarsal joint of the ankle (Grubb et al. 1988;
Donaldson et al. 1993). Further adaptation saw the FCA being injected directly into the
articular space within the ankle joint of the rat (Butler et al. 1992). Both methods produce a
stable monoarthritis lasting up to 30 days post-injection and beyond, with the FCA causing a
joint hypersensitivity and similar pathology as seen in human RA. The animals did not
display the irritability often observed in the polyarthritic model and gained weight in a
normal fashion, an indication of normal feeding behaviour. This unilateral model of articular
FCA administration has been applied to the knee joint of rats (Donaldson et al. 1993; Wilson
et al. 2006) and mice (Chillingworth and Donaldson 2003; Gauldie et al. 2004) where a
unilateral arthritis and associated joint hypersensitivity are induced without any systemic
side effects. Interestingly, an accidental self injection of FCA into the forearm of a research
worker has been documented to have resulted in severe inflammation that was successfully
treated with steroids (Shah 2002).
For the work reported in this thesis FCA was injected into the articular space of the
knee joint and was the method used to investigate peripheral sensitisation of nociceptive
afferents during a model of chronic inflammatory joint pain. The model has already been
established and characterized in this laboratory, meaning validation of the model was not
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necessary for this thesis (Dowd et al. 1998a; b; Gauldie et al. 2001). Results were directly
compared with these previous studies to ensure that similar outcomes were being observed.
In this way the number of animals required for the studies was reduced.
1.4.2 Other models of inflammatory pain
A number of different inflammatory agents have been used in order to investigate
acute inflammatory hypersensitivity in the hind paws of rats. Mustard oil applied topically
on the foot pad causes vasodilation and formation of an oedema with an associated short
lasting hypersensitivity due to the release of pro-inflammatory mediators from capsaicin-
sensitive sensory neurones (Jancso et al. 1967). Substance P injected into the plantar region
of the hind paw induces a dose related inflammation reaching a peak at 10 minutes and
declining after 60 minutes (De and Ghosh 1990). Similarly an intraplantar injection of
capsaicin causes pain-related behaviours such as guarding of the limb, licking of the paw and
an unwillingness to apply pressure to the foot, and an associated hypersensitivity to various
mechanical and thermal stimuli (Szolcsanyi et al. 1988; Gilchrist et al. 1996). Formalin and
carrageenan are also commonly used as inflammatory mediators in studies investigating the
mechanisms of action involved in acute inflammatory pain (Dubuisson and Dennis 1977;
Bland-Ward and Humphrey 1997; Guay et al. 2004).
Animal models similar in principle to the FCA-induced unilateral arthritis have been
used to produce a more persistent pain which has been likened to chronic pain observed in
human joint disease. The use of sodium iodoacetate as a blocker of the glycolytic energy
metabolism and synthetic processes in articular chondrocytes was first described over 20
years ago and produced osteoarthritic type reactions 2-4 months after a local injection in rats
(Kalbhen 1987). More recently intra articular injection of sodium iodoacetate into the knee
joint of rats has been validated as a model of OA, sharing many pathological changes that are
observed in human OA and a chronic degeneration of the joint (Kobayashi et al. 2003). The
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collagen induced arthritis model can be used in both mice and rats and provides an excellent
animal model of RA, as it shares both immunological and pathological features seen in the
human condition (Griffiths et al. 2007; Williams 2007).
1.5 Opioids
1.5.1 Opium alkaloids and morphine
Opium has been used in medicine for centuries and is obtained from the dried
powdered juice of the poppy plant, Papaver somnifrum containing over 25 alkaloids such as
morphine, codeine, thebaine and papaverine, which constitute its pharmacological activity.
The average quantities of the alkaloids present in opium vary dependent on the sample, but
the most abundant alkaloid is morphine, making up approximately 10% of the opium
(Reynolds and Randall 1957). The structure of morphine was first established following its
chemical synthesis in the mid-1900's (Gates and Tschudi 1952), although it was Serturner in
1803 who first isolated the drug and gave morphine its name, a derivative of the Greek god
of dreams, Morpheus. The pain relieving effects of the opioids, in particular morphine has
been exploited for thousands of years, although the associated side effects such as sedation
and nausea, together with the potential for abuse limit the clinical use of the drug. Despite
the potential for its illicit use, morphine and the opioids have remained in use for longer than
any other drug in history indicating its power as a strong analgesic, with the side effects
often accepted (Schlug and Gandham 2006). To date morphine is still the gold standard
opioid drug used in the treatment of severe pain.
1.5.2 The opioid receptor family
Binding assay work in the early 1970's using the opiate antagonist naloxone
demonstrated the existence of specific opioid receptors in the brains of mice, rats, monkeys
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and humans, with the distribution of the opiate-binding site being non-uniform (Kuhar et al.
1973; Pert and Snyder 1973; Simon 1973; Terenius 1973). Several classes of opioid receptor
were revealed through the use of novel alkaloids which were being synthesised by chemists
at the time (Martin et al. 1976). These results suggested the existence of three types of
receptor which were named mu, sigma and kappa after the drugs used in the studies. It is
now known that sigma is not an opioid receptor (Brownstein 1993) and has been replaced by
the delta opioid receptor which was described later (Lord et al. 1977). To date three major
opioid receptors, namely mu (p), delta (8) and kappa (k), have been described from
pharmacological studies, with the closely related opioid like receptor (ORL,) receptor also
mediating opioid like signals (Taylor and Dickenson 1998). Multiple p (Pasternak 1993), k
(Traynor 1989) and 8 (Traynor and Elliott 1993) receptor types have been proposed to exist
as potential splicing of the three receptor genes could lead to variants in the receptors.
The discovery of these receptors prompted the search for endogenous ligands acting
at any of these receptors. The pentapeptides met- and leu- enkephalin were the first
endogenous opioids to be purified and sequenced (Hughes et al. 1975; Kosterlitz and Hughes
1975). Many more peptides sharing the opioid N-terminal sequence YGGFL/M have been
purified from nervous tissue and the pituitary gland (for review see Akil et al. 1984). The
enkephalins, dynorphins and P-endorphin are the three well defined endogenous families of
opioid peptides. These peptides are produced in mammals from larger precursor protein
named proenkephalin, prodynorphin and proopiomelanocortin respectively (Nakanishi et al.
1979; Kakidani et al. 1982; Noda et al. 1982a; b). Opioid peptides are widely distributed in
the brain, with dynorphins and enkephalins occurring in the interneurons and descending
pathways from the brain to the dorsal horn in the spinal cord respectively. These peptides are
also produced by non-neuronal endocrine and exocrine glands such as the adrenal and
pituitary gland, and in cells of the immune system (Stein et al. 1990a; Przewlocki et al.
1992). The three genes encoding these proteins were cloned in the early 1980's with each
precursor giving rise to more than 20 opioid ligands (Takahashi et al. 1981; Comb et al.
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1982; Kakidani et al. 1982). These opioid ligands act as agonists on the p, 5 and k opioid
receptors with nanomolar affinities and preferential selectivity (Akil et al. 1998).
Opioid receptors belong to the G-protein coupled family being coupled to the
inhibitory Gj protein (Law et al. 2000) and through the inhibition of adenylate cyclase
activate inwardly rectifying potassium channels and inhibit voltage gated calcium channels
and hence decrease neuronal excitability (Bums et al. 1983). Traditionally the analgesic
effect of opioids was thought to be solely attributed to receptors present in the central
nervous system (Dubner and Bennett 1983; Basbaum and Fields 1984) with receptors being
expressed throughout the brain (Bodnar and Klein 2005). More recently opioid receptors
have been identified on peripheral nerve terminals in both rats and humans suggesting
systemically administered opioids can provide analgesia through peripheral opioid receptor
mediated effects (Stein 1995; Stein et al. 1996a). Immunostaining of small-diameter
unmyelinated fibres in subcutaneous paw tissue of the rat first revealed opioid receptors were
present in the periphery (Stein et al. 1990b).
1.5.3 Endomorphins
A new class of endogenous opioid peptides was recently discovered and isolated
from bovine brain tissue (Zadina et al. 1997). Endomorphin-1 and -2 (EMI and EM2) are
tetrapeptides which show the highest affinity and selectivity for the p-opioid receptor of any
mammalian peptide studied to date and have now been isolated from the human cortex
showing potent p-opioid receptor bioactivity including analgesia (Hackler et al. 1997; Stone
et al. 1997). EMI is 4000- and 15000-fold selective and EM2 is 13000- and 7500-fold
selective for p-opioid receptors compared to 8 and k, respectively. EMI is widely and
densely distributed throughout the brain in areas such as the parabrachial nucleus and the
nucleus of the solitary tract known to contain high densities of the p-opioid receptor (Martin-
Schild et al. 1999; Zadina et al. 1999). EM2 immunoreactivity is present in the amygdala,
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hypothalamus, lower brain stem and the terminal regions of the spinal cord (Martin-Schild et
al. 1997; Schreff et al. 1998; Wang et al. 2002; Wang et al. 2003) and in the capsaicin
sensitive, peptidergic C-fibre primary afferent fibres (Martin-Schild et al. 1998). Both EMI
and EM2 inhibited C-fibre evoked responses of dorsal horn neurones in a dose dependent
manner (Chapman et al. 1997) and show behavioural analgesic potency similar to morphine
(Stone et al. 1997; Goldberg et al. 1998).
As well as mediating an analgesic effect, EMI and EM2 act through the p-opioid
receptor to cause a decrease in heart rate, cardiac output and total peripheral resistance in the
rat, leading to a decrease in systemic arterial blood pressure (Wood and Traynor 1989;
Champion et al. 1997a; Czapla et al. 1998). Vasodilation in the rat hindquarters and a
decreased blood flow in the knee joint suggest that EMI and EM2 play an active role in the
periphery (Champion et al. 1997b). Both EMI and EM2 have been identified in the rat and
human spleen (Jessop et al. 2000) and more recently macrophages and B cells (Seale et al.
2004). Evidence suggests that the endomorphins may play an integral role in controlling pain
as a result of inflammation.
1.5.4 Opioid mediated analgesia
Clinicians are aware that patients display a wide range of responses when given
opioids for the treatment of pain, and different doses are required to achieve the optimum
response because individuals' sensitivity to the opioids is highly variable. Often in clinical
practice a trial and error approach has to be adopted as in some cases patients will report one
opioid is efficacious whereas another will provide no pain relief irrespective of the dose
(Cherny et al. 2001). Suggestions as to why these variations exist include patients having
genetic variation leading to differences in the availability of differently spliced opioid
receptors and potential differences in pharmacogenetic factors regulating the transport of the
receptors from the cell bodies to the target tissues (Kalso 2005). The prescribing of opioids
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such as morphine and fentanyl is an established treatment route for patients with cancer and
in palliative care settings (WHO, 1996). Guidelines for the use of such opioids in the
treatment of pain in chronic non-cancer pain have been suggested with the aim of improving
the patients' quality of life (Kalso et al. 2003). The appropriate and responsible prescribing
of opioids has been the subject of considerable debate (Portenoy 1996b; Breivik 2003), with
clinicians often keen to avoid the controversies and side effects associated with chronic
opioid use such as addiction and tolerance (Portenoy 1996a; Breivik 2005). However, trials
do exist reporting the long term safety and efficacy of taking opioids in randomised placebo-
controlled trials. A systematic review in 2004 reported that the mean decrease in pain
intensity in patients using opioids was 30%, yet only 44% were still using opioid therapy 7 to
24 months later, and just a minority of patients went on to use opioids as a form of long-term
pain management (Kalso et al. 2004). Titration of remifentanil (an ultra-short acting p-
agonist) against analgesia has been suggested as being a quick procedure to determine if a
non-cancer patient is likely to respond to opioid treatment, and may provide a novel routine
aiding the clinician in the decision of whether or not to prescribe opioids (Gustorff 2005).
1.5.4.1 Adverse side-effects of opioids
Physical and psychological dependence of opiates is displayed by a compulsive use
of the drugs to the detriment of the user's physical and psychological health with hoarding
and illegal acquisition of the drugs being common. In the clinic it has been suggested that
addiction should be defined as a psychological and behavioural condition characterised by
compulsive drug use and a loss of control, despite the drug causing more harm than good
(Portenoy 1994). The increase in opioid drug abuse was highlighted by Gilson et al. in a
2004 review of five commonly prescribed opioids in which cases of abuse rose to 646% and
113% in the cases of fentanyl and morphine respectively (Gilson et al. 2004). Awareness and
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guidelines in selecting patients to be treated with opioids are therefore very important
(Portenoy 1996a; b).
Addictive drugs are thought to hijack the neural systems controlling the reward
centres that evolved to mediate behaviours normally associated with food, water and sex
(Hunt and Urch 2006). Three main theories for the reason of addiction have been proposed; a
failure of the body to return to homeostasis following prolonged exposure and stimulation
(Koob and Le Moal 1997), behavioural sensitisation leading to a craving of the drug
(Robinson and Berridge 2003) and aberrant memory and learning mechanisms coming into
play that establish abnormal drug habits (Berke and Hyman 2000). The neurobiology of drug
addiction is not thoroughly understood but is thought to involve the mesolimbic and
dopaminergic pathways, with the amygdala, ventral striatum and ventral tegmental area of
the brain all being important.
Tolerance to opioids is seen in animals and humans (Collett 1998). The development
of a tolerance to some of the side-effects of opioids such as nausea and vomiting may occur,
although it is never seen in regards to constipation. Tolerance to the analgesic component of
opioids is far more controversial with the need to increase doses over time to achieve similar
efficacy. Many patients treated for either cancer or non-cancer related pain can achieve a
stable dose of a specific opioid without requiring an escalating need for the drug (Glynn and
Mather 1982; Portenoy and Foley 1986), and only increase their dose in response to
increased pain (Chapman and Hill 1989). For patients showing a disposition to tolerance,
rotation of the opioid preparations taken could remove the need to raise the doses and lead to
better management of a potential tolerance to the drugs (Fallon 1997; Twycross 1998).
As well as exhibiting properties of addiction and tolerance, opioids can produce
multiple adverse side-effects such as nausea and vomiting, constipation, respiratory
depression, sedation, hallucinations and pruritus (Schug et al. 1992; Lawlor and Bruera
1998). These effects are variable from patient to patient and are dependent on the route and
speed of administration, progression and severity of the pain, interactions with other drugs
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the patient is taking and the patient's emotional status. Of particular concern are respiratory
depression and constipation. Respiratory depression is the most common cause of opioid
related death and older patients and those with underlying respiratory disease are most at risk
(Schug et al. 1992). Constipation is the most commonly occurring side effect and although
not life threatening can be really uncomfortable. Activation of opioid receptors in the bowel
leads to decreased peristalsis, increased sphincter muscle tone and decreased intestinal
secretions. Extreme forms of constipation can present themselves in the form of narcotic
bowel syndrome (Sandgren et al. 1984). Recent studies using peripherally restricted opioid
antagonists have tried to eradicate this problem without compromising the centrally mediated
analgesic effects (Choi and Billings 2002; Kurz and Sessler 2003).
At this stage it is important to note that the majority of these side effects appear to be
centrally mediated and as the focus of this thesis is the peripheral mechanisms of opioids
then they shall be discussed no further. A review of the neurobiology involved in these side
effects can be found in Wall and Melzack's textbook of pain (Hunt and Urch 2006; Schug
and Gandham 2006) and (Bodnar and Klein 2005).
1.5.5 Opioids and inflammation
1.5.5.1 Opioid receptors in the periphery
Up until the late 1970's the belief was that the antinociceptive effects of opiates
operated solely through the activation of centrally located opioid receptors. These receptors
are made in the DRG, and it is perhaps not surprising that they can be transported to the
peripheral sensory nerves as well as central terminals. Multiple opioid receptors have been
shown to exist on primary afferent nerves (Fields et al. 1980; Stein et al. 1990b; Hassan et al.
1993; Coggeshall et al. 1997). Various animal behavioural tests were performed throughout
the 80's showing that peripherally-administered or restricted opioid antagonists could
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attenuate pain related behaviours that were in turn antagonised by naloxone (for review see
Stein 1991). Intra-plantar injection of p, S and k receptor agonists produced an increase in
the paw withdrawal threshold from a mechanical stimulus in an acute model of FCA-induced
footpad hypersensitivity in rats, interestingly this increase was only observed in inflamed
paws and not normal paws (Stein et al. 1989). Notably, opioid receptors have been shown to
be functional in the knee joint of both rats and humans in inflammatory conditions (Stein et
al. 1990a; Stein et al. 1996a).
1.5.5.2 Peripherally mediated analgesia in inflammatory joint pain
Evidence began to build that peripherally administered opioids produced analgesia
in inflammatory conditions (Ferreira and Nakamura 1979; Joris et al. 1987; Stein et al.
1988a; b; c). In the clinic, patients suffering from inflammatory joint diseases such as OA
and RA were receiving effective analgesia from morphine injected directly into the knee
joint without suffering the centrally mediated side-effects. Moreover the analgesia lasted for
weeks after a single injection (Stein et al. 1991; Joshi et al. 1993; Stein 1995; Likar et al.
1997; Stein et al. 1999).
Rat models of acute inflammation show that there is an enhanced axonal transport of
the p-opioid receptor from the DRG to the inflamed tissue (Hassan et al. 1993; Ji et al.
1995), resulting in an up-regulation of the receptor at peripheral nerve terminals (Stein et al.
1990b). Furthermore an up-regulation in the p-opioid receptor mRNA present in DRG tissue
following rat hind-paw inflammation can be seen (Zhang et al. 1998). A recent study
suggests that p-opioid receptors are in fact down-regulated at the site of inflammation (Li et
al. 2005) as the receptors are being transported to the periphery and the receptor production
in the DRG is not increased (Schafer et al. 1995). This appears to contradict both a previous
chronic inflammation study in rats where the p-opioid receptors were up-regulated following
systemic FCA administration (Ballet et al. 2003), and the clinical efficacy of intra-articular
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morphine in humans with RA, as described above. The effect of inflammation on the 8 and k
opioid receptors is less well investigated, with some reports suggesting that the S-opioid
receptors are either down-regulated or appear to remain unchanged in DRG of rats following
acute, adjuvant-induced inflammation (Ji et al. 1995; Maekawa et al. 1996). In contrast the 5-
opioid receptor has been seen to be up-regulated in a chronic model of FCA-induced
inflammation suggesting the changes in the expression of the opioid receptor are determined
by the stage of inflammation, during the transition from acute to chronic inflammatory pain
(Cahill et al. 2003). Several studies investigating peripherally restricted opioid agonists have
revealed analgesic effects mediated through all three of the opioid receptors (DeHaven-
Hudkins et al. 1999; Machelska et al. 1999; Wu et al. 2006).
1.5.5.3 Inflammatory cells
Following tissue injury or an inflammatory insult, immune cells such as the
leukocytes infiltrate the tissue as described in section 1.3.2. These cells release endogenous
opioids, such as P-endorphin, in response to EL-ip and corticotrophin releasing hormone
present at the site of inflammation (Cabot et al. 1997; Cabot et al. 2001). Small inactive
cytokines, injected into the footpad of rats elicited opioid release even in the absence of
injury or inflammation (Schafer et al. 1994; Schafer et al. 1996; Machelska and Stein 2002).
It appears that intrinsic pain inhibition is proportional to the number of invading leukocytes
(Rittner et al. 2001) and blocking the infiltration of these cells reduces the peripheral pain
control (Machelska et al. 1998; Machelska et al. 2002). In rats it appears that in the first 48
hours post-inflammatory insult, the opioid mediated analgesia is critical on the recruitment
of leukocytes via a cytokine mediated process and the presence of receptors at the site of
injury (Brack et al. 2004a; b). With EMI and EM2 recently being shown to appear in
inflammatory cells (Jessop et al. 2000; Seale et al. 2004) it appears that the body has an
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endogenous opioid mechanism for helping control pain at sites of inflammation and injury in
the periphery.
1.6 Voltage gated sodium channels (VGSCs)
1.6.1 The sodium channel family
Thermal, mechanical and chemical stimuli are detected in the periphery by sensors
and an excitatory action potential is transmitted to the dorsal horn of the spinal cord
conveying the information. This process is mediated in part through voltage gated calcium
and potassium channels, but mainly through VGSCs as they are responsible for the initial
depolarisation of the membrane (Hodgkin and Katz 1949; Hodgkin and Huxley 1952a; c).
To date, nine different sodium channel isoforms with corresponding genes have been
discovered in mammals (Goldin et al. 2000). A nomenclature system based on that used for
voltage gated potassium channels (Chandy 1991) has been adopted and is now the most
commonly used. This system classifies the channels as Navl-1 through to Navl-9. All these
channels have been identified as having greater than 50% homology in amino acid sequence
(Goldin et al. 2000). Sodium channels comprise an alpha subunit and several supporting beta
subunits. The alpha subunit consists of four homologous domains each containing six
transmembrane segments and is approximately 2000 amino acids long (Catterall et al. 1986).
The alpha subunit contains the pore forming structure, an ion selectivity filter, an
inactivation loop and the voltage sensing machinery, thus a single alpha subunit constitutes a
functional VGSC (Catterall 2000). The beta subunits target and anchor the alpha subunit to
specific sites on the plasma membrane and modulate gating properties (Isom 2001).
The VGSCs have also been further sub-divided into two general groups one in which
the channels are blocked by tetrodotoxin (TTX-sensitive, TTX-S) and the other where the
channels are resistant to TTX (TTX-resistant, TTX-R). Navl.l, Nav1.2, Nav1.3, Nav1.4,
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Nav1.6 and Nav1.7 all generate the TTX-S component sodium current (Rush et al. 1998).
These TTX-S channels are blocked by TTX in the nanomolar range, have low thresholds of
activation and are both rapidly activated and then inactivated. The TTX-R channels Nav1.5,
Nav1.8 and Nav1.9 tend to have high thresholds of activation, that are slow to activate and
then subsequently inactivate (see Blair and Bean 2002 for review). VGSCs are differentially
expressed throughout various subpopulations of sensory neurones with Navl-6 and Nav1.7
being present in virtually all sensory neurones in rats (Black et al. 1996). Navl-3 and Nav1.5
are expressed at high levels in embryonic sensory neurones but very low levels in adult,
suggesting these channels have an important developmental role (Waxman et al. 1994;
Renganathan et al. 2002). Unmyelinated sensory C-fibres all express Nav1.7, with Nav1.9
being associated exclusively with these nociceptive neurones (Fang et al. 2002; Djouhri et al.
2003b). Both Nav1.8 and Nav1.9 are present in most but not all nociceptors (Fang et al.
2002; Djouhri et al. 2003a). During an FCA-induced rat model of inflammatory pain the
sodium channels collectively are dramatically increased up to two months after subcutaneous
injection of the adjuvant into the hind-paw (Gould et al. 1998).
1.6.2 Role of sodium channels in inflammatory joint pain
1.6.2.1 Nav1.7
Recent clinical studies have provided convincing evidence that Nav1.7 plays a
crucial role in the detection of pain and pain sensitivity. Families suffering from congenital
indifference to pain (CIP), a condition characterised by an absence in the ability to sense
pain, all suffer from a mutation in the SCN9A gene that encodes Nav1.7 that leads to a
complete loss of functionality of the channel (Cox et al. 2006; Fertleman et al. 2006; Ahmad
et al. 2007). Conversely paroxysmal extreme pain disorder (Fertleman et al. 2006) and
inherited erythromelalgia (Lee et al. 2007) are two autosomal dominant pain conditions
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where point mutations in the SCN9A gene cause hyperpolarising shifts in the voltage
dependence of activation of the channel leading to increased neuronal excitability. These
mutations cause severe rectal and facial pain, and chronic burning sensations in the hands
and feet in the respective conditions.
An increase in Nav1.7 mRNA and protein levels are observed as a result of exposure
to nerve growth factor (Toledo-Aral et al. 1995) and carrageenan in rats (Tanaka et al. 1998;
Black et al. 2004). Knockdown of the channel in a predominantly nociceptive population of
mice DRG neurones reduces both acute and chronic pain behaviours (Nassar et al. 2004;
Yeomans et al. 2005). Following an intra-plantar injection of FCA in rats, the labelling of
Nav1.7 in L4-S1 DRG neurones 24 hours post-FCA injection was significantly increased
(Gould et al. 2004). A study evaluating the expression of the channel in painful human teeth
revealed a dramatic increase in Nav1.7, contributing to spontaneous pain and increased pain
levels experienced in dental disease (Sorensen et al. 2003). Trafficking of these functional
Nav1.7 channels into the nociceptive membrane could account for a portion of the increased
neuronal excitability following inflammatory injury (Wada et al. 2004).
1.6.2.2 Nav1.8
The role of Nav1.8 in chronic inflammatory pain has been extensively studied in rats
with rapid upregulation commonly seen in the early stages of inflammation following
various inflammatory insults such as carrageenan, (Black et al. 2004), FCA (Gould et al.
2004) and prostaglandin E2 (Villarreal et al. 2005). In particular Nav1.8 has been implicated
in the maintenance of inflammatory pain as there is a significant increase in channel mRNA
in the DRG tissue of male Sprague-Dawley rats, four days after carrageenan injection
(Tanaka et al. 1998). The increase in channel expression is associated with re-distribution of
the channels to peripheral nerve terminals as FCA-induced inflammation results in an
increase in the amount of Nav1.8 channels observed in peripheral axons (Coggeshall et al.
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2004). Nav1.8 knockdown mice have reduced pain behaviours following a peripheral
inflammatory insult (Khasar et al. 1998; Joshi et al. 2006) and Nav1.8 null mutant mice show
a delayed hypersensitivity following inflammatory insult (Akopian et al. 1999). Modulation
of this channel by inflammatory mediators has also been shown to increase the magnitude of
the Nav1.8 current by increasing activation and inactivation rates and thus increasing
neuronal excitability (Gold et al. 1996). Examples of this modulation have been shown to be
caused by protein kinase A (Fitzgerald et al. 1999), PGE2 (England et al. 1996) and
endothelin-1 (Zhou et al. 2002).
With the majority of studies showing elevated levels of Navl-8 that do not return to
pre-insult levels, it has been speculated that the channel plays a key role in the maintenance
seen in chronic inflammatory pain signalling in rodents. This makes the channel a desirable
target for novel analgesics, as prophylactic administration of channel blockers preventing the
establishment of inflammatory pain in the first place is an unachievable prospect. Intrathecal
administration of the jaO-conotoxin peptide MrVIB taken from cone snail attenuated the
reduction in thermal and mechanical paw withdrawal thresholds following intra-plantar FCA
injection in male rats (Ekberg et al. 2006). Interestingly, MrVIB was shown to protect rats
against acute post incisional pain when injected into the footpad prior to making the incision
suggesting the channels may also play an important role in the establishment of
inflammatory pain (Bulaj et al. 2006). The molecule A-803467 is a potent and selective
inhibitor of Navl-8 channels that showed significant efficacy in reducing both mechanical
and thermal hypersensitivity in rats subjected to a range of acute inflammatory insults (Jarvis
et al. 2007).
1.6.2.3 Nav1.9
There are limited studies describing the role of the Nav1.9 channel in inflammatory
pain conditions, and those that do exist provide conflicting data as to whether the channel is
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up-regulated, down regulated or unchanged during the typical inflammatory insults. In rats,
inflammation induced an up-regulation in Nav1.9 mRNA seven days after an FCA insult
(Tate et al. 1998), whereas Black et al. (2004) report no change in the expression of Nav1.9
mRNA and protein in DRG four days after an intra-plantar carrageenan injection.
Furthermore a decrease in the expression of the channel on primary afferent nerves in rats
two days after FCA-induced inflammation has been described (Coggeshall et al. 2004).
Nav1.9 null mutant mice have been developed that show reduced sensitivity to the
inflammatory mediators FCA, prostaglandin E2 and carrageenan (Amaya et al. 2006).
Studies using these mice revealed that the channel contributes to the persistent thermal
hypersensitivity and spontaneous pain behavior seen following peripheral inflammation
(Priest et al. 2005).
1.7 Aims of the thesis
The primary aim of this thesis was to test the hypothesis that functional opioid
receptors are present in the periphery during a model of FCA-induced joint inflammation,
and to subsequently determine whether EMI is an effective treatment for the chronic pain
associated with the inflammation. A secondary aim, undertaken during my placement at
GlaxoSmithKline, was to investigate how the expression of VGSCs change during the
development and subsequent maintenance of chronic inflammatory joint pain, concentrating
on Nav1.7, Nav1.8 and Navl-9, due to their high levels of expression on nociceptive
afferents. In each case a combination of techniques including, in vivo electrophysiology,
behavioural studies and immunohistochemistry were used to elucidate the role that the
receptors and channels play in establishing a chronic joint hypersensitivity.
Additionally a new piece of laboratory equipment capable of measuring primary
mechanical hypersensitivity of both the rat and mouse knee joint was developed and
validated as a novel behavioural readout for assessing experimental joint pain.
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2.1 Animal models of experimental arthritis
2.1.1 Animals
All experimental procedures described in this thesis were carried out in accordance
with the regulations and guidelines of the scientific procedures act (1986). Work was
performed under the personal licence PEL 60/9547 and the UK Home Office project licences
PPL 80/02019 at GlaxoSmithKline and PPL 60/2750 (Nov 04 - Aug 05) and PPL 60/3496
(Aug 05 onwards) at the University of Edinburgh unless stated otherwise.
402 male Wistar rats (Charles River, UK) and 24 male C57 Black-6 mice (C57BL/6,
Charles River, UK) were used in all the studies reported. Rats were housed in groups of a
maximum of 6 animals and mice in groups of 4 under a 12-hour light/dark cycle with free
access to water and standard animal feed. Animals were acclimatised for at least 5 days
following arrival prior to commencing experimental studies.
Endeavours were made throughout all studies to fulfil the 3R Home Office
guidelines of refining experimental design and techniques to minimise animal distress and
reducing the total number of animals used.
2.1.2 FCA-induced unilateral arthritis of the rat knee joint
A unilateral knee joint arthritis was induced in the left (ipsilateral) knee joint of adult
male Wistar rats (150-200g) by an intra-articular injection of Freund's complete adjuvant
(FCA, lmg.mf1 Mycobacterium tuberculosis suspended in heavy liquid paraffin oil with
Monooleate adjuvant, Sigma, UK). All rats were transiently anaesthetised using 3%
isoflurane in oxygen and had their left knee shaved and cleaned using a dilute Hibiscrub
solution. Rats were then injected with 150pl of FCA into the knee joint space using a 29-
gauge needle (BD Microfine, USA). The patella tendon was used to orientate the needle with
the injection site. Animals were allowed to recover from anaesthesia before being returned to
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their cage. Following FCA injection the animal's mobility and general behaviour was
observed and body weights were recorded to ensure the general health of each animal was
not compromised as a consequence of the injection. Rats receiving the injection of FCA are
defined throughout this thesis as FCA-injected, with animals receiving no injection being
termed naive.
Trial injections using the dye Evans Blue (Sigma, UK) were performed on cadavers
prior to any studies taking place to ensure 150/rl of FCA could be injected into the knee joint
cavity without visible leakage.
2.1.3 FCA-induced unilateral arthritis of the mouse knee joint
A unilateral knee joint arthritis was induced in the left (ipsilateral) joint of adult
male C57BL6 mice (23-28g) by an intra-articular injection of FCA (lmg.mT1,
Mycobacterium tuberculosis, Sigma, UK). Mice were transiently anaesthetised using 3%
isoflurane in oxygen and a small incision was made over the left knee joint which enabled
the patella tendon to be visualised. Mice were then injected with 20pl of FCA directly into
the joint space of the knee joint with the 30-gauge needle (BD Microfine, USA) mounted on
a 50pl Flamilton syringe passing through the patella tendon. Naive animals were untreated.
Animals were allowed to recover from anaesthesia before being returned to their cage.
Following FCA injection the animals' mobility and general behaviour was observed by the
licensee and the named animal care welfare officer and body weights were recorded to
ensure the general health of each animal was not compromised as a consequence of the
injection.
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2.2.1 Assessment of weight distribution
An evaluation of how the animals distribute their weight across the hind limbs when
standing was measured using either a rat or mouse incapacitance tester (Linton Instruments,
UK). The apparatus comprises two force transducers mounted side by side, capable of
measuring the downward force placed through them over a set period of seconds (see Figure
2.1). Animals were placed in a Perspex holding box with each hind limb centred on a
transducer platform. The force placed through each transducer was recorded over a 3 second
period (Clayton et al. 1997). The 'weight' carried by the FCA-injected ipsilateral limb was
divided by that carried by the un-injected contralateral limb to provide a weight distribution
(WD) ratio. A ratio of 1.0 resulted when the animal distributed its weight equally across both
hind limbs, as occurs in naive animals.
Position of fore paws
Perspex holding box
I
Position ofhind paws on the two
separate force transducers
Figure 2.1 Photograph of the rat incapacitance tester used to assess the weight distribution of rats. An
identical device but with a smaller Perspex holding box and smaller force transducers was used for
measurements in murine studies.
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2.2.2 Assessment of limb withdrawal threshold
Animals were lightly but securely held by a colleague and a gradually increasing
squeeze was applied across the knee joint between the thumb unit and forefinger of the
operator. At the point the force applied across the knee became noxious, the animal
withdrew its leg from the stimulus and this was the test endpoint. Very rarely the animal
vocalised before withdrawing from the apparatus and on these occasions vocalisation was
taken as the test endpoint. The maximum force (gf) applied across the joint was
automatically recorded on the digital display and noted as the limb withdrawal threshold
(LWT). Ipsilateral and contralateral LWTs were taken for each animal with the ipsilateral
limb being measured first and the contralateral limb acting as the internal control. The FCA-
injected ipsilateral LWT was divided by the un-injected contralateral LWT to give a PAM
withdrawal threshold ratio.
The full details of the development and validation of the PAM device for use in both
rats and mice is covered in Chapter 5 of this thesis.
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l sf
: MENU CONTROL >
, STEP I BACK SELECT / CONFIRM
P.A.M









Figure 2.2 Photograph of the PAM device used to assess the limb withdrawal threshold of rats when a
localised pressure was manually applied across the knee joint. The same base unit was used but with a
smaller (in diameter) force transducer connected when assessing the limb withdrawal threshold of
mice.
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2.2.3 Assessment of inflammation induced by FCA
A single measurement of the joint diameter of both the ipsilateral and contralateral
knee was measured before and then at 24 hours and subsequently on selected days post-FCA
injection using a hand held digital micrometer (Mitutoyo, Japan; see Figure 2.3). The
diameter of the ipsilateral joint was expressed as a ratio of the contralateral joint diameter.
Figure 2.3 Photograph of the digital micrometer used to measure the knee joint diameter of both rats
and mice.
2.3 Recording electrical activity from the primary afferent neurons
innervating the knee joint
2.3.1 Anaesthesia and general surgical procedures
Extracellular neuronal recordings were made in vivo from the MAN of the left knee
joint in both naive and FCA-injected rats. Initially rats were anaesthetised with pentobarbital
sodium (60mg.mr1, i.p.). The animal was laid on its back on a heating blanket and a
thermistor probe was inserted into the rectum. The heating blanket was homeostatically
controlled to maintain the animal's core body temperature at 37°C (Harvard Apparatus
Limited, UK). Before any surgical procedures began, and at regular intervals throughout
surgery, forceps were used to pinch the footpad of the hind-paw to ensure the animal was at
a suitable level of anaesthesia, determined by the lack of a reflex limb withdrawal.
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Once fully anaesthetised animals had their trachea intubated to facilitate breathing
and allow artificial ventilation (Ventilator, 50-1718, Harvard Apparatus Limited, UK) if
required (see Figure 2.4). In order to monitor the arterial blood pressure (B.P.), the right
carotid artery was cannulated (outer diameter of cannula = 0.75mm) and linked to a
Maclab/4S (AD Instruments, UK) through a pressure transducer (Bell and Howell, UK) so a
live B.P. trace was displayed and recorded by the program Chart v.5 using an Apple Mac.
The right femoral artery and vein were cannulated to allow test drugs and anaesthetic
to be administered throughout the experiment. The arterial cannula (outer diameter of
cannula = 0.75mm) was inserted into the lower part of the descending aorta, above the
femoral bifurcation so that following intra-arterial (i.a.) drug delivery normal blood flow
would carry the drug to the left hind-limb. The right femoral vein was cannulated (outer
diameter of the cannula = 0.63mm) to allow a continuous infusion of pentobarbital (325pl.hr"
') diluted to 40% in saline (24mg.mr'). The B.P. was recorded for the duration of each
experiment and was ideally maintained at around 130/90mmHg. If the systolic blood
pressure dropped below 80mmHg and could not be recovered by turning off the infusion of
anaesthetic then the experiment was not analysed beyond that point.
2.3.2 Peripheral nerve dissection - the medial articular nerve (MAN)
Once the general surgical procedures had been performed and blood pressure and
anaesthesia was stable, the peripheral nerve was dissected. To achieve this, the left hind limb
was fixed in plaster of Paris to a brass support plate held fast in a stand and clamp
arrangement. An incision was made in the skin around the medial aspect of the knee to
produce a circular well of approximately 25mm in diameter where the MAN could be seen to
branch at 90° towards the knee away from the saphenous nerve. A circular well was formed
using thread to stitch the exposed edges of the skin to a brass ring held on the stand and
clamp. The pouch was filled with heavy liquid paraffin (HLP, Sigma UK) oil to create an
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electrically isolated system (see Figure 2.4). The saphenous nerve was cut proximally to
eliminate any descending efferent neural activity from the recording and input from skin
afferents was removed by separating the skin and overlaying connective tissue from the
tissue surrounding the knee joint using blunt forceps. The MAN was carefully dissected out
from the surrounding tissue using fine forceps and was cleaned and the whole nerve was
placed over the platinum/iridium wire electrodes (Pt90/Irl0, 0.125mm, Goodfellow, UK)






Foot plastered rigid to clamp












Rectal thermistor — Linked
to homeostatic heat pad
Figure 2.4 Photograph of an anaesthetised rat in a typical experimental setup for recording the
neuronal activity of the afferents of the MAN innervating the rat knee joint. The left hind-paw was
fixed to a solid brass platform using plaster of Paris to enable a stable recording to be taken.
2.3.3 Single electrode recording from the MAN
The afferent activity of the whole MAN was recorded as the potential difference
between the two platinum/iridium wire electrodes across which the nerve was placed. The
raw electrical signal was passed from the electrode into the head-stage (Digitmer Ltd., UK)
and then onto an AC pre-amplifier (Neurolog NL104, Gain = 20,000, Low Pass = 0.1Hz).
The signal was filtered (10Hz - 1000Hz bandwidth; Neurolog, NL115), displayed on an
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oscilloscope (DL1540C, YokoGawa, Japan) and connected to a loud speaker (audio amp,
Neurolog NL120). Finally the neural signal was digitally processed by a Micro 1401 MKII
interface (Cambridge Electronic Design, UK) connected to a personal computer running
Spike 2 software (CED, UK; version 5.01, see Figure 2.5 for summary of the signal
processing). Events or tests were marked on the recording as text on the trace, and drug
delivery and test points were noted using these keyboard markers, as well as in an
experimental laboratory book. Data files were saved and later analysed offline following the
completion of the experiment. A typical in vivo electrophysiology recording was conducted







Figure 2.5 A schematic diagram showing how the raw neuronal signal from the MAN was collected,
processed, digitised and then stored on a PC.
2.3.4 Spontaneous neural activity
The spontaneous activity of the afferents in the MAN bundle was measured in the
first instance during the first 600s of each experiment, and for a period of 10s before any
mechanical stimulation or drug administration (sees Figure 2.6). Spontaneous activity was
measured as both the absolute number of action potentials (A.P.) and the action potential
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2.3.5 Drug administration
Drugs were administered close to the knee joint in a volume of lOOpl via the cannula
in the right femoral artery and immediately flushed with 200pl of saline. The latency (sec)
from the drug injection to the commencement ofneuronal discharge and the duration (sec) of
the firing were both measured. The effect of the drug was expressed as the change in either
the absolute number of A.P. or the action potential frequency (impulses.s"1), between that of
the test period and the spontaneous period.
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Figure 2.6 Screenshot from Spike2 of a raw filtered neuronal trace from the MAN and the responses
during a typical set of mechanical stimulations using the lg, 7g and 21g von Frey filaments.
Spontaneous activity was measured for a 10s period before each individual hair was applied for 10s.
The identification of individual units is shown in Figure 2.7.
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2.3.6 Mechanical activity
Mechanical stimuli were applied to the surface of the knee joint exposed within the
pouch using von Frey filaments (VFF, Stoelting, Scientific Marketing Associates, UK). A
specific spot within the receptive field of the MAN, which was not directly over the nerve
and would not disturb the nerve, was marked as the test location to ensure accurate repeat
applications of the filaments. Filaments of 1, 7 and 21g were applied to the joint capsule to
the point where the filament began to bend, at this time the applied force per unit area would
be 14mN, 98mN and 255mN respectively. The filaments were applied by hand perpendicular
to the knee in ascending order for a test period of 10s with a 10s break in between each test
(see Figure 2.6). The effect of each individual filament was measured as the change in either
the absolute number of action potentials or the action potential frequency (impulses.s"1),
between that of the test period and the preceding ten seconds.
2.3.7 Identification of nerve fibre types
Tests were performed at the end of each experiment to identify the fibre types
observed throughout the experiment. In order to classify the fibres as being C-fibre a
constant voltage isolated stimulator (Digitimer Ltd., UK) was used to apply an electrical
stimulus within the receptive field. A series of ten single square wave pulses (1-40V at 1Hz
at 0.16-1.6ms) were delivered by a stimulating electrode which was positioned at a known
distance from the recording electrodes. The distance between the stimulating and recording
electrodes was divided by the latency of response to calculate a conduction velocity (m.s"1).
As the stimulating electrode was placed so close to the recording electrodes within the
boundaries of the receptive field (typically 8-12mm apart) only C-fibres could be identified
as faster fibre responses were lost in the stimulus artefact. C-fibre responses were defined as
those occurring 10-120ms after the electrical stimulus (conduction velocity of cl.5m.s~1).
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Capsaicin (3-30pg.mT ) was injected i.a. to help classify the fibre types in terms of
being either positive or negative for the ion channel TRPV1, therefore allowing the fibre to
be categorised as a polymodal nociceptive C-fibre.
2.3.8 The sorting of the neuronal signal into individual units using Spike 2
The raw filtered neuronal trace was saved to PC and analysed offline using the
Spike2 V.5.01 software. A trigger level was set on the original trace to discriminate the
spontaneous, mechanical or drug induced action potentials from the noise band (see Figure
2.7a). The experiment was then analysed from start to finish identifying any units of the
same size and shape, if eight or more were identical then a waveform template for that unit
was produced. Throughout the experiment several waveform templates were identified (see
Figure 2.7b). The original neuronal trace was then re-scanned and the units corresponding to
the different waveform templates were highlighted in different colours and separated into
individual traces (see Figure 2.7c).
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Figure 2.7 Screenshots from Spike V.5.01 software analysis on one mechanical application of the
VFF for a period of approximately 10 seconds, a) The original neuronal trace (lower trace, in green)
had a trigger level set to differentiate the action potentials from the background noise (top trace, in
black), b) In this example two waveform templates were created from the two different units firing in
response to the VFF application. Template 01 shows the waveform of a unit which fires 1551 times
during this experiment (blue). The original neuronal trace was then re-scanned and the units
corresponding to the different waveform templates were highlighted in different colours and separated
into two individual traces c).
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2.4 Immunohistochemistry (IHC)
2.4.1 Retrograde labelling of the DRG using Fast Blue
The protocol for using the dye FB as a retrograde tracer to label knee joint afferent
L3-L5 DRG had been established in house at GlaxoSmithKline by Dr. Jo C. Martindale, and
has also been used to study TRPV1 receptor expression (Fernihough et al. 2005). Animals
were transiently anaesthetised using 3% isoflurane in oxygen, and the left (ipsilateral) knee
joint was shaved and cleaned using a dilute Flibiscrub solution. Using a 30-gauge needle (BD
Microfine, USA) attached to a 100/u.l Hamilton syringe; 10/xl of 2% FB (Illing Plastics,
Germany) was injected into the joint space of the left knee. Animals were allowed to recover
from anaesthesia before being returned to their cage, which was layered with soft paper
bedding. Trial injections were performed on cadavers prior to the study to ensure that 10/xl of
FB could be injected into the knee joint cavity without visible leakage, minimising the
chance that afferent cell bodies surrounding the knee would be falsely labelled.
2.4.2 Tissue processing and sectioning
Animals were killed using a rising concentration of C02 followed by cervical
dislocation. Ipsilateral DRGs were removed from levels L3, L4 and L5 and rinsed in
phosphate buffered saline (PBS). In some cases lumbar spinal cord and brains were also
removed from the animal. DRGs were immediately embedded in optimum cutting
temperature (OCT, TissueTek, Canada) compound and snap frozen in isopentane cooled on
dry ice. DRGs were wrapped in tin foil and carefully labelled before being stored at -80°C
until they were sectioned.
Frozen DRGs were mounted on a chuck using OCT and sectioned using a Leica
CM3050S cryostat. Sections were cut (12/rm) and thaw-mounted in series on 10 slides
(Superfrost Plus Gold, Menzel-Glaser, Germany) with each slide containing 5-8 sections at
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different levels throughout the DRG. Slides were carefully labelled and stored in the dark at
-80°C.
2.4.3 Immunohistochemistry
Sections of DRGs were prepared as previously described. Slides were removed from
the freezer and allowed to air dry in the dark for one hour. Sections were then fixed in 4%
paraformaldehyde (PFA) for 30 minutes. Slides were twice washed for five minutes with
PBS to remove any excess PFA. The tissue sections were covered for one hour in a non¬
specific blocking solution of 10% normal goat serum, 10% bovine serum albumin and 80%
PBS. Sections were then labelled with a specific primary antibody diluted in blocking
solution and left overnight in the dark at 4°C. Additional sections were incubated with
blocking solution with the omission of the specific primary antibody to act as a negative
control.
Slides were removed from the refrigerator and sections were washed three times
with PBS, each wash lasted five minutes. Tissue sections were covered in the appropriate
secondary antibody, diluted to 1:200 in PBS, and left in the dark for two hours at room
temperature. Sections were washed a further three times in PBS and covered by a coverslip
using Citifluor solid mounting kit (CFPVOH and AF100, Citifluor, UK). Slides were left at
room temperature to air dry, before being stored in the refrigerator prior to analysis by
microscopy.
2.4.4 Antibody work-up and positive controls
Prior to commencing the TRPV1 and sodium channel IHC studies, antibody work¬
up was performed by investigating a range of primary antibody concentrations in order to
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establish the optimum concentration of the TRPV1 and sodium channel primary antibodies
to achieve the best signal to background fluorescent signal.
2.4.5 Sodium channel immunohistochemistry
The primary antibodies used were affinity isolated rabbit immunoglobulins raised
against unique synthetic peptides immunogens corresponding to the sodium channels Navl .7
(K241), Nav1.8 (K106), and Nav1.9 (K186) all diluted in blocking solution 1:200. These
specific alpha sodium channel subtype antibodies (GlaxoSmithKline, Harlow, UK) were all
developed to cross-react with both human and rat antigens (Amaya et al. 2000; Coward et al.
2001a; b).
The secondary antibody used to reveal sites of antibody labelling was Goat anti-
rabbit Alexa 488 (A11094, Molecular probes, UK) diluted 1:200 with PBS.
2.4.6 TRPV1 immunohistochemistry
Primary antibodies used were guinea-pig polyclonal TRPV1 (AB5566, Chemicon,
UK) antibody diluted in blocking solution 1:1000. Levels of antibody labelling were
revealed using the secondary antibody; goat anti guinea-pig Alexa 488 (A11073, Molecular
Probes, UK) diluted 1:200 in PBS.
2.4.7 Microscopy and analysis
Each group contained six animals from which the ipsilateral L3-L5 DRGs were
collected. Fluorescence in DRGs was observed using a Leica DMR microscope. Sections
were initially observed under an excitation frequency of 380nm to reveal and count the total
number of FB positive cells in 5-8 sections from each DRG. Setting the microscope filter to
excite the sections at 488nm then enabled the cells labelled with the secondary antibody to
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be visualised. By flicking the filters between the two different excitation wavelengths the
total number of double-labelled cells were identified and counted. From the total FB count
and the double labelled count, the mean animal co-localisation percentage (± SEM) of cells
that were positive for each of the sodium channels or the TRPV1 receptors within the FB
positive sub-population was calculated at each time point. Only cells with visible nuclei were
counted in order to avoid duplicating the count. All analyses were carried out with the
observer blind to the groupings, and representative photomicrographs were captured
throughout.
2.5 Statistical Analysis
Data generated from behavioural, electrophysiological and immunohistochemical
experiments were collated and analysed using Microsoft Excel and GraphPad Prism 4
software. Group data was expressed as the mean ± standard error of the mean (SEM).
Statistical tests were selected according to whether the data sets being analysed were
paired or unpaired, and normally distributed or not normally distributed (Motulsky 1995).
Normally distributed data sets were analysed using parametric tests and non-normally
distributed data were analysed using non-parametric tests. Unpaired t-tests were used to
analyse the differences between the means of two normally distributed groups with similar
variances. In cases where the data was not normally distributed the Mann-Whitney U-test
was preferred. The Student's paired t-test (parametric) and Wilcoxon U-test (non-parametric)
tests were used to compare the means of paired groups. A one-way analysis of variance
(ANOVA) was used to determine whether statistically significant differences existed
between three or more independent groups. If a significant difference did exist then a Dunn's
multiple comparison post-hoc test was performed to determine specifically which groups
were significantly different. A repeated measures ANOVA was used in cases where the
groups are subjected to repeated measures such as behavioural assessments during a dosing
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period. The means of three or more groups of non-parametric data were analysed with a
Kruskal-Wallis test and a post-hoc analysis done using Dunn's multiple comparison.
Correlations between normally distributed groups were determined using Linear
(Pearson) correlation and non-parametric data were compared using a Spearman Rank
Correlation.
In all cases the null hypothesis that the observed difference between the group means
or medians was due to chance was rejected at the 0.05 level. Therefore P<0.05 was
considered statistically significant and the P value was quoted to show the proximity to the
0.05 limit.
Area under the curve (AUC) analysis was used to reveal any behavioural changes in
individual animals during the dosing period of the behavioural studies. A Microsoft Excel
macro designed by Dr. S.T. Bate (GlaxoSmithKIine), employing mathematical integration to
calculate area, was used to calculate an AUC value for the change in behaviour during the
dosing period for each animal. A pre-administration value of the behavioural readout (for
instance WD ratio) was used as a baseline, and values recorded on subsequent days were
used as recordings of how the behavioural assessment changed from day to day (Figure 2.8).
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Figure 2.8 Summary diagram illustrating an example of how an AUC value was calculated using the
Microsoft Excel macro. The daily assessments of the behavioural readout for an individual animal (O)
were plotted during the dosing period (day 11-15). The pre-treatment value prior to dosing on day 11
was used as a baseline value and the macro calculated the areas above (red lines) as positive values,
and the areas underneath (blue lines) as negative values. The individual areas were then summed to
give the total AUC value for that animal in response to that drug.
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Chapter 3
Neural recordings made from the Medial articular
nerve (MAN)
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3.1 Introduction
FCA-induced unilateral arthritis in rats has been validated as a model of human
arthritis (Davis and Perkins 1993; Donaldson et al. 1993) and has been used for behavioural
studies as a pre-clinical screen for novel analgesics in drug discovery (Wilson et al. 2006).
Electrophysiological investigations of the primary afferent nerves in the knee provide
information on the more localised mechanisms involved in the generation of nociceptive
signals from the joint. Electrophysiological recordings of the MAN have historically been
performed in cats (Coggeshall et al. 1983; Schaible and Schmidt 1983a; b; 1985; Mackie et
al. 1995), but as it became generally unacceptable to use domestic animals in research
experiments, even laboratory bred, a similar preparation has been used to study neural
activity in the rat MAN (Dowd et al. 1998a; b). The rat model has been used to investigate
the sensitivity of the nerve to chemical mediators and mechanosensitivity (Gauldie et al.
2001; Just and Heppelmann 2002). More recently the preparation has been used to test the
antinociceptive properties of drugs administered close to the knee joint via intra-arterial
injection (Hanesch et al. 2003; Gomis et al. 2004). The same electrophysiological
preparation was used in this chapter and throughout this thesis to investigate discharge
properties of the MAN in FCA-injected knee joints of rats with a view to understanding the
mechanisms involved in the hypersensitivity observed in the conscious animal following the
induction of a unilateral arthritis.
Various studies in pain research have assessed how great an applied mechanical
pressure has to be in order to evoke a limb withdrawal, and how the withdrawal threshold
changes with controlled changes in the experimental conditions (Hargreaves et al. 1988;
Schaible and Schmidt 1988; Sluka 1997). The Randall and Selitto algesymeter was one of
the first pieces of apparatus of its kind designed to apply a graded, measureable, mechanical
stimulus to the paw of conscious animals (Randall and Selitto 1957). The paw is placed on a
plinth and an increasing weight is applied to the dorsal surface of the paw. When the weight
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becomes noxious the animal withdraws its paw from the apparatus and the force in grams
required to evoke the withdrawal is recorded. Although the algesymeter is an excellent
behavioural tool, the mechanics and sheer size of this apparatus do not easily enable this
technique to be used on anaesthetised animals during electrophysiological recordings.
Mechanical von Frey filaments (von Frey 1894a; b) are a less invasive method of testing
mechanical allodynia and hyperalgesia in both behavioural (Bingham et al. 2005) and
electrophysiological studies (Martindale et al. 2007). Filaments manufactured to apply a
force in the range of approximately 0.5-25g have been used in the past to demonstrate the
presence of tactile allodynia and hyperalgesia in the paw of animals subjected to either
neuropathic or inflammatory insults (Kim and Chung 1992; Bingham et al. 2005). The use of
this range of hairs for noxious and innocuous stimulation is supported by a study where it
was demonstrated that the application of a mechanical stimulus greater than 15g was noxious
in conscious animals eliciting a paw withdrawal from the stimulus (Chaplan et al. 1994). In
animals it is very difficult to know if a withdrawal from a given stimulus is due to pain, itch
or irritation. However, the threshold for withdrawal seen in rats is similar to that seen in
human clinical trials in which participants report the sensation in response to this stimulus as
being painful (Rolke et al. 2006a; b).
Mechanical von Frey filaments within the range of 1 to 21g ( were used, in the work
described in this chapter, to evoke neural discharge of the MAN nerve when applied directly
onto the joint. As described in section 2.3.2 the electrophysiological technique requires the
skin around the knee joint to be removed, allowing the filaments to be placed directly onto
the muscle layer surrounding the knee joint.
Capsaicin is a ligand for the TRPV1 receptor and has been used throughout this
thesis to trigger a nociceptive C-fibre response when given close to the knee joint via an
intra-arterial injection. As discussed in section 1.2.4.2 the TRPV1 receptor is predominantly
found on nociceptive C-fibres, with peripherally administered capsaicin causing acute, dose-
related excitation of these fibres (Baumann et al. 1991). Healthy volunteers given an
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intradermal injection of capsaicin experience an intense burning pain as the C-fibres are
depolarised and a nociceptive signal is propagated (LaMotte et al. 1992). TRPV1 receptor
expression has been shown to be up-regulated in knee joint afferent DRG in a rat model of
OA (Fernihough et al. 2005) and in peripheral tissues following FCA-induced inflammation
(Ji et al. 2002). In contrast the expression of TRPV1 remains unchanged at the 'acute' (3
days) and 'chronic' stages (21 days) of a rodent model of an antigen-induced arthritis (Bar et
al. 2004). An aim of this study was to examine the expression of TRPV1 in knee joint
afferent DRG cell bodies up to 28 days after intra-articular injection of FCA. This was
performed as part of a larger study investigating the levels of VGSCs in naive and FCA-
injected animals and is described in much more detail in Chapter 6 of this thesis. It is
appropriate to include the data set in this chapter as it relates directly to capsaicin-evoked
discharge of the MAN.
The overall aim of this chapter was to compare and note the changes in the
electrophysiological properties of the MAN in naive and FCA-injected knee joints. By
collating the results of all electrophysiology experiments performed, any differences in the
spontaneous discharge and sensitivity of the MAN to mechanical and chemical stimulation
could be detected and reported. Furthermore, using in vivo electrophysiology this model of
unilateral arthritis was characterised prior to subsequent investigations into the role of EMI
and morphine as analgesics in experimental inflammatory joint disease.
3.2 Methods
3.2.1 Study design
Induction of unilateral arthritis was carried out 14-28 days prior to neural recordings
as described in section 2.1.2. All animals were transiently anaesthetised with halothane (3%
in lAL.min"1 02). In total 88 animals were given an injection of FCA into the left knee joint
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whereas 76 animals received no injection. On the day of the electrophysiology recordings the
knee joint diameter and weight of each animal were measured. Recordings were made as
described in section 2.3. Briefly rats were anaesthetised with pentobarbital sodium
(60mg.ml"' i.p.) and the trachea, right carotid artery and right femoral artery and vein were
cannulated. A continuous i.v. infusion of 40% pentobarbital (24mg.mr' in saline) was given
over the course of the experiments at approximately 325pl.hr"1, with adjustments made based
upon the individual animal's condition, to maintain a steady state of anaesthesia. The nerve
was dissected from the surrounding connective tissue and placed onto the platinum/iridium
wire electrodes as described in section 2.2.3.
Having placed the whole nerve bundle on the electrodes a neural recording was
started. Initially the nerve was left for ten minutes in order to measure any on-going
discharge. The nerve was then stimulated by lOpg.ml"1 capsaicin (0.1ml, injected via the
intra-arterial cannula), or by mechanical von Frey filaments as described in section 2.3.5 and
2.3.6 respectively. In order to help identify the fibres as either C-fibre polymodal nociceptors
or type I A5-mechanoreceptors, sensitivity to capsaicin, mechanosensitivity and conduction
velocities were measured towards the end of the recording if not already performed as part of
the earlier tests.
A separate study (n=54) was conducted to examine the expression of TRPV1 in knee
joint afferent cell bodies in L3-L5 DRG of FCA-injected rats at day 7, 14, 21 and 28 post-
FCA in comparison with time matched controls. Full details of the immunohistochemical
methods used are described in section 2.4 with details of the antibody and concentrations
used given in section 2.4.6.
3.2.2 Drugs
Capsaicin (Sigma, UK, MW= 305), was dissolved in 80% phosphate buffered
solution, 10% Tween 80 and 10% ethanol (Sigma, UK). A 0.1ml injection of 3-30pg.mr'
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solution was administered intra-arterially to evoke neural firing of TRPV1 expressing
unmyelinated C-fibres.
3.2.3 Statistical analysis
To determine whether there were any statistically significant differences between the
group of naive animals and the group of FCA-injected animals, for instance when comparing
body weights, a simple unpaired t-test was used to compare group mean values. In cases
where statistical assessments of values obtained from the same animals were possible, such
as when comparing the left and right knee joint diameters, a parametric paired t-test, or a
non-parametric Mann-Whitney test, was employed as appropriate. When comparing the
control and FCA-injected groups at each time point in the IHC study, a two-way analysis of
variance was used as the statistical test.
3.3 Results
A total of 164 in vivo electrophysiology experiments were conducted during the
work performed for this thesis. Of these 164 experiments, 115 (70%) were successful in
obtaining usable recordings for data analysis (Figure 3.1). The 49 experiments that were not
successful failed for reasons such as; the animal died during anaesthesia, the medial articular
nerve was damaged in the dissection process, the blood pressure was too low resulting in
inaccurate data sets and being unable to find an active nerve, despite there being no obvious
technical reason such as electrode failure.
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□ Positive neural recording (70%)
□ No recording achieved (30%)
Figure 3.1 The proportion of electrophysiology experiments yielding successful recordings. Of 164
experiments started, 70% (115/164) were successful in achieving a positive neural recording from the
MAN.
3.3.1 Behavioural assessments of arthritis
3.3.1.1 Body weight
The mean body weight of the FCA-injected animals was not significantly different
from that of the naive animals on the day of the electrophysiological recording (P>0.05,
unpaired t-test, Figure 3.2a). Animals injected with FCA continued to gain weight up until
the time they were used for the recording (Figure 3.2b).
3.3.1.2 Assessment of inflammation induced by FCA
Measurement of the knee joint diameter in both naive and FCA-injected animals
revealed that the FCA-injected knee was inflamed and therefore significantly larger than the
un-injected knee in the same animal, or the corresponding untreated knee in naive animals
(PcO.OOl, one-way ANOVA, Figure 3.3a). FCA did not cause inflammation in the
contralateral knee joint enabling it to be used as an internal control. The mean knee diameter
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ratio of naive animals was 1.00 ± 0.01mm compared to the significantly higher value of 1.13
± 0.01mm measured for FCA-injected animals (P<0.001, Mann-Whitney, Figure 3.3a). A
box and whiskers plot shows there is a greater spread of knee diameter (KD) ratios in the
FCA-injected animals, indicating that there is inter-animal variation in the degree of
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Figure 3.2 (a) The mean body weights measured on the day of the electrophysiological recording of
naive rats (n=76) and rats injected with FCA (n=88) 14-28 days prior to the recording. There was no
significant difference in the mean body weights of naive or FCA-injected animals on the day of
recording (P>0.05. unpaired t-test) and (b) FCA animals maintained an appropriate, gradual, increase
in weight following injection of FCA indicating the animals were not experiencing any hindrance to
their normal behaviours and were not in severe pain.
Figure 3.3 (a) Knee joint diameters of naive (n=76) and FCA-injected (n=88) animals (red bar
indicates the mean value) and (b) box and whiskers plots showing the range and median knee joint
diameter ratios on the day of the electrophysiology recordings. Measurements showed that the knee
joint diameter of the FCA-injected limb (left) was significantly greater than the un-injected limb (***
P0.001, paired t-test), and therefore the FCA-injected animals had a significantly higher KD ratio
than naive animals (*** P<0.001, Mann-Whitney t-test).
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3.3.2 Neural recordings from the MAN
Neural discharge was recorded from 118 individual afferent fibres innervating 52
naive knee joints and 163 fibres innervating 63 FCA-injected knee joints that were
spontaneously active, capsaicin positive or produced an action potential in response to
stimulation of the knee joint with a rigid hand held plastic probe. In 34 out of the 52 (65%)
naive animal experiments and 50 out of the 63 (79%) FCA-injected animal experiments,
capsaicin was given to help further identify the fibre types being recorded. In naive knee
joints 75% (70/93) of the fibres were mechanosensitive, capsaicin positive polymodal C-
fibres, and 25% (23/93) were AS-mechanoreceptors (Figure 3.4). This proportion did not
change in FCA-injected knee joints as 97/130 (75%) of the fibres were identified as C-fibres,
and 33/130 (25%) were identified as A8-mechanoreceptors (Figure 3.4). The conduction
velocity of the polymodal C-fibres was estimated as 0.97 ± 0.09m.s_1 (n=30).
















Figure 3.4 Number of fibres innervating the nai've (n=34, number of fibres=93) and FCA-injected
(n=50, number of fibres=130) knee joint that were capsaicin -positive or -negative. There was no
significant difference in the proportion of fibres expressing the TRPV1 receptor as 75% of both naive
and FCA-injected animals responded to capsaicin (P>0.05, Fisher's exact test).
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3.3.2.1 Spontaneous or on-going neural discharge
In the present investigation 36% (42/118) of fibres were spontaneously active in
naive joints (Figure 3.5a) with the mean discharge frequency being 0.135 ± 0.047
impulses.s"1 (Figure 3.6). In the FCA-injected joint 48% (79/163) of the fibres were
spontaneously active (Figure 3.5b) with the mean discharge frequency being 0.156 ± 0.035
impulses.s"1 (Figure 3.6). Both, the proportion of fibres that were spontaneously active and
the mean discharge frequency of the fibres were significantly greater in FCA-injected joints
than naive (F<0.05, Fishers exact test, Figures 3.5 and P<0.05, t-test Figure 3.6).
□ Fibres showing no spontaneous activity
□ Fibres showing some spontaneous activity
Naive FCA
Figure 3.5 Proportions of (a) naive (n=52, number of fibres =118) and (b) FCA-injected knee (n=63,
number of fibres=163) joint afferent nerve fibres showing spontaneous neural activity in the ten
minutes prior to any mechanical or chemical stimulation of the joint. There was a significantly greater
proportions of spontaneously active fibres in the MAN of FCA-injected joints than naive joints
(P<0.05, Fishers exact test).
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Figure 3.6 The mean spontaneous discharge frequency of fibres innervating the naive (n=76, number
of fibres =117) and FCA-injected knee (n-88, number of fibres=148) in 600s before any other tests
were performed. There was significantly more spontaneous activity observed in FCA-injected knee
joint afferents than there was in naive joint afferents (P>0.05, unpaired t-test).
3.3.2.2 Capsaicin evoked neural discharge
In 24 naive and 22 FCA experiments the first test to be performed following the
measure of spontaneous activity was an injection of capsaicin which evoked a rapid onset,
high frequency response from polymodal C-fibres innervating both the naive and FCA-
injected joints (Figure 3.7d). The mean response duration was 15.92 ± 2.67s and 13.73 ±
2.56s (Figure 3.7a) and the mean discharge frequency was 16.85 ± 2.41 impulses.s"1 and
13.41 ± 1.96 impulses.s"1 in naive and FCA-injected joints respectively. There was no
significant difference between the duration of response, the change in discharge frequency
from basal frequency or change in total number of impulses from basal in naive and FCA-
injected animals (F>0.05, unpaired t-test, Figure 3.7a-c).
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Figure 3.7 Capsaicin evoked neural discharge of fibres innervating the naive (open rectangles) and
FCA-injected (filled rectangles) knee joints. There was no significant difference between the naive
and FCA-injected animals when examining (a) the duration of response, (b) the change in discharge
frequency and (c) the change in absolute number of action potentials evoked by the injection lpg
capsaicin (P>0.05, unpaired t-test). (d) A screenshot of a typical response of the MAN following
injection of lpg capsaicin into an FCA-injected animal at day 18 post-FCA. The arrow indicates the
time at which the drug was injected.
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3.3.2.3 Mechanically evoked neural discharge
In 18 naive and 23 FCA experiments the first test to be performed following the
lOmin measurement of spontaneous activity was to use a range of von Frey filaments to
evoke firing in the MAN. Filaments of 1, 7 and 2 lg caused the MAN fibres to fire when
applied to the knee joint capsule (Figure 3.8a-f). There was a significantly larger response to
the ten second application of both the 7 and 2lg von Frey filament in FCA-injected joints
compared to naive (P<0.05, unpaired t-test, Figure 3.8b and d). There was no statistical
difference in the change in frequency of firing evoked by the lg hair in FCA-injected or
naive animals (P>0.05, unpaired t-test, Figure 3.8a).
(d) (e) (f)
II I I I I
10s
Figure 3.8 The change in frequency of neural discharge from baseline in the fibres innervating the
naive and FCA-injected knee joint evoked by (a) 1, (b) 7 and (c) 21g von Frey filaments. There is a
significant increase in the response to the 7 and 21g von Frey filament in the FCA-injected joints
compared to naive (P<0.05, PO.Ol, unpaired t-test). No change in frequency of firing was observed
between naive and FCA-injected animals evoked by the lg filament. Typical responses of the nerve to
stimulation by the von Frey filaments taken are shown in d-f, recordings taken from an FCA-injected
animal (18 days post-FCA).
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3.3.3 Immunohistochemistry
3.3.3.1 TRPV1 receptor expression
Expression of the capsaicin sensitive TRPV1 receptor was examined in a
subpopulation of L3-L5 DRG cell bodies innervating the knee joint. FB was used to
highlight the cell bodies of fibres innervating the knee joints and a specific TRPV1 receptor
primary antibody was used to identify TRPV1 positive cell bodies. The level of TRPV1
receptor-expressing cells within the FB-positive population did not change from pre-FCA
measurements at any time point studied following an intra-articular injection of FCA (Figure
3.9). Moreover there was no significant difference in the mean percentage levels of TRPV1
expression in control animals at any time point investigated when compared to FCA
(P>0.05, two-way ANOVA). The total number of FB-positive cells analysed in this study
was 798 (Group mean = 89 ± 7), with the Pre-FCA value of 38% calculated from 47 of the
125 FB-positive cells expressing the TRPV1 receptor.


























Pre-FCA 7 14 21 28
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Figure 3.9 Quantitative analysis showing the percentage of FB cells in ipsilateral L3-L5 DRG which
expressed the TRPV1 receptor, measured at various time points following injection of 2% FB (lOpl,
control) or FB + FCA (150pl, lmg.mf1, FCA) into the left knee joint. Control animals are defined as
those receiving only FB. There was no significant difference in the percentage of FB cells expressing
TRPV1 in control or FCA-injected animals at any time point (P>0.05, two-way ANOVA).
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3.4 Discussion
Electrophysiological recordings showed the spontaneous, mechanical and chemical
properties of the MAN in naive and FCA-injected animals. Out of 164 experiments
conducted, over 70% were successful in obtaining a positive neural recording. Guidelines on
the use of pentobarbital sodium in small animals were followed to prevent unwanted adverse
effects, but unfortunately on some occasions even a small overdose led to complications
such as a fatal fall in blood pressure or a rapid loss in body temperature, making the animal
unviable and the data collected unusable. Occasionally a nerve would be dissected and
placed on the electrodes and it appeared that there were no active fibres in the nerve bundle.
In preparations where this occurred the electrodes were replaced and the recording
equipment was checked for faults. Following these alterations, if there were still no active
units seen then a further branch of the nerve would be dissected and investigated. Dissection
of the nerve was a more difficult process in the inflamed joints compared to the nai've joints.
FCA caused an increase in blood vessels around the joint, increasing the risk of bleeding,
with the local oedema making the joint capsule and surrounding area a less rigid structure.
Damage to the MAN during the dissection process and anaesthetic attributed effects were the
main reasons for an experiment being unable to produce a positive recording. With respect to
the previously mentioned complications, a success rate of approximately 70% in both nai've
and FCA-injected animals can be considered a commendable achievement in this
experimental protocol, comparing favourably with previous experimenters in the laboratory
(McQueen, oral communication).
To ensure the fibres investigated were involved in nociceptive signalling, a noxious
mechanical stimulation was applied to the knee joint capsule using a plastic probe and
identification of the fibre types using capsaicin and conduction velocity tests were later
performed. Studies from the cat knee joint suggest that only 70% of C-fibres and 55% of A8-
fibres are nociceptive and therefore clear identification in these studies is essential to ensure
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the fibres investigated were nociceptive (Schaible and Schmidt 1983b). Unfortunately
conduction velocities of A5-fibres were unobtainable as the stimulating electrodes were in
such close proximity to the recording electrodes that the A5-responses were lost in the
stimulus artefact. Therefore it was presumed that the fibres responding to noxious
mechanical stimulation, but not providing a measureable conduction velocity were A5-
mechanonociceptors. Identification of the neural profile of the MAN revealed that C-fibres
accounted for 75% of the fibres studied with A8-fibres making up the other 25%, a value that
was the same in both naive and FCA-injected joints. These results are in accord with values
obtained from previous studies conducted in this laboratory where 61% (Dowd et al. 1998b)
and 93% (Gauldie et al. 2001) of the fibres were identified as C-fibres, and histological
studies in the cat knee joint where 80% of the afferents were identified as unmyelinated C-
fibres (Langford and Schmidt 1983). No efferent neural activity was recorded during these
experiments as the sciatic nerve was cut proximally from the recording to prevent any
descending signals.
Results from the present study show that there were a greater proportion of
spontaneously active MAN fibres, discharging at a higher frequency in FCA-injected knee
joints than in naive knee joints. This is a common characteristic observed in nociceptors
innervating inflamed ankle and knee joints of varying species (Guilbaud et al. 1985; Schaible
and Schmidt 1985; McQueen et al. 1991). Another feature of the FCA-injected knee joint
fibres in this study is that they show an increased responsiveness to high threshold
mechanical stimulation using von Frey filaments when compared to naive fibres. In
behavioural studies von Frey filaments of 15g and above placed on the paw of rats are
described as noxious as they cause repeated limb withdrawals (Chaplan et al. 1994). This is a
finding that correlates with clinical studies where patients describe the same 15g stimulus as
being painful (Rolke et al. 2006a; b). In the present study filaments of 1, 7, and 21g (14, 98
and 255mN respectively) were placed directly onto the muscle surrounding the knee, with
any protection that the skin supplies as a barrier being absent. In this respect it may not be
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unreasonable to consider the 7g hair as being a potentially noxious stimulus. The only way to
confirm this would be to perform a behavioural study in which von Frey filaments would be
applied on the knee joint of conscious animals with the skin surrounding the knee joint
removed, in order to determine the behavioural withdrawal threshold. This is clearly not a
feasible study to perform as the animals would be susceptible to a high risk of infection and
moreover the procedure would not be allowed by Home Office regulations. Therefore the
true nature of the 7g stimulus can only be speculated upon. Increased responsiveness to
mechanical stimuli has been previously reported in a cat model of joint inflammation,
occurring as a result of an increase in afferent discharge, and a spinal sensitisation resulting
from this persistent afferent input (Neugebauer and Schaible 1990).
The response of the MAN fibres in naive and FCA-injected joints to the
administration of capsaicin did not differ in terms of the duration; change in frequency
discharge or in the total number of impulses evoked. These results are consistent with
previous PhD studies in this laboratory, with the values being approximately the same and
with no changes being observed in the properties of capsaicin evoked neural firing in naive
or FCA-injected animals (Dowd 1999). Inflammatory pain studies in mice, rats and guinea-
pigs report that capsazepine was ineffective in attenuating mechanical hyperalgesia produced
by an FCA-induced paw inflammation (Walker et al. 2003). Previous IHC studies have
revealed that the TRPV1 receptor can be up-regulated in knee joint afferent DRG in a model
of osteoarthritis (Fernihough et al. 2005). Conversely a recent study described no change in
TRPV1 receptor expression at an early or late stage during a model of antigen-induced
arthritis (Bar et al. 2004). Studies conducted that are reported in the present study concur
with the later study, as there was no apparent change in the expression of TRPV1 in a
distinct population of DRG cell bodies of afferents innervating the knee joint, up to 28 days
post-FCA. The fact that the TRPV1 receptor levels remain the same in naive and FCA-
injected animals is consistent with the electrophysiological results obtained, which showed
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no alteration in response to capsaicin in the FCA-injected joints in comparison with naive
joints.
The intra-articular injection of FCA is a well studied pre-clinical model of human
arthritis and chronic pain (see section 1.4.10). The injection of FCA had no adverse effects,
other than the expected joint swelling, on the animals used in these electrophysiological
investigations. This was evidenced by the fact that FCA-injected animals continued to gain
weight consistently, and showed no significant difference in weight compared to nai've
animals on the day of recording. This further confirms that the model only induces a mild
arthritis in the injected joint, without the systemic effects described in less refined FCA
models (Casey and Dubner 1989). In addition FCA caused a significant swelling in the
injected knee compared to the un-injected knee in the same animals, or the knees of naive
animals.
The main aim of these studies was to compare the electrophysiological properties of
the MAN innervating the FCA-injected knee joints with those of the naive knee joints.
Results are consistent with previous studies performed in this laboratory and therefore no
further validation of the FCA-model and the recording technique is required, allowing a
reduction in the number of animals used in this thesis. The data indicates that the preparation
provides a viable method for recording nociceptive C- and A5-fibres innervating the knee
joint. Furthermore this electrophysiological preparation can be confidently used in order to
study the antinociceptive properties of EMI and morphine which are discussed in a later
chapter. Using capsaicin evoked nociceptive neural activity and the quantitative mechanical
von Frey filament stimulation, any change in discharge patterns in the MAN following EMI
and morphine administration should show any peripherally driven antinociceptive properties
of the drugs.
In conclusion, this pilot study verified that FCA induces a mild inflammatory knee
joint hypersensitivity in rats which occurs in part as the result of an increase in spontaneous
neural discharge and a hypersensitivity to mechanical stimulation of the MAN.
82
Chapter 4: The role ofperipheral opioid receptors in joint pain
Chapter 4
The role of peripheral opioid receptors in joint pain
83
Chapter 4: The role ofperipheral opioid receptors in joint pain
4.1 Introduction
The primary palliative aim when treating RA is to provide adequate management of
the chronic pain associated with the disease and therefore improve the patient's quality of
life (Heiberg and Kvien 2002; Heiberg et al. 2005). The long term use of COX-2 inhibitors
has been questioned following the discovery that the use of these compounds may lead to an
increased chance of the patient suffering cardiovascular complications such as a myocardial
infarction or thrombotic stroke, due to the drugs preventing formation of PGI2 which has
been shown to inhibit platelet aggregation, cause vasodilation and prevent smooth muscle
proliferation in the vasculature (Fitzgerald 2004). Opioids often provide excellent analgesia
to a high number of patients; however just like the COX-2 inhibitors, the long term use of
opioids is hampered by the intolerable side-effects resulting from receptors located in the
central nervous system and viscera (section 1.5.4.1). Analgesia, together with the associated
side-effects, has been observed in animal models of FCA-induced arthritis, highlighting a
positive translation of actual clinical symptoms into a successful pre-clinical model (Walker
et al. 1996). Restricting the administration of these drugs to the site of injury in the
periphery, for instance in or around the knee joint in the case of RA, may provide similar
analgesia to that observed with systemic administration of the drugs, with minimal
undesirable side-effects. Knee joint pain, as assessed using the visual analogue scale (VAS)
and pain rating indices (PRI), was reduced in patients treated with low doses of intra¬
articular morphine following knee joint arthroscopy (Stein et al. 1991; Joshi et al. 1993),.
Furthermore, intra-articular morphine provided excellent analgesia to RA and OA patients,
without any adverse side effects (Likar et al. 1997; Stein et al. 1999), and there is compelling
evidence that the analgesia is mediated through opioid receptors located on primary afferent
neurons (see section 1.5.5.1).
The endogenous opioids EMI and EM2 are present in human immune cells known
to migrate to sites of tissue injury. The expression of EMI and EM2 has been shown to be
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increased in the synovial tissue taken from inflamed hind paws and the spleen and thymus
when compared to control animals in a rat model of adjuvant-induced arthritis (Jessop et al.
2002). This suggests that the endogenous opioids play an important role in an in-built
mechanism for providing analgesia at sites of tissue inflammation. Exogenous EMI given
into the knee joint has been shown to reduce synovial protein extravasation and increase
knee joint vascular resistance (Barin and McDougall 2003; McDougall et al. 2004a). Both of
these effects are mediated through opioid receptors present on capsaicin-sensitive
unmyelinated fibres, suggesting the action is via a neurogenic mechanism which inhibits the
release of the pro-inflammatory mediators SP and CGRP. The same group (McDougall et
al.) report that a build up of EMI, which occurs in the knee joint during the initial
inflammation, results in a down-regulation of the p-opioid receptor and a subsequent loss of
the effects of exogenously administered EMI. In these studies EHC revealed a reduction in
the expression of both EMI and the p-opioid receptor in the rat knee synovium and the
primary afferent fibres innervating the inflamed knees 1 week after FCA-injection
(McDougall et al. 2004b). Furthermore, the antinociceptive effect of EM-1 that is observed
in normal knee joints following hyper-rotation of the knee was absent in animals at 1 week
post-FCA (Li et al. 2005). These findings provide compelling evidence that exogenous p-
opioid receptor agonists, such as EMI and morphine, should not cause analgesia when
administered directly into the knee joint. However as seen from the clinical evidence
described above, low doses of morphine do in fact provide excellent analgesia in patients
suffering from inflammatory arthritis. The difference between the pre-clinical model and the
actual clinic scenario could cast doubts over the validity of the rat model as a correlate of
human RA. However, it may simply be the case that in the rat model of monoarthritis, at one
week post-FCA the initial inflammatory drive is still very strong and has not yet subsided,
accounting for the observed loss in opioid receptor mediated antinociception. It may actually
be more appropriate to study times later then one week post-FCA when aligning this pre¬
clinical model with the clinical condition.
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4.1.1 Hypothesis
The aim of this study was to test the hypothesis that functional opioid receptors are
expressed on rat knee joint nociceptors within the MAN at times later than one week post-
FCA. To do this, behavioural studies were performed to investigate the effect of intra¬
articular EMI and morphine, on the way the animals distribute their weight over the FCA-
injected and non-injected hind limbs. In two separate studies, three doses of EM-1 were
administered on days 14, 16 and 18 post-FCA, and a single dose of morphine was
administered on day 14 post-FCA, directly into the FCA-injected knee joint under brief
halothane anaesthesia and any changes in the hind limb weight distribution were recorded.
Electrophysiology studies were also separately performed to investigate the effect of
EMI and morphine on the neural discharge in nociceptors recorded from the MAN evoked
by mechanical von Frey filaments and capsaicin. Mechanical hyperalgesia and allodynia of
the joint is often observed in the clinic, with patients reporting tenderness of the joints to
touch and movement. Dosing with capsaicin is a clinically relevant way of investigating if
EMI and morphine alter the neural discharge evoked by capsaicin, as capsaicin creams such
as Axsain are used in the clinic as topical analgesics (Rains and Bryson 1995) and the
mechanism of action of the agonists is mediated through TRPV1 receptors present on
unmyelinated C-fibres.
4.2 Methods
4.2.1 Design of behavioural studies
Throughout the behavioural experiments the body weights of the animals were
recorded and their general behaviour observed to ensure that the animals were not suffering
any adverse effects following administration of the test drugs or FCA.
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4.2.1.1 Behavioural assessment of intra-articularmorphine
On the first day of the study (day 0) the weight distribution ratio of 32 adult male
Wistar rats was assessed using the rat incapacitance tester, as described in section 2.2.1.
Following this assessment all the animals were anaesthetised (3% halothane in 1.51.min"1 02)
and received an intra-articular injection of 150pl of lmg.mr1 FCA into the left knee joint as
described in section 2.1.2. On days 4, 7, 11 and 14 post-FCA, weight bearing assessments
were made to confirm that the expected FCA-induced unilateral joint hypersensitivity had
been induced. The animals were ranked and randomised into four dosing groups (n=8) based
on the day 14 weight distribution ratio. The animals were then briefly anaesthetised (3%
halothane in 1.51.min_1 02) and a second injection of either morphine sulphate (1, 3 or lOmg
in 0.1ml) or vehicle (saline) was administered into the left knee joint. All drugs were dosed
blind and the code was not revealed until the entire data set had been processed. Animals
were allowed to recover in their cages before further behavioural measures of the weight
distribution were made at 30, 60, 90, 120 and 180 minutes post drug injection. Further





Day 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Figure 4.1 Figure illustrating the protocol for the morphine behavioural study. Intra-articular injection
of FCA or morphine (1, 3 or lOmg.ml"1) was administered as indicated by the red and blue arrows
respectively. The days highlighted in red are the days on which behavioural measurements were made.
4.2.1.2 Behavioural assessment of intra-articular EM1
On the first day of the study (day 0) the weight distribution ratio of 32 adult male
Wistar rats was assessed using the rat incapacitance tester, as described in section 2.2.1. All
animals then received 150pg of FCA into the left knee joint as described in section 2.1.2. On
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days 1, 3, 7, 9 and 11 post-FCA, weight bearing assessments were made to confirm the
expected FCA-induced unilateral joint hypersensitivity. The animals were then ranked and
randomised into four dosing groups (n=8) based on the day 11 weight distribution ratio. On
days 14, 16 and 18 the animals were briefly anaesthetised (3% halothane in 1.51.min_1 02)
and on each occasion received a further injection of 100pi of EMI (30, 100 or 300mg in
0.1ml) or vehicle (saline) into the left knee joint. On each of these three occasions the
animals recovered in their cages before a further weight distribution assessment was
performed 30 minutes post-drug injection. Further weight distribution assessments were
made on days 21 and 23 post-FCA.
PQA Endomorphin
END
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Figure 4.2 A schematic diagram illustrating the protocol for the endomorphin behavioural study.
Intra-articular injection of FCA (red arrow) or endomorphin (blue arrow, 1, 3 or lOmg.ml"1) was
administered on the days indicated by the arrows. The days highlighted in red are the days on which
behavioural measurements were made.
4.2.1.3 Design of experiments involving neural recordings
Induction of a unilateral arthritis was carried out 14-28 days prior to neural
recordings as described in section 2.1.2. Animals were briefly anaesthetised and received
either an injection of 150pl of FCA (lmg.ml1) into the left knee joint or were untreated.
Animals receiving no injection are defined as 'naive' throughout this chapter. Animals were
prepared for a neural recording under terminal anaesthesia as described in section 2.3.
Briefly rats were anaesthetised with pentobarbital sodium (bOrng mf1 i.p.) and the trachea,
right carotid artery and right femoral artery and vein were cannulated. A continuous i.v.
infusion of 40% pentobarbital (24mg.mr' in saline) was given over the course of the
experiments at approximately 325pl.hr"1 to maintain a steady state of anaesthesia, which was
1 1 J
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adjusted according to the needs of the individual animal to ensure a consistent level of
anaesthesia throughout. Arterial blood pressure was recorded throughout the experiment, and
any changes in blood pressure following administration of a drug were calculated. The MAN
was dissected from the surrounding connective tissue and placed onto the platinum/iridium
wire electrodes as described in section 2.2.3. Having successfully positioned the nerve across
the electrodes a neural recording was started. All drugs were administered intra-arterially in
a volume of 0.1ml, as described in section 2.3.5. At the end of each experiment conduction
velocities were obtained from the recorded units to help further classify the fibres.
4.2.1.4 Capsaicin evoked neural discharge
Control experiments were performed in both FCA-injected (n=6) and naive (n=5)
animals to ensure that repeat doses of capsaicin could be given without desensitising the
MAN. Five doses of capsaicin (lpg) were given at 45 minute intervals. The change in
discharge frequency of the MAN fibres (impulses.s"1) from the background caused by the
injected capsaicin was recorded. Between each dose of capsaicin two saline washes were
given to thoroughly clear the cannula and remove any excess drug from the system. A saline
injection was given as a vehicle control injection for the EMI and morphine.
4.2.2 Effect of morphine and EM1 on neural discharge evoked by capsaicin
The effect of morphine and EMI on the capsaicin evoked firing of the MAN was
investigated in both FCA-injected (morphine n=6, EMI n=5) and naive (morphine n=5, EMI
n=6) animals. The protocol followed is shown in Figure 4.3. Briefly the first two doses of
lpg capsaicin were given with a 45 minute interval, with a further 45 minute break at which
point a single dose of 0.3mg of morphine or O.lmg of EMI was injected. The next dose of
capsaicin was given 20mins after the drug, with the final doses again being 45 minutes apart.
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The change in discharge frequency of the MAN fibres (impulses.s"1) from the background
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Figure 4.3 Schematic of the test protocol used in the capsaicin-evoked neural discharge experiments.
The times that the close arterial injections of capsaicin (red arrows) and EMI or morphine (blue
arrow) were given are shown.
4.2.2.1 Mechanically evoked neural discharge
Control experiments were performed in both FCA-injected (n=5) and naive (n=6)
animals to ensure that repeated stimulation of the MAN by mechanical von Frey filaments
produced consistent responses. For each test the von Frey filaments of 1, 7 and 21g were
applied in ascending order as described in section 2.3.6. Ten tests were performed at 20
minute intervals with the administration of a vehicle control injection (saline) 15 minutes
after test 5 (see Figure 4.4). The change in discharge frequency of the MAN fibres
(impulses.s"1) from the background activity was measured following the application of the
von Frey filaments and administration of saline.
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Figure 4.4 Schematic showing the test protocol showing the times ofmechanical stimulation (red
arrows) and the time when either EMI or morphine were delivered (blue arrow). Pre-treatment with
naloxone (500pg) in certain experiments occurred 3 minutes before the test drug was delivered.
4.2.2.2 Effect ofmorphine and EM1 on mechanical evoked neural discharge
The effect ofmorphine and EMI on the mechanically evoked firing of the MAN was
investigated in both FCA-injected (morphine n=5, EMI n=5) and naive (morphine n=6, EMI
n=6) animals. Five mechanical tests were performed before and after dosing of administering
morphine (300pg) or EMI (lOOpg, Figure 4.4). The change in discharge frequency of the
MAN fibres (impulses.s"1) from the background activity in response to each von Frey
filament was measured before and after the administration of all the drugs.
To investigate whether the effect of morphine and EMI was mediated through an
opioid receptor mechanism further experiments were performed in FCA-injected animals
using naloxone (morphine n=4, EMI n=4). Naloxone (500pg), the opioid receptor antagonist
was administered 3 minutes before either morphine or EMI to antagonise the action of the
drug at the opioid receptors.
4.2.3 Drugs
Morphine and EMI were administered directly into the knee joint in a volume of
100pi during the behavioural experiments. It was assumed that lOOpl of the injected drug
remained within the knee joint cavity and was immediately diluted 1:1 by the lOOpl of
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synovial fluid already present in the FCA-injected knee (Barton 2007). Morphine sulphate
salt pentahydrate (Sigma, UK, MW=758.8) was dissolved in sterile saline and administered
at concentrations of lmg.mT , 3mg.mr' and lOmg.mT1. These doses resulted in a maximum
dose of 0.1, 0.3 and lmg of compound being administered into the knee respectively. These
doses were chosen as they were comparable with those used in behavioural studies in the
same model where rats weighing approximately 300g received a 3mg.kg"' oral dose twice
daily, a protocol which gave a significant analgesic effect (Wilson et al. 2006). The more
potent p-opioid receptor agonist EMI (Sigma, UK, MW=610.7) was dissolved in sterile
saline and administered at concentrations of 30pg.mr', lOOpg.mf1, 300pg.mr', with the
maximum amount of drug present in the knee being 3pg, lOpg and 30pg respectively.
In the in vivo electrophysiology studies, capsaicin (Sigma, UK, MW= 305) was
dissolved in 80% phosphate buffered solution, 10% Tween 80 and 10% ethanol (Sigma,
UK). A dose of lpg was chosen based upon previous studies in the laboratory where lpg of
capsaicin delivered intra-arterially evoked neural discharge without desensitising the fibres.
Morphine and EMI were prepared as described above and injected at a concentration of
300pg and lpg respectively following the results obtained from the behavioural studies.
4.2.4 Statistical analysis
• Individual group mean values were analysed for statistical differences using a
Wilcoxon t-test or an un-paired t-test depending on whether the data were paired or
un-paired respectively.
Results obtained from the behavioural studies were expressed as the group mean (±
SEM) for the WD ratios.
The statistical test used to compare differences within the same group over time was
a one-way ANOVA followed by Dunn's post-hoc test, as appropriate.
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• The test used to compare differences between two or more different groups over
time was the two-way ANOVA followed by Bonferroni's post-hoc test.
• In order to compare the AUC values calculated from each dose of drug over the
dosing period, a Kruskal-Wallis ANOVA was used followed by Dunn's post-hoc to
compare the different doses with the vehicle.
• The statistical test used to compare the group mean neural discharge frequencies
evoked at different time points, or by the different von Frey filaments in the
electrophysiology studies was a one-way ANOVA followed by Dunn's post-hoc test.
• In all cases a P value of <0.05 was considered statistically significant.
4.3 Results
4.3.1 Behaviour
The injection of FCA into the left knee joint did not have any detrimental effect on
the animals' general behaviour over the duration of the morphine and EMI studies. Despite a
small decrease in weight on day 1 following the injection of FCA, animals gained weight on
everyday post-FCA, a clear indication that the animals were not in severe pain and were able
to perform normal behaviours such as feeding, grooming and drinking. Moreover, neither the
single injection of morphine (Figure 4.5) nor the three injections of EMI (Figure 4.6) into
the knee joint prevented the animals from continuing to gain weight. Furthermore there was
no significant difference in the group mean body weights for the different groups dosed with
morphine (0.1-lmg) or EMI (3 -30pg, F>0.05, two-way ANOVA).
93
Chapter 4: The role ofperipheral opioid receptors in joint pain
(a) -0— All FCA-injected animals (b) -A— Vehicle
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Figure 4.5 Figure illustrating (a) the pooled mean body weights for all rats (n=32, days 0-11) and (b)
the same set of animals shown in their designated dosing groups for morphine (n=8, days 14-21)
following injection of FCA on day 0. Animals gained weight daily over the duration of the study
period. Intra-articular injection of morphine (0.1, 0.3 and lmg) on day 14 had no effect on the weight
gain of the animals and consequently there was no significant difference in the group mean body
weights on days 14 to 21 (P>0.05, two-way ANOVA, n=32).
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Figure 4.6 Figure illustrating (a) pooled body weights of all animals (n=32, days 0-11) and (b) the
same animals in their designated dosing groups for EMI (n=8, days 14-23) following injection of
FCA on day 0. Despite a statistically insignificant decrease in weight from day 0 to day 1 (P>0.05,
paired t-test, n=32), animals gained weight daily over the duration of the study period. Intra-articular
injection of EMI on days 14, 16 and 18 (indicated by the grey arrows) had no effect on the weight
gain of the animals and consequently there was no significant difference in the group mean body
weights on days 14 to 23 (P>0.05, two-way ANOVA, n=32). The consistent weight gain provides
evidence that the animals were not in severe pain or discomfort throughout the studies and were able
to continue normal behaviours such as feeding and drinking. The shaded area indicates the drug
treatment period.
4.3.1.1 The effect of intra-articularmorphine
Baseline weight distribution recordings were made on day 0 and the weight placed
through the left and the right hind limb was 53 ± lg in both instances, giving a calculated
WD ratio of 1.00 ± 0.01 (n=32). Treatment with FCA resulted in the WD ratio on days 4, 7
and 11 post-FCA, decreasing to values significantly lower than the day 0 value (P<0.05, one¬
way ANOVA, n=32, Figure 4.7a).
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Figure 4.7 Graphs showing the effect of intra-articular FCA and morphine (l-lOmg.ml") on die
distribution of the animals' body weight between their hind limbs, (a) FCA resulted in a significant
decrease in WD ratio on days 4, 7 and 11 post-FCA when compared to day 0 (*** represents P<0.001,
one-way ANOVA, n=32). (b) The WD ratio on day 14, immediately before morphine treatment
began, was significantly lower than the pre-FCA value. The mean WD ratios of the morphine 0.1-lmg
and vehicle- treated animals on (c) day 14 following the intra-articular administration of the drug and
(e) days 14-21 post-FCA. The groups of animals dosed with 0.3 and lmg morphine had statistically
higher WD ratio values than the vehicle treated group on day 18, 4 days after treatment (* P<0.05,
two-way ANOVA, n=8) (d) The WD ratio AUC values during the 3 hours post-morphine on day 14
calculated from the baseline pre-morphine values were analysed to compare the drug-treated groups to
the vehicle-treated group. *** represents statistical significance (P<0.001) using a one-way ANOVA
followed by a Dunn's post-hoc test.
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Due to the animals' unwillingness to carry weight through the FCA-injected knee
joint, more weight is carried through the leg ipsilateral to the FCA-injected knee (132 ± 2g)
than the FCA-injected leg (53 ± 2g) and the mean weight distribution ratio on day 14 prior to
dosing was 0.39 ± 0.02 (n=32, Figure 4.7b).
The effect of administering 0.1, 0.3 and lmg of morphine or vehicle into the knee
joint on the weight distribution of the animals was assessed at half hourly intervals up to 3
hours post-morphine (Figure 4.7c). There was no significant difference in the group mean
WD ratios as measured on day 14 prior to the treatment with morphine or vehicle (Table
4.1). Anaesthetic effects from the intra-articular injections were absent 10 minutes after the
injection as animals rapidly recovered and exhibited normal cage behaviour such as
movement, exploration and feeding. The first behavioural assessment at 30min post-
morphine revealed a dose-related reduction in the joint hypersensitivity as animals dosed
with lmg of morphine had a significantly higher WD ratio of 0.71 ± 0.09 compared to the
vehicle value of 0.37 ± 0.07 (P<0.01, two-way ANOVA, n=8, Table 4.1).
From each animal 5 assessments of the WD were made at half hour intervals
following administration of morphine or vehicle on day 14. Using each animal's day 14 pre-
morphine WD ratio as a basal value, an AUC for the five following assessments was
calculated. Results showed significantly higher AUC values for the groups treated with
morphine (300pg and lmg) compared to the vehicle dosed group. Morphine induced
analgesia meaning that animals placed more weight through the limb that was previously
hypersensitive, increasing the WD ratio value back towards 1.0 (F<0.001, one-way
ANOVA, Figure 4.7d).
A WD ratio was calculated from measurements of the weight bearing results made
on days 18 and 21 post-FCA (4 and 7 days post-morphine or -vehicle) to observe any long
term effect of the intra-articular injection of drug. On day 18 post-FCA there was still a
significant difference between the 3 and lOmg.mr1 morphine dosed groups compared to the
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vehicle treated group (P<0.05, two-way ANOVA, n=8). There was no significant difference
between any of the groups on day 21 post-FCA (Figure 4.7e).
Time (minutes) Vehicle Morphine 0.1mg Morphine 0.3mg Morphine 1mg
Pre-injection 0.44 0.39 (ns) 0.37 (ns) 0.38 (ns)
30 0.37 0.52 (ns) 0.61 (ns) 0.71 (**)
60 0.35 0.53 (ns) 0.71 n 0.61 (ns)
90 0.41 0.47 (ns) 0.67 (ns) 0.66 (ns)
120 0.43 0.59 (ns) 0.80 (**) 0.70 (*)
180 0.27 0.50 (ns) 0.65 ("*) 0.74 (***)
Table 4.1 The WD ratio values of FCA-injected animals measured on day 14 at the different time
point post- morphine or vehicle injection. Brackets illustrate whether there was any significant
difference between the morphine groups compared to the vehicle treated group of animals at each time
point studied (ns represents no statistical difference, * P<0.05, ** PcO.Ol, *** P<0.001, two-way
ANOVA).
4.3.1.2 The effect of intra-articular EM1
Weight distribution recordings were made on day 0 to provide basal data, with the
mean amount of weight placed through the left and right hind limb being 110 ± 2g and 113 +
3g respectively, resulting in a day 0 WD ratio of 1.00 ± 0.02 (n=32). Treatment with FCA
resulted in the WD ratio on days 1, 3, 7, 9 and 11 being significantly lower than the day 0
value (P<0.05, one-way ANOVA, n=32, Figure 4.8a). The hypersensitivity is still present on
day 11 post-FCA when the animals placed 75 ± 4g through the FCA-injected limb and 199 ±
3g through the non-injected limb. This resulted in the day 11 post-FCA WD ratio being
significantly lower then the pre-FCA value (PcO.001, 0.31 ± 0.02 vs. 1.00 ± 0.02, Wilcoxon
t-test, n=32, Figure 4.8b).
The effects of EMI at 3, 10 and 30pg or vehicle into the knee joint on three separate
occasions (day 14, 16 and 18 post-FCA) on the weight distribution of the animals was
investigated on days 14-23 (Figure 4.8c). There was no significant difference between the
mean WD ratios of the four groups as measured on day 11 prior to the dosing (Table 4.2).
Measurements made to investigate the effect of the injected drug during the dosing period
98
Chapter 4: The role ofperipheral opioid receptors in joint pain
revealed that there was a significant increase in the WD ratio of the EMI 30pg group on day
14, 21 and 23 post-FCA and the EMI 3pg group on day 18 post-FCA when compared to the
vehicle group (P<0.05, two-way ANOVA, n=8, Figure 4.8c and Table 4.2). AUC values
were calculated for individual animals throughout the duration of the dosing period (day 14-
18 post-FCA), using the day 11 values as the basal value. Results showed significantly
higher AUC values for the 10 and 30pg EMI dosed groups compared to the vehicle dosed
group (* .P<0.05, ** P<0.01, one-way ANOVA, Figure 4.8d).
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Figure 4.8 Graphs showing that (a) FCA resulted in a significant decrease in WD ratio on days 3, 7. 9
and 11 post-FCA as compared to day 0 values (*** represents PO.OOl, one-way ANOVA, n=32). (b)
The WD ratio on day 11 was significantly lower than the day 0 value (*** PO.OOl, 0.31 ± 0.02 vs.
1.00 ± 0.02, Wilcoxon t-test, n=32). (c) The mean WD ratios of the EMI and vehicle- treated animals
on day 11-23 post-FCA. The 30pg group mean WD ratio was significantly higher than the vehicle
group on days 21 and 23 post-FCA. (d) The WD ratio AUC values for the dosing period (day 14-18
post-FCA) were calculated from the basal day 11 values and were analysed to compare the drug-
treated groups to the vehicle-treated group. EMI at 10 and 30pg were significantly larger than the
vehicle treated group of animals (* f<0.05. ** P<0.01, one-way ANOVA, n=8).
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Time (days
post-FCA) Vehicle EM1 3pg EM1 10pg EM1 30pg
11 0.30 0.30 (ns) 0.31 (ns) 0.31 (ns)
14 0.27 0.36 (ns) 0.38 (ns) 0.62 (**)
15 0.29 0.40 (ns) 0.33 (ns) 0.50 (ns)
16 0.31 0.41 (ns) 0.40 (ns) 0.52 (ns)
17 0.33 0.38 (ns) 0.47 (ns) 0.54 (ns)
18 0.30 0.59 (*) 0.40 (ns) 0.49 (ns)
21 0.33 0.49 (ns) 0.45 (ns) 0.59 (*)
23 0.37 0.56 (ns) 0.38 (ns) 0.68 (**)
Table 4.2 The WD ratio values measured on day 11-23 post-FCA, following intra-articular injection
of EMI or vehicle on days 14, 16 and 18. Brackets show whether there was any significant difference
between the EMI groups compared to the vehicle treated group of animals during the dosing period.
There was no significant difference between the mean WD ratio of the four groups on day 11, the last
measurement before dosing on day 14 (ns represents no statistical difference, * P<0.05, ** PcO.Ol,
two-way ANOVA).
4.3.2 Effect of EM1 and morphine on neural discharge of the MAN
Neural discharge was recorded from 83 afferent fibres in 32 experiments where
capsaicin evoked discharge was investigated, and 41 experiments from a total of 93 afferent
fibres where mechanically evoked discharge was investigated. Afferents were classed as
polymodal C-fibres or mechanosensitive A8-fibres based on their conduction velocity,
sensitivity to capsaicin and response to noxious mechanical stimulation as previously
described (see section 3.3.2). The few fibres that did not respond to capsaicin or noxious
mechanical stimulation were not considered to be nociceptive and were not investigated
further in these studies.
In experiments which investigated capsaicin evoked firing of the MAN, 16 out of 83
fibres (19%) were mechanosensitive, but did not respond to capsaicin and were classed as
AS-fibres, whilst the other 67 fibres (81%) were responsive to both capsaicin and mechanical
stimulation and were identified as being polymodal nociceptors. In the mechanically evoked
firing of the MAN experiments 28 out of 93 fibres (30%) were identified as
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mechanosensitive A5-fibres and 65 out of 93 fibres (70%) were identified as polymodal C-
fibres responding to both noxious mechanical stimulation and capsaicin (see Table 4.3).
Capsaicin evoked Firing (n=32) Mechanically evoked firing (n=41)
A6-fibres 16/83 (19%) 28/93 (30%)
C-fibres 67/83 (81%) 65/93 (70%)
Table 4.3 Proportions of fibre types of fibre types innervating the knee joints investigated in the
capsaicin and mechanically evoked firing of the MAN experiments.
4.3.2.1 Blood pressure and heart rate
The effect of capsaicin, morphine and EMI on the arterial blood pressure (B.P.) and
heart rate of the anaesthetised animal was recorded to detect pharmacological changes
evoked by the drugs administered (Table 4.4). The mean control B.P. in experiments prior to




Dias B.P. 117 100 106
Mean B.P. 129 110 117
Heart Rate 409 418 388
Primary Effect
Sys B.P. 131 138 108
Dias B.P. 108 104 68
Mean B.P. 116 116 81
Heart Rate 392 406 332
Delta D.P. 3 5 -36
Delta H.R. -17 -7 -56
Secondary effect
Sys B.P. 160 111 -
Dias B.P. 120 77 -
Mean B.P. 133 88 -
Heart Rate 397 372 -
Delta B.P. 14 -21 -
Delta H.R. -13 -46 -
Table 4.4 Table summarising the effects of lpg capsaicin, 300pg morphine and lOOpg EMI on the
mean blood pressure and heart rate of the anaesthetised animals during the neural recordings.
Capsaicin and morphine had a two phase effect on the blood pressure, whereas EMI only had a single
stage effect. All drugs had the effect of decreasing the heart rate of the animals. Capsaicin caused an
initial drop in heart rate followed by a secondary phase increase. Morphine caused an initial increase,
with the secondary effect to be a decrease in blood pressure. Administration of EMI resulted in a
decrease in blood pressure.
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Injection of capsaicin resulted in a two phase effect on the B.P. with a primary
decrease of 3 ± lOmmHg, and a slower secondary increase of 14 ± lOmmHg from the initial
control value. The heart rate decreased to 392 ± 12bpm and 397 ± lObpm at the peaks of
these two responses respectively when compared to control values of 409 ± 9bpm.
Morphine also resulted in the B.P. to be changed in two distinct phases. The initial
response saw a mean increase in the B.P. of 5 ± 2mmHg followed by a secondary response
of a mean decrease of 21 ± 4mmHg. The heart rate of the animals slowed throughout both
stages, decreasing by 7 ± 6bpm and 46 ± 8bpm when compared to control respectively.
Injection of EMI resulted in a single phase effect on the B.P. with the mean control
of 117 ± 7mmHg dropping 36 ± 4mmHg to a post-drug mean B.P. of 81 ± 5mmHg. The
heart rate fell by 56 ± lObpm during this post-drug period.
4.3.3 Capsaicin-evoked neural discharge
4.3.3.1 Repeat capsaicin and vehicle control experiments
Repeat injections of capsaicin evoked action potential discharge of the fibres in the
MAN. In both naive (n=5, fibres=18) and FCA-injected (n=6, fibres=12) animals capsaicin
was injected on five separate occasions at intervals of 45 minutes between each test.
Consistent discharge frequencies were observed with no sensitisation or desensitisation of
the nerve. There was no significant difference between the mean discharge frequency
(impulses.s"1) of all the tests performed in both naive and FCA-injected animals (P>0.05,
one-way ANOVA, Figure 4.9a and 4.9b respectively). The mean discharge frequencies
evoked in these experiments ranged from 14-21 impulses.s"1 which is in keeping with the
range of 13-22 impulses.s"1 obtained from all the experiments involving capsaicin as
described in section 3.3.2.2. Injection of vehicle (saline) at 70 minutes as a control for opioid
agonist injections, in between the second and third capsaicin test had no effect on the
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capsaicin response. There was no significant difference between the mean discharge
frequencies of the first or second capsaicin test at 0 and 45 minutes, confirming that these
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Figure 4.9 Capsaicin evoked neural discharge of fibres innervating (a) the nai've (n=5, fibres= 18) and
(b) the FCA-injected (n=6, fibres=12) knee joint before and after vehicle (saline) administration.
There was no significant difference in the neural discharge frequency at any time point following
repeat capsaicin injections (P>0.05, one-way ANOVA).
4.3.3.2 Effect ofmorphine on capsaicin evoked discharge
In both nai've (n=5, fibres=12) and FCA-injected (n=6, fibres=12) animals, two
doses of capsaicin were injected 45 minutes apart prior to the test drug morphine (300pg).
There was no significant difference between the mean discharge frequencies of the first and
second capsaicin tests in either case (F>0.05, Wilcoxon t-test, Figure 4.10a and 4.10b). In
naive animals the injection of morphine did not effect the subsequent responses to capsaicin
at 110, 155 and 200 minutes, in comparison with the first two tests (P>0.05, one-way
ANOVA, Figure 4.10a). In FCA-injected animals morphine resulted in a significant
reduction in the mean discharge frequency evoked by the capsaicin test performed at 200
minutes when compared to the basal test at 0 minutes (P<0.01, one-way ANOVA, Figure
4.10b).
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Figure 4.10 Graphs showing capsaicin (1 jag) evoked neural discharge of fibres innervating (a) naive
(n=5, fibres=12) and (b) FCA-injected (n=6, fibres=12) knee joint in two tests prior to and three tests
following injection of 300pg morphine, (a) There was no significant difference in the neural discharge
frequency at any time point in naive animals (P>0.05, one-way ANOVA). (b) Morphine (300pg)
caused a significant reduction in the capsaicin evoked neural discharge at 200 minutes when compared
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Figure 4.11 Capsaicin (lpg) evoked neural discharge of fibres innervating (a) naive (n=6, fibres=15)
and (b) FCA-injected (n=5, fibres= 17) knee joint before and after administration of lOOpg of EMI.
There was no significant difference in the neural discharge frequency at any time point following
repeat capsaicin injections (P>0.05, one-way ANOVA).
4.3.3.3 Effect of EM1 on capsaicin evoked discharge
The two initial injections of capsaicin in both naive (n=6, fibres=15) and FCA-
injected (n=5, fibres=17) animals did not differ significantly from each other (/J>0.05,
Wilcoxon t-test, Figure 4.11a and 4.11b). Injection of EMI had no effect on the mean
evoked discharge frequency in both naive and FCA-injected animals. There was no
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significant difference in the pre-injection capsaicin tests compared to any of the three post-
injection capsaicin tests (P>0.05, one-way ANOVA, Figure 4.11).
4.3.4 Mechanically-evoked neural discharge
4.3.4.1 Repeat mechanical and vehicle control experiments
In both naive (n=6, fibres=13) and FCA-injected (n=5, fibres=14) animals, the von
Frey filaments, were applied to the surface of the tissue surrounding the knee joint capsule
for 10s with a rest period of 10s in between each filament. These tests were repeated ten
times at intervals of 20 minutes between each set of three applications. Consistent discharge
frequencies were observed in both naive and FCA-injected animals following repeat
applications of the 1, 7 and 21g (14, 98 and 255mN) filaments over the course of the
experiments (Figure 4.12a and 4.12b). There were no significant differences between the
mean discharge frequency (impulses.s*1) evoked by the filaments, in naive or FCA-injected
animals, when each filament was analysed independently of the other two (F^O.05, one-way
ANOVA, Figure 4.12). Moreover the linear regression analysis for each filament in both
naive and FCA-injected animals, was not significantly different from zero suggesting the
trend is for the nerve to be neither sensitised nor desensitised by repeat von Frey filament
applications. Injection of vehicle (saline) at 95 minutes had no effect on the discharge
frequencies evoked by any of the individual filaments in the following tests. There was no
significant difference between the mean discharge frequencies evoked by the 1, 7 and 21g
filaments when comparing the pre-saline tests with the post-saline tests (P>0.05, one-way
ANOVA, Figure 4.12b and 4.12d).
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♦ 1g filament x 7g filament o 21g filament I I Before saline ■■After saline
(a) (b)
Figure 4.12 Graphs showing the mean change in the frequency of neural discharge above basal
activity in (a) and (b) naive and (c) and (d) FCA-injected animals evoked by a 10s stimulation with a
1, 7 and 21g von Frey filament, (a) and (c) Repeat applications of the 1, 7 and 21g filaments 20
minutes apart produced consistent mean discharge frequencies over the course of the experiment.
There was no significant difference in the mean discharge frequencies of the 1, 7 and 21g filaments
over time when analysing the filaments individually (P>0.05, one-way ANOVA). Moreover the angle
of the linear regression slope for each filament, in both naive and FCA-injected animals, is not
significantly different from zero (P>0.05, linear regression). Injection of saline at 95 minutes had no
effect on the neural discharge frequency evoked by the von Frey filaments in both (b) naive and (d)
FCA-injected animals. There was no significant difference in the mean change in discharge frequency
evoked when comparing the pre-saline 1, 7 and 21g values with the corresponding post-saline values
(P>0.05, one-way ANOVA).
4.3.4.2 Effect of EM1 andmorphine on mechanically evoked discharge
In naive animals, morphine caused a significant reduction in the mean discharge
frequency evoked by the 21g filament when comparing the five pre-opioid tests with the five
post-opioid tests (P<0.05, one-way ANOVA, n=6, fibres=l4, Figure 4.13a). There was no
significant difference however, between the mean discharge frequencies evoked by the l and
7g filament pre- and post-morphine (P>0.05, one-way ANOVA, Figure 4.13a). Injection of
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EMI in naive animals, had no effect on the mean discharge frequencies evoked by any of the
von Frey filaments studied when comparing the tests pre- and post-EMl (P>0.05, one-way
ANOVA, n=6, fibres=13, Figure 4.13b).
In FCA-injected animals injection of morphine (300pg) resulted in a significant
decrease in the mean discharge frequency evoked by the 21g filament, when comparing the
post-drug evoked firing to the pre-drug evoked firing (E<0.05, one-way ANOVA, n=5,
fibres=ll, Figure 4.13c). Injection of EMI (lOOjxg) resulted in significant decreases in the
post-drug mean change in discharge frequency compared to pre-drug with all the filaments
investigated (* F<0.05, *** PcO.OOl, one-way ANOVA, n=5, fibres=10, Figure 4.13d).
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Figure 4.13 Graphs showing the effect of morphine (300pg) and EMI (lOOpg) on von Frey filament
evoked firing in (a) and (b) naive and (c) and (d) FCA-injected animals. The mean change in the
frequency of neural discharge from background activity in naive animals evoked by application of the
1, 7 and 21g von Frey filament before and after injection of (a) morphine (n=6, fibres=14) and (b)
EMI (n=6, fibres=13). In naive animals morphine had no effect on the neural discharge frequency
evoked by the 1 and 7g von Frey filaments, but significantly reduced the mean discharge frequency
evoked by the 21g filament compared to the pre-morphine value (PcO.OS, one-way ANOVA, n=6). In
naive animals injection of EMI had no effect on the change in mean discharge frequency evoked by
any of the filaments pre- and post-EMl (P>0.05, one-way ANOVA, n=6). The mean neural discharge
frequency in FCA-injected animals evoked by application of the 1, 7 and 21g von Frey filament
before and after injection of (c) morphine (n=5, fibres=11) and (d) EMI (n=5, fibres= 10). Significant
attenuation of the mean change in neural discharge from on-going discharge was observed following
injection of morphine and EMI. Following injection of morphine the mean discharge evoked by the
21g filament was significantly lower than the mean discharge evoked from the corresponding pre-
morphine tests (P<0.05, one-way ANOVA, n=5). Injection of EMI resulted in the mean discharge
evoked by all three filaments being significantly reduced when compared to their corresponding pre-
EM1 values (*P<0.05, ***P<0.001, one-way ANOVA, n=5).
4.3.4.3 Naloxone
In FCA-injected animals pre-treatment with naloxone 180 seconds before the
injection of morphine or EMI prevented the opioid-induced reduction in discharge
frequencies evoked by both morphine and EMI described in the previous section. There was
no significant difference between the pre and post-drug mean neural discharge frequencies
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evoked by the 1,7 and 21g von Frey filament following injection of naloxone and morphine
(P>0.05, one-way ANOVA, n=4, fibres=9, Figure 4.14a) and naloxone and EMI (F>0.05,
one-way ANOVA, n=4, fibres=9, Figure 4.14b).
(a)
] Before morphine + naloxone
I After morphine + naloxone
(b)
] Before EM1 + naloxone
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Figure 4.14 Effect of the opioid antagonist naloxone (500pg) on the mean neural discharge frequency
in FCA-injected animals evoked by application of the 1,7 and 21g von Frey filament before and after
injection of (a) morphine (300pg, n=4, fibres=9) and (b) EMI (lOOpg n=4, fibres=9) where naloxone
was injected 180 seconds before the test drugs. Injection of morphine and EMI, following pre-
treatment with naloxone, resulted in there being no significant difference between pre- and post-drug
discharge frequencies at all 3 von Frey filaments (F>0.05, one-way ANOVA).
4.4 Discussion
The main finding from these studies is that peripherally administered morphine and
EMI attenuated FCA-induced joint hypersensitivity, as measured by the behavioural shift in
the amount of weight placed through the inflamed knee. Furthermore morphine and EMI
also reduced the nociceptive discharge evoked mechanically by von Frey filament
stimulation of the knee joint capsule in electrophysiological recordings from the MAN.
These effects were evident in animals 14-23 days post-FCA injection in the behavioural
experiments and 14-28 days post-FCA in the in vivo electrophysiology experiments and were
abolished by the pre-treatment of the opioid receptor antagonist naloxone. This evidence
supports the hypothesis that functional opioid receptors are present on a population of
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nociceptive afferents innervating the knee joint of rats at a more advanced stage of the FCA-
inflamed knee joint model than previously investigated (Li et al. 2005).
4.4.1 Discussion of behaviour results
Intra-articular administration of morphine and EMI reduced FCA-induced joint
hypersensitivity. This was measured using the incapacitance tester, which revealed an
increase in WD ratio towards the normal basal value of 1.0. Single doses of morphine (0.3
and lmg) given directly into the knee joint significantly attenuated the FCA-induced
hypersensitivity at various times on the day of dosing in comparison with vehicle, an effect
that was still present 4 days after the initial dose. Similarly, EMI injected directly into the
knee joint at a dose of 300pg.mf' produced a significant reversal of the FCA-induced joint
hypersensitivity back towards a normal weight distribution, half an hour after the initial
injection on day 14. Furthermore, the overall effect of the three injections of the different
doses of EMI given was a significant attenuation of the FCA-induced joint hypersensitivity
in the 10 and 30pg dosed animals, compared to the vehicle dosed animals over the five day
period. This effect was still present on days 21 and 23 post-FCA and occurred in the highest
dose. These results are in accord with the clinical findings that a single intra-articular
injection of morphine provided a long lasting analgesia of up to 5 days post injection in
patients suffering from arthritis in the knee joint (Likar et al. 1997; Stein et al. 1999).
Morphine and EMI were injected directly into the FCA-injected knee joint under
brief halothane anaesthesia, a route of administration that has been previously used clinically
(Christophidis and Huskisson 1982). The mechanism of action of general anaesthetics in
mammals is not fully understood and halothane has been implicated in sensitising cutaneous
primary afferent nociceptors to heat stimuli in the anaesthetised monkey, a process that was
fully reversible (Campbell et al. 1984; Franks and Lieb 1994). In the present study animals
were allowed a minimum 30 minute recovery period after the injection prior to performing
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the behavioural assessments which allowed any anaesthetic effects to wear off. It is probable
that the low concentrations of halothane used and the short period of time the animals were
anaesthetised ensured that the observed analgesic effects were not due to the brief
anaesthesia, but were the result of morphine or EMI. Moreover, as the WD ratio calculated
from the incapacitance tester is dependent on the amount of weight carried by both hind
limbs, it would be reasonable to consider the un-injected limb as an internal control for any
effect of the general anaesthesia, as any effect present in the injected leg would also be
present in the un-injected leg.
The first 30pg dose of EMI caused a statistically significant increase in the group
mean WD ratio from the pre-drug, a change that was comparable with the increase observed
following the first dose of morphine at lmg. The 30pg dose of EMI injected into the knee
joint was equivalent to an estimated maximum concentration of 245pM and produced a
similar analgesic efficacy to the higher dose of morphine, which was equivalent to an
estimated maximum concentration of 6.6mM. In a previous behavioural study the ED50 of
EMI dosed directly into the spinal cord of mice was half that of the morphine dosed in the
same study (Zadina et al. 1997). The reason for the higher efficacy of EMI in both the
Zadina study and the present study is due to the fact that EMI has a higher affinity and
specificity for the p-opioid receptor, therefore causing the potent analgesic effect associated
with p-opioid receptor agonists (Zadina et al. 1997). To examine whether the analgesic
effects observed in the present behavioural study were due to p-opioid receptor activation, a
follow-up behavioural study could be conducted in which EMI is dosed in the same
injection along with a p-opioid receptor selective antagonist such as CTOP, the
conformational^ constrained synthetic cyclic peptide related to somatostatin (Pelton et al.
1986).
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4.4.2 Discussion of capsaicin-evoked neural discharge results
Close intra-arterial injection of capsaicin resulted in fast onset nociceptive discharge
activated through the ligand-gated ion channel TRPV1 (Caterina et al. 1997). Activation of
the fibres in response to capsaicin was similar in both naive and FCA-injected animals as
discussed in section 3.3.2.2., with repeat administration producing consistent levels of neural
discharge due to the 45 minute rest period in between each dose. Desensitisation of C-fibres
has been previously reported in a study where a capsaicin solution was applied topically to
the skin of rats (Lynn et al. 1992). Furthermore capsaicin administered to neonates can be
neurotoxic, resulting in the destruction of the majority (95%) of nociceptors in rats
(Fitzgerald 1983; Karai et al. 2004). It was important in the present study that capsaicin
should not desensitize the TRPV1 receptor as strong evidence exists that this is the analgesic
mechanism of action of capsaicin based topical creams used by patients suffering from
painful neuropathies (Szallasi 2002).
Neither morphine nor EMI had any affect on the capsaicin-evoked increase in
nociceptive discharge in naive animals. The only significant effect of either drug in this set
of experiments was observed on the final test in FCA-injected animals following close
arterial delivery of morphine. Any effect of morphine or EMI would be expected to occur
earlier than 110 minutes after the injection, since the p-opioid receptor is G-protein coupled
and an analgesic effect mediated through an immediate secondary messenger system can
occur as soon as 10 minutes after the drug is given (Ikeda et al. 2000). An alternative
hypothesis for the significant reduction in capsaicin evoked neural discharge observed at this
late time point is that morphine-induced vasoconstriction of blood vessels supplying the knee
joint and the MAN microcirculation (Schaafsma et al. 1997) could lead to less of the
exogenous capsaicin circulating around the MAN.
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4.4.3 Discussion of mechanically-evoked neural discharge results
Graded von Frey filament stimulation is a quantitative method of investigating
mechanical allodynia and hyperalgesia in behavioural and electrophysiology studies in rats,
already discussed in section 3.4. As in the capsaicin work described above repeat mechanical
stimulation produced a consistent neural discharge in response to each of the three von Frey
filaments over the duration of the 180 minute experiments in both naive and FCA-injected
animals. In the naive animals, morphine reduced the discharge frequency evoked by the 21g
filament and had no effect in response to the 1 and 7g applications when pre- and post-drug
responses were matched. There was no significant difference between the pre- and post-drug
neural response to any of the filaments following the injection EMI. As the 7 and 21g
filament are considered to be nociceptive in this experimental paradigm, it could be
concluded from the results presented here that the dose of EMI chosen was not high enough
to produce an antinociceptive effect of the noxious mechanical stimulation in naive animals.
However, the cardiovascular effects associated with both drugs show that the doses of
morphine and EMI used were sufficient to cause a significant decrease in the B.P and heart
rate of the animals at the time of injection, and any increase in dose may lead to a potentially
fatal decrease in blood pressure and was therefore not risked at this time.
In FCA-injected animals both morphine and EMI, given at the same dose as used in
naive animals, resulted in an observable reduction in the mechanically evoked discharge by
the 1,7 or 21g filament. Morphine significantly reduced the frequency of firing evoked by
the 21g filament, and EMI also caused a significant reduction in the frequency of firing of
the nerve evoked by all 3 filaments when comparing pre- and post-responses. The
antinociceptive effect of these opioids in the arthritic animals is clearly mediated through a
p-opioid receptor mechanism, because pre-treatment with naloxone abolished the opioid-
induced reduction in neural discharge. The difference in antinociceptive potency observed
between naive and FCA-injected animals could be due to a number of FCA-induced
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inflammatory mechanisms. FCA has been shown to demyelinate peripheral A8-fibres
(Mizisin et al. 1987) and this process could lead to opioid receptors on the primary afferent
nerve axons becoming exposed to the locally administered drugs that are not normally
accessible in the naive animals because the intact perineural membrane acts as a barrier.
Perineural damage following inflammation has been reported to occur within 12 hours of the
inflammatory insult as a result of a low local pH (Antonijevic et al. 1995).
Inflammation has also been associated with an up-regulation of the p-opioid receptor
in DRG of small diameter primary afferent nerves C-fibres, with axonal transport of the
receptors to the periphery being dependent on neuronal conduction (Puehler et al. 2004).
Evidence also exists suggesting that inflammation increases p-opioid receptor binding
affinity and enhances the efficacy of full and partial p-opioid receptor agonists in G-protein
coupling (Zollner et al. 2003).
4.4.4 Summary
The results of the present study, together with publications from Stein's research
group and collaborators on mechanisms of peripherally-mediated opioid analgesia (Stein
1991; Schafer et al. 1995; Stein 1995; Machelska et al. 1999; Stein et al. 2003; Zollner et al.
2003) support the hypothesis that functional opioid receptors are present on peripheral
nociceptive afferent nerve fibres innervating the inflamed rat knee joint. A typical value for
the proportion of non-inflamed unmyelinated peripheral sensory nerve axons expressing the
p-opioid receptor is 29% (Coggeshall et al. 1997). It is reasonable to hypothesise that
inflammation triggers an increase in the production of p-opioid receptors in the DRG of
nociceptors, and these opioid receptors are transported to the periphery as part of the
inflammatory response. This would certainly help explain the clinical analgesic action of
peripherally administered opioid agonists in the management of inflammatory joint pain.
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The results presented in this chapter do not concur with studies reporting that the
supply of the opioid receptors from the DRG to the periphery is such that it is unable to
maintain a functional population of receptors as they are down-regulated as a consequence of
inflammation (McDougall et al. 2004a; b; Li et al. 2005). As the models of inflammation
used in those studies and the present study are the same, utilising an intra-articular injection
of FCA, it is puzzling that the results produced appear to contradict each other. An
explanation may be that a proportion of the functional opioid receptors are down-regulated at
the time points studied in the McDougall group publications, but some functional receptors
are still present, all be it in reduced numbers. The doses administered in these studies may
not have been sufficiently high enough to elicit a response in the remaining functional
receptors, leading the group to conclude that they are completely absent at that time. In order
to further understand and evaluate the full therapeutic potential of opiate receptor agonists in
the treatment of chronic inflammatory pain it will be necessary to perform similar pre¬
clinical studies in chronic stages of other inflammatory pain models that exist. Moreover
investigations performed long after the initial inflammatory insult may be more comparable
to the established chronic pain observed in the clinic.
In conclusion, the present study supports the hypothesis that peripherally
administered or restricted opioid receptor agonists may play an important role in long term
pain management, with the benefit of avoiding the undesirable centrally mediated side-
effects seen following systemic opioid administration.
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Chapter 5
Development and validation of the pressure
application measurement (PAM) device
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5.1 Introduction
Chronic joint pain is the most common symptom described by patients suffering
from musculoskeletal conditions such as OA (Tallon et al. 2000; Dieppe and Lohmander
2005). The prevalence of both OA and RA is high within the UK adult population, with
estimated incidences of 12.5% (Bedson et al. 2005) and 0.8% (Symmons 2002) respectively.
Patients suffering from RA generally report to health care professionals that improving the
joint pain associated with their condition as having the highest priority (Heiberg and Kvien
2002; Heiberg et al. 2005).
There have been many studies searching for a single, reliable, and clinically
convenient measure of pain in inflamed joints in patients with RA (Lansbury and Haut 1956;
Mainland 1967). Measuring joint pain in the clinic is often performed by the patient in the
form of a 'subjective' self-assessed questionnaire (Gooberman-Hill et al. 2007). Several of
these questionnaires, such as the visual analogue scale, have been developed to provide a
score of pain status and functionality of the affected joint (Melzack 1975; Bellamy et al.
1988; Roos et al. 1998; Anderson 2001; Adamson et al. 2004). Responses to these
standardised questions can lead to high volumes of low cost, quantitative data that can be
easily used to monitor whether a patient's condition improves, is maintained or worsens over
time, however are not usable in pre-clinical animal models.
As an alternative to patient self-assessments, instruments and physical examinations
have regularly been used to directly assess joint tenderness (Sokka 2003). The Ritchie
articular index (Ritchie et al. 1968) is an examination that involves firmly squeezing the knee
joint and then grading the tenderness of the joint based on the patients reaction using a four
point scale (Table 5.1).
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Score 0 1 2 3
Patients reaction Not tender Tender Tender and Tender, winced
winced and withdrew
Table 5.1 A summary table detailing the Ritchie index used for assessing joint hypersensitivity in OA
and RA patients. A score of 0-3 is awarded depending on the patients' reaction to squeezing of the
joint.
This method is a generally accepted measure of assessing joint pain, but it still
remains subjective and therefore potentially unreliable. The algesiometer and
sphygmomanometer were the first objective instruments designed to measure joint
tenderness by applying a graded pressure across the joint (Mandel 1956). Currently used in
the clinic, the dolorimeter is an instrument that measures joint tenderness in much the same
way (Langley et al. 1983). A gradually increasing localised pressure is applied
perpendicularly across the affected joint using this device until the patient reports tenderness
or pain, at which point a sensitivity score is recorded. In a drug withdrawal study the
dolorimeter was able to detect subtle changes in joint tenderness whereas the Ritchie
articular index was not (Langley et al. 1983), suggesting that by removing subjectivity from
the test improves the accuracy of the final outcome.
There is demand in the clinic to successfully manage long-term chronic joint pain
(Ashburn and Staats 1999; Rubin 2005), and as a result several rodent models of chronic
inflammatory joint pain have been developed as discussed in the introduction to this thesis.
These models are commonly used as pre-clinical screens to measure the efficacy of novel
analgesics which aim to improve on the treatments currently available. In order to do this
successfully, it is essential that results and assessments from animal models in pre-clinical
tests accurately reflect observations made in the clinic. Animal self-assessments are
obviously not possible, and with the lack of verbal communication, several behavioural
readouts have been developed which can be used to assess joint sensitivity in rodents in a
reliable and ethical manner.
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Historically thermal, mechanical and electrical stimuli have been employed to
determine nociceptive thresholds in animals and to date several different behavioural
readouts have been used (Le Bars et al. 2001). For instance, the tail-flick test to heat involves
focusing a beam of light on the tip of the tail and the latency of tail withdrawal is measured
(Stein et al. 1988; Sluka and Westlund 1993). The Randall and Selitto analgesy-meter is
operated and an increasing mechanical force is applied to the dorsal surface of the foot of
rodents until the weight becomes noxious and the animal withdraws from the apparatus as a
reflex (Randall and Selitto 1957; Attal et al. 1988). Behavioural readouts designed to assess
gait analysis (Clarke et al. 1997; Hamers et al. 2001; Vrinten and Hamers 2003) and paw
elevation time on a rotating cylinder (Tonussi and Ferreira 1992) measure pain indirectly in
the form of the mobility of the whole animal. All of these techniques are limited by the fact
that they cannot be applied directly to the knee to assess localised joint pain.
A patient with knee joint pain will guard the affected joint by shifting their weight to
the other leg, although in RA if both joints are affected then this may not be evident. The
incapacitance tester is a commonly used behavioural evaluation that provides an assessment
of the hind limb weight distribution in rodents that correlates with the clinical assessment of
pain on standing (Schott et al. 1994; Clayton et al. 1997). The apparatus (described in section
2.2.1.) measures the amount of weight the animal places through each hind limb over a three
second period. Under normal conditions naive rodents will distribute their weight evenly
across both hind limbs (Kobayashi et al. 2003). Animals with a unilateral joint
hypersensitivity alter their resting stance to place less weight on the affected limb. Following
treatment with a range of clinically effective gold standard analgesics this uneven stance can
be reversed back towards an equal weight distribution (Wilson et al. 2006).
Calibrated forceps housing force transducers have been developed to assess paw
limb withdrawal thresholds in behavioural studies, and are often used in electrophysiological
experiments to evoke a measureable noxious stimulus (Yu et al. 2002; Luis-Delgado et al.
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2006). The transducers measure the force applied between the tips of the forceps which is
then displayed on a separate unit. Using the forceps a gradually increasing squeeze is placed
on the paw of the animal. When the animal vocalises or withdraws from the apparatus the
test is ended and the force applied is recorded. The application of a compression or squeeze
force across the affected area is comparable to the Ritchie index and dolorimeter used in the
clinic, but still does not focus on the knee joint due to the size of the apparatus and how wide
the forceps would have to be opened to be applied to the knee joint.
In this chapter the development and validation of a pressure application
measurement device (PAM) for use in both mice and rats is described (Strickland et al. 2005;
Barton et al. 2007c). Adopting a similar principle to the clinical dolorimeter, a gradually
increasing squeeze force is applied across the knee joint until the animal withdraws its limb
from the apparatus. At this end-point the maximum force applied across the joint in grams is
recorded to provide a quantitative objective measure of the sensitivity of the knee joint (see
Section 2.2.2.).
The aim of the studies reported in this chapter was to evaluate the sensitivity of the
readout in animals with a unilateral joint hypersensitivity and determine whether PAM could
detect a reversal of this hypersensitivity when the animals were dosed with clinically
effective analgesics. To validate the rat specific PAM device, a dose response study to
prednisolone (Pyne et al. 2004), was conducted in parallel with single doses of morphine and
celecoxib known to be effective as shown in previous studies (Caldwell et al. 2002;
Schnitzer et al. 2005). A smaller study to validate the mouse specific PAM device was
conducted investigating any analgesic effect of prednisolone (Gauldie et al. 2004).
Throughout the studies results for PAM were compared with the already established WD
results obtained from the incapacitance tester.
120
5.2 Methods
Chapter 5: Development and validation ofPAM
5.2.1 PAM apparatus
The first working PAM model was designed and built by Dr. H.M. Brash, a medical
physicist at The University of Edinburgh, in collaboration with Prof. D.S. McQueen and Dr.
A.W. Wilson (formerly of GlaxoSmithKline) who proposed the initial concept. The
development and validation of the device was a project undertaken jointly by Dr. N.J. Barton
and myself as part of independent Ph.D. studies (Strickland et al. 2005). At various stages
through this project PAM was modified and fine-tuned to optimise its application based on
feedback provided by Dr. N..T. Barton and myself. We developed two fully functioning PAM
devices, one designed for use on rats and the other for use on mice (Barton et al. 2007c).
The PAM apparatus consists of a recording base unit containing a digital display and
control buttons which is connected to a force transducer embedded in a moulded plastic
thumb unit (Figure 5.1). The plastic unit is secured to the thumb using a Velcro fastened
elasticated strap. Due to the difference in the size between a rat and a mouse knee joint,
different force transducers were used in each species specific PAM device. In each case the
force transducers have a circular contact area made of smooth, 1 mm thick, rigid rubber. The
rat instrument utilises a force transducer with a contact diameter of 8mm and surface area of
50.3mm2 capable of measuring between 0 - 1500g (transducer - FSG-15N1A, Honeywell,
Farnell, UK). The force transducer employed in the mouse PAM device has a contact
diameter of 5mm, a surface area of 19.6mm2, and has a measurable range of 0 - 500g
(transducer - FSF-05N2C, Honeywell, Farnell, UK).
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Figure 5.1 Photograph of the thumb unit of the pressure application measurement (PAM) device in
use with a Male Wistar rat. The rat was lightly but securely held and the knee was subject to the
gradually increasing squeeze force applied between the forefinger and force transducer until a point
where the animal withdrew its limb from the apparatus.
5.2.2 Limb withdrawal threshold (LWT) assessment
The PAM device was used to assess the LWT as described in Section 2.2.2. At the
point the animal withdraws from the apparatus the highest force applied is automatically
displayed and manually recorded on a data sheet. The group mean LWT (gf) and the mean
LWT ratio (± SEM) were calculated for each animal at each time point. Assistance was
provided throughout by either Dr. N.J. Barton or Mrs. S.M. Bond.
5.2.3 Rat study design
An initial pilot study was performed in rats (n=16) to establish whether PAM was
able to detect a localised hypersensitivity of the knee joint following an intra-articular
injection of FCA (see Section 2.1.2). The aim of the study was to compare the LWTs of
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FCA-injected knee joints with non-injected knee joints within the same animals, and with
naive animals. The study was also designed to compare PAM results with the already
established weight distribution readout results. On each test day; the body weight, knee joint
diameter, LWT and weight distribution were measured as described in section 2.2.
Measurements followed a strict protocol to ensure the animals had breaks between
measurements and did not become stressed by the procedure. Briefly, an animal was
weighed and three consecutive weight distribution readings were taken and the animal was
returned to the cage. Five minutes later, the animal had alternate measurements of the
ipsilateral and contralateral limb assessed using PAM. This was repeated 3 times with a
minute break in between each measurement. Finally the animal had its knee joint diameter
measured. On day 0 baseline values were taken and animals were ranked, randomised and
assigned to either the FCA (n=8) or the naive (n=8) group, and received the appropriate
treatment. Further measurements were then made 2-3 times a week up to day 28.
Following the pilot study, a larger drug study (n=56) was performed in our
laboratory by Dr. N.J. Barton and Mrs. S.M. Bond to investigate whether PAM could be
used to detect an analgesic effect expected from compounds with differing mechanisms of
action. PAM was tested using the opioid morphine, the steroid prednisolone and the non¬
steroidal anti-inflammatory celecoxib, PAM was tested as to whether it could detect a
reversal in the FCA-induced knee joint hypersensitivity as observed previously in the pilot
study. In order to perform a thorough pharmacological investigation, whilst using the
minimum number of animals, a dose response effect of prednisolone (1, 3 and lOmg.kg"1)
and single doses of morphine (3mg.kg"') and celecoxib (15mg.kg_1) were examined with the
drugs dosed chronically over a five day period.
As a consequence of the results observed in the pilot study, a pre-study behavioural
assessment was introduced to habituate the animals to the PAM device. Baseline
measurements were made on day 0 and subsequently animals were given either an intra-
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articular injection of FCA (n=48) or naive treatment (n=8). Measurements were made 2-3
times a week up to day 10. FCA-injected animals were ranked by how severe the joint
hypersensitivity was on day 10, from most severe (low LWT ratio) to least severe (high
LWT ratio). The animals were then assigned to one of 6 treatment groups ensuring that each
group had an even spread of severity of FCA-induced hypersensitivity. The following drugs
were then blindly dosed subcutaneously (s.c.) at a volume of 2ml.kg"1 on days 14-18:
• Vehicle (ethanol 5%, Polyethylene Glycol [PEG] 45% and distilled water 50%)
• Prednisolone lmg.kg'1 (dosed once a day at 9am)
• Prednisolone 3mg.kg"' (dosed once a day at 9am)
• Prednisolone lOmg.kg"1 (dosed once a day at 9am)
• Morphine 3mg.kg": (dosed twice daily at 9am and 4pm)
• Celecoxib 15mg.kg_1 (dosed twice a daily at 9am and 4pm)
One hour after the morning dose behavioural measurements were made with further
behavioural assessments being carried out on days 21, 24 and 28.
5.2.4 Mouse study design
In addition to the two rat studies performed, a murine study (n=24) was carried out
to validate the PAM device for mice. On each test day; the body weight, knee joint diameter,
LWT and weight distribution were measured following the same protocol as the rat studies
described above. Pre-injection measurements were made on day 0 and animals were assigned
to either FCA (n=16) or naive (n=8) action group. Following injection of FCA, animals had
their behaviour, weight and knee joint diameter assessed 2-3 times a week up to day 10. The
FCA-injected animals were then ranked by their day 10 LWT ratio and assigned to either the
prednisolone (n=8) or vehicle (n=8) treatment group. On days 13-17 animals were dosed
blindly once a day with either prednisolone lmg.kg"1 or vehicle (s.c.) at a volume of
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3ml.kg"1. Behavioural assessments took place one hour after dosing. After the completion of
the dosing period, a final behavioural assessment was made on day 20.
5.2.5 Statistical analysis
Data were collected and collated in Microsoft Excel. The data were then analysed in
GraphPad prism defined by the criteria stated in Section 2.5. Differences between two
individual group mean values were analysed using a Wilcoxon t-test or an un-paired t-test
depending on whether the data were paired or un-paired respectively. Results obtained from
the behavioural studies were expressed as the group mean (± SEM) for both the WD and
LWT ratios. The statistical test used to compare differences within the same group over time
was a one-way ANOVA followed by a Dunn's post-hoc test as appropriate. The test used to
compare differences between two or more different groups over time was the two-way
ANOVA followed by Bonferroni's post-hoc test. In order to compare statistically the AUC
values calculated from each dose of drug over the dosing period, a Kruskal-Wallis ANOVA
was used followed by a Dunn's post-hoc to compare the different doses back to vehicle. In
all cases P<0.05 was considered statistically significant.
5.3 Results
In all the studies performed, the intra-articular injection of FCA had no adverse
effects on the general health of the animals. Rats continued to gain body weight normally
throughout the studies (Figure 5.2). There was no significant difference in the mean body
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Figure 5.2 Figure illustrating the effect of an intra-articular injection on the body weights of rats in
the pilot study. There was no significant differences in the group mean body weights between FCA-
injected and naive animals (P>0.05, two-way ANOVA). Following FCA injection (day 0) the animals
did not gain as much weight over the following 24 hours as the naive animals, but then gained weight
normally thereafter. The group mean body weight of the FCA-injected animals was always slightly
lower than that of naive animals.
5.3.1 Pilot study in rats
5.3.1.1 Assessment of the limb withdrawal threshold
On day 0, baseline recordings revealed that the mean ipsilateral LWT was 720 ±
31gf and the mean contralateral LWT was 791 ± 34gf, these were not significantly different
from each other (P>0.05, Mann Whitney, n=16). Considering the baseline values with the
animals in their assigned groups, there was no significant difference between the group mean
LWTs for each individual limb (P>0.05, one-way ANOVA, n=8; Figure 5.3a), meaning
there was no difference in the results obtained from the left and right knee, and no significant
difference between the mean FCA LWT ratio and the mean naive LWT ratio (F>0.05, Mann
Whitney, n=8; Figure 5.4a).
In FCA-injected animals, the group mean ipsilateral LWT on day 1 decreased by
55% to 316 ± 45gf, a significant difference compared to both the previous day's group mean
value (P<0.05, Wilcoxon) and also to the naive group mean value at the same time point
(P<0.05, Mann Whitney). Interestingly, the mean ipsilateral LWT of the naive group
increased significantly by 28% to 1028 ± 48gf by day 1 compared to day 0 (P<0.05,
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Wilcoxon). Similar increases in the LWT were observed in the contralateral limbs of both
the FCA and naive groups over the first 24 hours rising 10% and 15% respectively (see
Figure 5.3a). The mean LWT ratio of the FCA-injected animals decreased a significant
amount from the day 0 value of 0.87 ± 0.1, to the day 1 value of 0.36 ± 0.07 (P<0.05,
Wilcoxon).
Throughout the 28 day test period, the mean ipsilateral LWT of the FCA-injected
animals remained significantly lower than the naive and contralateral mean LWTs (P<0.05,
two-way ANOVA; Figure 5.3a). Similarly the mean LWT ratio of the FCA-injected animals
remained significantly lower than the mean LWT ratio of the naive animals over the 28 day
test period (P<0.05, two-way ANOVA; Figure 5.4a).
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Figure 5.3 Figure showing the (a) PAM LWTs, (b) the weight carried by each hind limb over a three
second period and (c) the knee joint diameter of naive and FCA-injected rats over a 28 day pilot study.
The inflammation of the FCA-injected limb was manifest as an increase in the knee joint diameter and
was accompanied by a significant decrease in the LWTs and the amount of weight the animals placed
through the limb. * represents statistical significance (P<0.05) comparing each group at each time
point using a two-way ANOVA followed by a Bonferroni post-hoc test.
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5.3.1.2 Assessment of weight distribution
Prior to any treatment the mean weight carried by the ipsilateral and contralateral
hind limbs was 101 ± 3g and 97 ± 4g respectively, giving a WD ratio of 0.96 ± 0.01 (n=16).
At time 0 there was no significant difference between the group mean weight placed through
any of the hind limbs (P>0.05, one-way ANOVA, n=8; Figure 5.3b) and no significant
difference between the mean WD ratio of the FCA or naive animals (P>0.05, Mann
Whitney, n=8; Figure 5.4b).
The mean weight placed through the ipsilateral and contralateral hind limbs of FCA-
injected animals on day 1 was 40 ± 7g and 140 ± 7g respectively. The ipsilateral value was
significantly lower than the previous days group mean value (P<0.05, Wilcoxon) and also to
the naive ipsilateral group mean value at the same time point (P<0.05, Mann Whitney).
Subsequently, the mean WD ratio of the FCA group fell by 63% to 0.36 ± 0.04. This was
significantly lower than in the naive group where animals placed an average of 116 ± 4g and
110 ± 5g through the ipsilateral and contralateral limbs respectively, a WD ratio of 1.07 ±
0.03 (P<0.05, Mann Whitney, n=8).
The mean weight placed through the FCA-injected limb remained significantly
lower than the naive and both contralateral hind limb weights throughout the 28 day period
(P<0.05, two-way ANOVA; Figure 5.3b). Similarly the WD ratio of the FCA group
remained significantly lower than the naive group on each test over the test period (P<0.05,
two-way ANOVA; Figure 5.4b).
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Figure 5.4 Figure showing the (a) PAM LWT ratios, (b) the weight distribution ratios and (c) the knee
joint diameter ratios of rats over a 28 day pilot study. The PAM LWT ratio of both FCA and naive
animals had a similar 28 day profile to that of the weight distribution ratio. * represents statistical
significance (PcO.05) comparing each group at each time point using a two-way ANOVA followed by
a Bonferroni post-hoc test.
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5.3.1.3 Assessment of inflammation induced by FCA
Baseline recordings of the ipsilateral and contralateral knee joint diameter taken on
day 0 were 9.86 ± 0.05mm and 9.91 ± 0.07mm respectively. There was no significant
difference between these values (F>0.05, Mann Whitney, n=16). The mean knee joint
diameter ratios on day 0 were 1.00 ± 0.01 in the naive group and 1.01 ± 0.01 in the FCA
group again with no significant difference between the groups (F>0.05, Mann Whitney,
n=8).
On day 1 the mean diameter of the FCA-injected knee was 13.11 ± 0.56mm, an
increase of 25% from the previous day and a significantly higher value than the naive
ipsilateral value of 10.20 ± 0.16mm (F>0.05, Mann Whitney, n=8; Figure 5.3c). The peak
mean joint diameter of the FCA-injected knee was 13.50 ± 0.19mm and observed on day 2.
Following this reading the knee joint diameter gradually returned towards naive and
contralateral levels.
The swelling in the FCA-injected knee remained significantly greater than the naive
animals on days 1-15 (F<0.05, two-way ANOVA; see Figure 5.3c). The knee joint diameter
ratio of the FCA group remained significantly higher than that of the naive animals on all
days in the 28 day test period with the exception of day 21 (F<0.05, two-way ANOVA;
Figure 5.4c).
5.3.1.4 Correlation of rat PAM LWT ratio and WD ratio
In order to compare the LWT and WD readouts directly, the ratios obtained on the
11 experimental days over the 28 day study period were plotted against each other on an XY
plot with a linear regression line (see Figure 5.5). The ratios were used because in both
readouts the contralateral limb acts as an internal control, having previously established that
it didn't change. A strong positive correlation between the ratios obtained from each readout
was observed using Spearman's Linear correlation (Spearman r=0.76, F<0.0001).
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Figure 5.5 Plot showing the correlation between the PAM LWT ratios and the WD ratios obtained
from the same animals during the rat pilot study. There was a strong positive correlation between the
two readouts, which was highly significant (Spearman r=0.76, P<0.0001, n=176, 16 measurements
per day for 11 days)
5.3.2 Drug studies in rats
5.3.2.1 Assessment of the limb withdrawal threshold
The study discussed in section 5.3.2 was performed by Dr. N. Barton and Mrs. S.
Bond, although the analysis of results was performed independently. Prior to FCA-injection
the mean ipsilateral LWT was 1066 ± 24gf and the mean contralateral LWT was 1037 ±
21gf, which were not significantly different from each other (P>0.05, Wilcoxon, n=55).
There was no significant difference between the mean LWT ratios in any of the dosing
groups at this time point (P>0.05, one-way ANOVA, n=8).
FCA resulted in a joint hypersensitivity which was apparent by day 2 and was still
present on day 10. On days 2, 4, 7 and 10 the mean FCA-injected LWTs were significantly
lower than the corresponding contralateral LWTs in the same animals and the LWTs of
naive animals (P<0.05, two-way ANOVA, n=47; Figure 5.6a). The mean group LWT ratios
of FCA-injected animals were significantly lower than the naive LWT ratios at each time
point through days 2-10 (P<0.05, two-way ANOVA, n=47; Figure 5.6d).
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Figure 5.6 Summary of the rat mean values of the absolute (a) PAM LWTs, (b) weight placed
through each hind limb and (c) knee joint diameters for each limb following naive or FCA treatment
from day 0 up to day 10, when drug treatment commenced. The mean group ratios of (d) PAM LWTs,
(e) weight distribution and (f) knee joint diameter of the individual dosing groups from day 0 to day
10. * represents statistical significance (P<0.05) comparing the groups at each time point using a two-
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Drugs were administered daily for a five day period starting on day 14 (Figure 5.7a
& 5.8a). AUC values for the LWT ratios over the 5 day dosing period were calculated for
each individual animal, using the day 10 reading as the baseline, to observe if there was any
reversal of hypersensitivity due to the drugs being administered compared to vehicle. Results
showed that PAM was able to detect the expected significant analgesic effect of morphine
3mg.kg" , celecoxib 15mg.kg_1 and the top dose of prednisolone during the dosing period
(P<0.05, one-way ANOVA, n=8; Figure 5.7c & 5.8c).
Following the cessation of the dosing period on day 18, further assessments were
made on day 21, 24 and 28. The analgesic effects observed during the dosing period were
absent on days 21, 24 and 28, and the LWT ratios of the drug groups returned to not being
significantly different to the vehicle group (P>0.05, two-way ANOVA, n=8).
5.3.2.2 Assessment of weight distribution
There was no significant difference (P>0.05, Wilcoxon, n=55) between the weight
placed through the limbs to be injected with FCA (64 ± lgf) compared to the contralateral
limbs (63 ± lgf) prior to FCA-injection. There was also no significant difference between the
mean WD ratios of each of the dosing groups at this time point (P>0.05, one-way ANOVA,
n=8).
The injection of FCA caused a joint hypersensitivity that was present at days 2-10.
Animals placed significantly less weight through the FCA-injected limb than the
corresponding contralateral limb in the same animals and both limbs of naive animals
(P<0.05, two-way ANOVA, n=47; Figure 5.6b). The mean group WD ratios of FCA-
injected animals were significantly lower than the naive WD ratios at each time point
(P<0.05, two-way ANOVA, n=47; Figure 5.6e).
A five day dosing period began on day 14 where drugs were administered daily
followed by the behavioural assessments one hour later (Figure 5.7b & 5.8b). The WD ratios
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for each individual animal over the 5 day dosing period were transformed into AUC values,
using the day 10 reading as the baseline. Any analgesic effect of the drugs was investigated
by comparing the AUC values for each dosing group to the AUC values from the vehicle
group. Results showed that the incapacitance tester detected the analgesic effect of morphine
3mg.kg_1, celecoxib ISmg.kg"1 and the top dose of prednisolone (lOmg.kg"1) during the
dosing period (P<0.05, one-way ANOVA, n=8; Figure 5.7d & 5.8d).
Following the cessation of the dosing period, the WD ratios of the drug groups on
days 21, 24 and 28 reverted to those of the vehicle group. The reduction of hypersensitivity
observed as a result of administering the drugs was absent and dosing groups were no longer
significantly different to the vehicle group (P>0.05, two-way ANOVA, n=8).
5.3.2.3 Assessment of inflammation induced by FCA
There was no significant difference (P>0.05, Wilcoxon, n=55) between the knee
joint diameter of the ipsilateral limbs (8.81 ± 0.13mm) compared to the contralateral limbs
(8.97 ± 0.09mm) prior to FCA-injection. There was also no significant difference between
the mean knee joint diameter ratios of each of the dosing groups on day 0 (P>0.05, one-way
ANOVA, n=8).
FCA resulted in a unilateral inflammation that caused the ipsilateral knee becoming
significantly greater in diameter than contralateral and naive knee joint diameters on days 2,
4, 7 and 10 post-FCA (P<0.05, two-way ANOVA, n=47; Figure 5.6c). The mean group knee
joint diameter ratios of FCA-injected animals were significantly lower than the naive knee
joint diameter ratios at each time point through days 2-10 (P<0.05, two-way ANOVA, n=47;
Figure 5.6f).
Administration of morphine 3mg.kg"', celecoxib 15mg.kg"', or prednisolone at 3 or
lOmg.kg"1 did not significantly affect the swelling observed in the ipsilateral limbs of FCA-
injected animals compared to vehicle (P>0.05, one-way ANOVA, n=8; Figure 5.9).
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Prednisolone at lmg.kg"1 did however reduce the amount of swelling in the ipsilateral limbs
compared to vehicle, seen as a significant increase in the AUC group value compared to
vehicle (P<0.05, one-way ANOVA, n=8; Figure 5.9)
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Figure 5.7 Figure showing the mean (a) PAM LWT ratios and (b) WD ratios of the morphine-,
celecoxib- and vehicle-treated animals following injection of FCA from day 10 through to day 28. The
dosing period (day 14-18) is indicated by the shaded area. The corresponding PAM and WD ratio
AUC graphs (b & d) during the dosing period were analysed to compare the celecoxib (15mg.mr')
and morphine (3mg.mr') treated groups to the vehicle-treated group. * represents statistical
significance (P<0.05) comparing the dosing groups to vehicle using a one-way ANOVA followed by
Dunn's post-hoc test.
136





I 1 I 1 1 1 I 1 1 1
10 12 14 16 18 20 22 24 26 28












' Pred Img.kg (n=8)























I l 1 l 1 1 1 1 1 1
10 12 14 16 18 20 22 24 26 28












' Pred Img.kg"1 (n=8)















Figure 5.8 Figure showing the mean (a) PAM LWT ratios and (b) WD ratios of the prednisolone- and
vehicle-treated animals following injection of FCA from day 10 through to day 28. The dosing period
(day 14-18) is indicated by the shaded area. The corresponding PAM and WD ratio AUC graphs (b &
d) during the dosing period were analysed to compare the prednisolone 1-lOmg.kg"1 groups to the
vehicle-treated group. * represents statistical significance (P<0.05) comparing the dosing groups to
vehicle using a one-way ANOVA followed by a Dunn's post-hoc test.
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Figure 5.9 Plots showing the mean knee joint diameter ratios observed at days 10-28 post-FCA and
the accompanying AUC ratio graphs from the dosing period of the rat drug study for (a & c) celecoxib
and morphine and (b & d) prednisolone. The dosing period (day 14-18) is indicated by the shaded
area. * represents statistical significance (P<0.05) using a one-way ANOVA followed by Dunn's post-
hoc test to compare the vehicle group to each dosing group.
5.3.3 Pilot study in mice
5.3.3.1 Assessment of the limb withdrawal threshold
On day 0 the ipsilateral and contralateral mean LWTs of mice were 414 ± lOgf and
381 ± 14gf respectively and were not significantly different (P>0.05, Wilcoxon, n=24).
When analysing the mean LWT ratios of the assigned groups; FCA + prednisolone lmg.kg"1,
FCA + vehicle, and naive there was no significant difference between the group mean values
of 1.14 ± 0.09, 1.21 ±0.1 and 1.15 ± 0.1 respectively (P>0.05, one-way ANOVA, n=8).
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By day 1 post-FCA the mean ipsilateral LWT of FCA-injected animals decreased by
60% to 162 ± 9gf compared to the day 0 values (P<0.05, Wilcoxon, n=16, Figure 5.10a) and
was significantly lower than naive at the same time point (P<0.05, Mann Whitney, n=8). The
PAM LWT ratio of the FCA injected animals was also significantly reduced over the 1 day
period from 1.17 ± 0.27 to 0.63 ± 0.04 (P<0.05, Wilcoxon, n=8, Figure 5.10d). Surprisingly
there was a significant decrease in the LWTs of contralateral limbs from day 0 to day 1 with
the group mean LWT decreasing by 22% to 297 ± 12gf (P<0.05, Wilcoxon, n=8, Figure
5.10a). The group mean LWT ratio of the naive animals did not change significantly
following FCA. The mean LWT ratios of FCA-injected animals remained significantly lower
than naive animals on days 3 and 10 (P<0.05, two-way ANOVA, n=24; Figure 5. lOd).
Prednisolone caused a reversal of hypersensitivity in FCA-injected mice that was
significantly different to vehicle on days 16 and 17 (P<0.05, two-way ANOVA, n=24;
Figure 5.11a). The mean AUC values calculated for prednisolone lmg.kg"1 and vehicle over
the 5 day dosing period were significantly different (P<0.05, Mann Whitney, n=8; Figure
5.1 Id). Following the cessation of dosing the LWT ratio of the prednisolone group on day 20
reverted back to being no longer significantly different to the vehicle group (P>0.05, Mann
Whitney, n=8).
5.3.3.2 Assessment of weight distribution
The mean weight placed through the ipsilateral and contralateral limbs was 9.9 ± lg
and 9.8 ± lg respectively, which were not significantly different from each other (P>0.05,
Wilcoxon, n=24). On day 0 the group mean WD ratios of the prednisolone, vehicle and nai've
groups were 1 ± 0.03, 1 ± 0.03 and 1 ± 0.02 respectively and were not significantly different
(P>0.05, one-way ANOVA, n=8).
Injection of FCA caused the mean weight placed through the ipsilateral limb of
FCA-injected animals to fall significantly to 7.22 ± 0.49g. This was significantly lower than
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the day 0 values (P<0.05, Wilcoxon, n=16, Figure 5.10b) and naive at the same time point
(P<0.05, Mann Whitney, n=8). The WD ratio of the FCA injected animals was also
significantly reduced over the 24 hours from 1.01 ± 0.20 to 0.64 ± 0.06 (P<0.05, Wilcoxon,
n=8, Figure 5.10b). The mean WD ratio of FCA-injected animals remained significantly
lower than naive animals on days 1, 3 and 10 post-FCA (P<0.05, two-way ANOVA, n=24;
Figure 5.10e).
During the dosing period prednisolone reversed hypersensitivity in FCA-injected
mice, such that the LWT ratio was significantly higher to vehicle on day 17 (P<0.05, two-
way ANOVA, n=24; Figure 5.11a). The mean AUC values calculated for prednisolone
lmg.kg"1 and vehicle over the 5 day dosing period were significantly different (P<0.05,
Mann Whitney, n=8; Figure 5.lie). Following the cessation of dosing the WD ratio of the
prednisolone group on day 20 was no longer significantly different to that of the vehicle
group (P>0.05, Mann Whitney, n=8).
5.3.3.3 Assessment of inflammation induced by FCA
The mean ipsilateral and contralateral knee joint diameters taken prior to FCA-
injection were 4.02 ± 0.02mm and 4.01 ± 0.02mm and were not significantly different from
each other (P>0.05, Wilcoxon, n=24). Injection of FCA (n=16) caused the mean ipsilateral
knee joints to swell significantly (P<0.05, one-way ANOVA; Figure 5.10c) to 4.82 ±
0.10mm, compared to both the naive group (4.13 ± 0.06mm, n=8) and all the contralateral
limbs (4.05± 0.02mm, n=24) at the same time point. The group mean knee joint diameter
ratios of the FCA-injected animals (n= 16) remained significantly lower than naive animals
(n=8) up to day 10 (P<0.05, two-way ANOVA; Figure 5. lOf).
Prednisolone had no significant effect on the knee joint diameter ratio on any day
during the dosing period or on the mean AUC values calculated during this time period
(P>0.05, two-way ANOVA and Mann Whitney; Figure 5.11c & 5.1 If).
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Figure 5.10 Figure showing the mean values of the absolute (a) PAM LWTs, (b) weight placed
through each hind limb and (c) knee joint diameters in mice for each limb following naive or FCA
treatment from day 0 up to day 10 prior to drug treatment. The mean group ratios of (d) PAM LWTs,
(e) weight distribution and (f) knee joint diameter of the individual dosing groups from day 0 to day
10. * represents statistical significance (P<0.05) comparing the groups at each time point using a two-
way ANOVA followed by a Bonferroni post-hoc test.
141


















10 12 14 16 18










































































Time post FCA (days)
'
FCA + Prednisolone "Img.kg"1




















Figure 5.11 Summary of results performed using mice showing the mean (a) PAM LWT ratios, (b)
WD ratios and (c) knee diameter ratios of the prednisolone (lmg.kg"1) and vehicle-treated animals
following injection of FCA from day 10 through to day 20. The dosing period (day 13-17) is indicated
by the shaded area. * represents statistical significance (P<0.05) comparing the prednisolone group to
vehicle using a two-way ANOVA followed by a Bonferroni post-hoc test. The corresponding PAM,
WD and knee joint diameter ratio AUC graphs (d, e and f) during the dosing period were analysed to
compare the drug-treated groups to the vehicle-treated group. * represents statistical significance
(P<0.05) comparing the prednisolone group to vehicle using a Mann Whitney test.
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5.3.3.4 Correlation ofmouse PAM LWT ratio and WD ratio
In order to compare the two different readouts investigated in the mouse
pilot study a correlation of the LWT ratio results and WD ratio results was calculated. The
ratios measured over the 10 experimental days of the 20 day study period were plotted
against each other (see Figure 5.12). A strong positive correlation between the readouts was
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Figure 5.12 Plot of the correlation between the PAM LWT ratios (FCA-injected:contralateral) and the
WD ratios (FCA-injected:contralateral) obtained from matched animals during the mouse pilot study.
There was a positive correlation between the two readouts, which was highly significant (Spearman
r=0.66, PcO.OOOl, n=240, 24 measurements per day for 10 days)
•• •
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5.4 Discussion
This chapter describes how the PAM device has been developed and validated as a
novel behavioural tool for assessing knee sensitivity in two rodent models of chronic
inflammatory joint pain (Strickland et al. 2005; Barton et al. 2007c). Results obtained in
these studies show that PAM provides a reliable, quantitative measurement of knee joint
hypersensitivity in both mice and rats following an induction of joint inflammation as a
result of an intra-articular injection of FCA. Furthermore, the PAM apparatus can be used to
detect the analgesic action of prednisolone in mice and rats, and of morphine and celecoxib
in rats, manifested as a reduction in joint hypersensitivity compared to vehicle. A strong
correlation was observed between the LWT ratios calculated from PAM and the WD ratios
calculated from the incapacitance tester in both species, indicating that PAM will be a
valuable screening tool for testing novel analgesics in pre-clinical animal models of joint
pain.
The practical use of PAM was a very simple procedure for both the user and the
animal being tested. A straightforward holding or scruffing technique is all that was required
to prepare the animal for a LWT measurement to be taken. On average the time taken from
picking the animal out of its cage to placing it back, having taken both an ipsilateral and
contralateral reading, is estimated as being approximately thirty seconds. This meant that
screening a large number of animals in one session was a feasible prospect. Handling and the
initial testing of the animals, is arguably a stressful experience for the animals and therefore
habituation tests were introduced to try and familiarise them to the experience. Stress is a
response to a potentially threatening situation and can lead to analgesia (Takahashi 1991) as
a result of the activation and subsequent dysregulation of the hypothalamic-pituitary-
adrenocortical axis. Radiotelemetry devices may be used in future studies to monitor blood
pressure in the conscious animals, giving an indication of how stressful the handling and
testing process is (Kramer and Kinter 2003). Unfortunately the cost of such devices, and the
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time taken to surgically implant them, makes this method of monitoring the animals
unfeasible in a laboratory of our size. The major disadvantage of the PAM device was that
two people are required at all times, one person to hold the animal and a second person to
operate PAM. For the majority of behavioural readouts only one person is normally required
to take the measurements (Randall and Selitto 1957; Chaplan et al. 1994; Clayton et al.
1997). The same personnel were used for holding the animal and operating the PAM device
throughout the study, with the roles maintained throughout. This practice ensured any
operator differences were avoided.
PAM was modified throughout its development with the size of the rubber contact
pad in particular receiving fine-tuning. Pressure exerted onto the skin above the knee joint
may activate nociceptive afferents in several tissues, depending on the shape and surface
area of the contact. A small contact area may have resulted in the exclusive activation of
cutaneous nociceptive fibres innervating the skin, in much the same way as von Frey hairs
(Chaplan et al. 1994; Khalsa et al. 1997), whereas adopting a larger contact area resulted in
the preferential activation of deep tissue afferents within the knee joint, because the force
applied is spread out over the skin (Treede et al. 2002). Experiments using a topical local
anaesthetic have shown that the contribution of cutaneous afferents to pain evoked by a flat
blunt pressure is minimal (Kosek et al. 1995).
Pressure is defined as the force per unit area applied on a surface, perpendicular to
that surface. It was decided not to present the data obtained from PAM in units of pressure as
it cannot be assumed that the entire surface of the rubber contact is always evenly apposed
on the side of the joint, and furthermore as a squeeze pressure is applied, the joint will
deform and this will occur differently in inflamed and non-inflamed joints. Therefore the
decision was taken to express results obtained from PAM in terms of the force in grams
applied (gf) and it was therefore essential to present the results together with information
about the size of the rubber contact surface used on the joint. For example, if we applied a
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force of 300g, a contact diameter of 1mm would result in the force being applied over a
pointed area of 7.86 x 10"3 mm2, and would result in a pressure spot of 3.8 x 104gf.mm2. If
the same force were then to be applied using a circular contact with a diameter of 8mm, the
force will be applied over a flattened area of 50.3mm2, and would result in a much lower
pressure of 5.97gf.mm"2.
In the studies described here the rat PAM device used a circular rubber contact pad
with a diameter of 8mm and the mouse PAM device used a circular rubber contact pad with
a diameter of 5mm. If it were assumed that the knee did not deform and that the force
applied was distributed evenly over the rigid rubber contact, then the pressure applied at the
point of limb withdrawal was approximately 20gf.mm"2 in both species. Similar values were
reported using the Randall and Selitto analgesy-meter where a circular contact plinth of
diameter 1.4mm was used to obtain naive rat LWT results of 60g giving a pressure applied
of approximately 40gf.mm"2 (Anseloni et al. 2003). Furthermore values obtained using
calibrated forceps in both behavioural and electrophysiological studies of the rat report a
noxious pressure of the paw being in the region of 50gf.mm"2 (Neugebauer and Li 2002;
Luis-Delgado et al. 2006). Although differences do occur in the approximate values, this is
probably due to differences in the strain and weight of the animals and more importantly the
gross anatomical differences of the paw and knee.
To date the only other behavioural assessment described capable of directly
measuring knee joint sensitivity involves the use of calibrated forceps equipped with strain
gauges (Yu et al. 2002; Han et al. 2005; Skyba et al. 2005). The authors describe the forceps
for use on rats only, which may mean that they are not suitable for use with mice. PAM
however, is capable of being used in both species. The contact area of the forceps was blunt
and had a surface area of 16mm2 (4mm long x 4mm wide). This surface contact area was
considerably smaller than that of 50.3mm2 that was utilised in the rat PAM device. Moreover
the contact surface of the forceps was exposed metal, whereas the PAM contact area was a
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rigid rubber disc. The differences in the size and finish of the contact area may lead to the
devices activating different proportions of nociceptive afferents in the skin and deep tissues
as described above. The large padded contact area used in PAM provides a measurement
more representative of a 'compression' of the whole knee joint rather than the small contact
area of the forceps which may in fact be investigating a 'pinch' of a small portion of the knee
joint (Skyba et al. 2005). PAM also has the advantage that with minor modifications, such as
the size of the rubber contact, the device could potentially be applied to different anatomical
locations, such as the footpad or the ankle, and in different disease models and species.
Results recorded by PAM were consistent, with no significant differences observed
between the left and right LWTs of the non-injected knees in all the studies. During the pilot
study in rats a large increase in the LWT of the un-injected limbs was observed from day 0
to day 1, following the induction of inflammatory arthritis. This increase was due to the fact
that there was no habituation period and the day 0 reading was the first time the animals had
been handled and introduced to the device. Following this pilot study in rats a one day
habituation assessment was introduced prior to the drug study in rats, and this resulted in the
increase in LWT from day 0 to day 1 being absent. Moreover the absolute values of the
LWTs of non-injected limbs remained constant at ~1100gf over the 28 day study period.
This is in contrast to a calibrated forceps study in which the LWT of the paw increases as the
animal gains weight (Luis-Delgado et al. 2006).
PAM was able to detect an FCA-induced hypersensitivity in both mice and rats,
observed as a decrease in the absolute LWT for the injected limb, alongside a decrease in the
LWT ratio. Prednisolone (Pyne et al. 2004) is a gold standard used in drug screening that
was used alongside celecoxib (Warner and Mitchell 2004) and morphine (Peloso et al. 2000;
Caldwell et al. 2002) in the dosing studies, as drugs that are known to be clinically effective
at relieving pain and hypersensitivity of arthritis. The highest doses of all three drugs
147
Chapter 5: Development and validation ofPAM
investigated caused a significant reduction in the joint hypersensitivity of FCA-injected
animals when compared to vehicle.
In all studies the animals' weight distribution measurements were taken alongside
PAM LWTs in order to compare the two readouts. The weight distribution ratio is a readout
that measures how much vertical compression through the length of the limb that the knee
joint can take, created by gravity acting downwards on the body weight of the animal and the
fixed horizontal platform. The PAM LWT ratio measures how much horizontal compression
across the width of the knee that the joint can take, created as a squeeze between the force
transducer and forefinger. Both readouts utilise a mechanical stimulus, applied to the knee
joint up until the point of becoming noxious eliciting a reflex withdrawal from the stimulus.
In both pilot studies correlation graphs plotting the LWT ratio against the WD ratio showed
strong positive correlations between the two measures. Furthermore the AUC graphs created
from the results of the dosing period in the drug groups are very similar, with statistically
significant reductions in the hypersensitivity of the FCA-injected knee joint being observed
in the same groups in both readouts. These similarities suggest that PAM is capable of
accurately detecting FCA-induced hypersensitivity of the knee joint and subsequently dose
related, drug-induced reduction of this hypersensitivity.
Previous studies carried out in this laboratory used a subjective three point scoring
system to rate joint hypersensitivity, with 0 being no different from naive and 3 being the
most sensitive, by squeezing the knee joint between the fingers until the animal withdrew its
limb (Gauldie et al. 2004). This method was comparable to the Ritchie index used in the
clinic to assess the tenderness in patients joints based on a four point scale (Ritchie et al.
1968). The clinical dolorimeter has regularly been used to evoke a mechanical squeeze to
objectively assess joint tenderness in patients suffering from both osteoarthritis and
fibromyalgia (Ottillinger et al. 2001; Harris et al. 2006). PAM now provides an objective
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behavioural assessment for pre-clinical screening in conscious animals that is comparative
with the clinical dolorimeter (Langley et al. 1983).
In conclusion, the studies presented in this chapter show that PAM, a novel
behavioural tool for objectively assessing localised primary hypersensitivity, has been
validated during two animal models of chronic inflammatory joint pain. Moreover, the
device can be used in future studies, either to complement or replace existing readouts as a
pre-clinical screening tool for assessing the efficacy of novel pharmacological compounds
designed for treating chronic inflammatory joint pain.
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Chapter 6
The role of Nav1.7, Nav1.8 and Nav1.9 in FCA-induced
chronic inflammatory joint hypersensitivity
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6.1 Introduction
VGSCs are fundamental in regulating the excitability of neurons, and changes in the
expression of these channels can lead to chronic pain (Waxman et al. 1999; Lai et al. 2004).
There are nine sodium channel a-subunits (Goldin et al. 2000), and a great deal of research
has focused on the role that the TTX-S Nav1.7 and the TTX-R NavL8 and Nav1.9 isoforms,
which are predominantly expressed in peripheral damage sensing neurones (Black et al.
1996; Fang et al. 2002; Djouhri et al. 2003a; b), play in both neuropathic and acute
inflammatory pain. The expression of Nav1.7, Nav1.8 and Nav1.9 has been shown to be
highly dynamic in DRG tissue and their modulation may present a therapeutic opportunity
for the selective manipulation of primary sensory neurons, as discussed in chapter 1. It has
long been hypothesised that Navl-7, Nav1.8 and Nav1.9 all appear to have some role in
either the establishment or maintenance of the hypersensitivity observed in models of acute
(<7 days post-insult) inflammatory pain (Tanaka et al. 1998; Black et al. 2004; Gould et al.
2004; Nassar et al. 2004; Priest et al. 2005; Villarreal et al. 2005; Ekberg and Adams 2006).
Numerous studies have been performed describing the long-term changes in the expression
levels of these individual sodium channels during neuropathic pain as they are either up- or
down-regulated following injury to the nervous system (for reviews see Lai et al. 2003; Amir
et al. 2006; Rogers et al. 2006). Until this study little information existed on sodium channel
expression in DRG tissue during a chronic (>7 days) model of pain following an
inflammatory insult. One study had investigated the effect of intraplantar FCA on the
expression of the entire sodium channel population up to 6 months post-insult, but did not
provide details of changes in the individual channel isoforms (Gould et al. 1998).
Recent clinical studies have provided convincing evidence to suggest that the
sodium channel Nav1.7 plays a crucial role in the detection of pain and pain sensitivity.
Families suffering from congenital indifference to pain (CIP), a condition characterised by
absence of the ability to sense pain, all suffer from a mutation in the SCN9A gene that
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encodes Navl-7 that leads to a complete loss of functionality of the channel (Cox et al. 2006;
Ahmad et al. 2007; Goldberg et al. 2007). Conversely paroxysmal extreme pain disorder
(Fertleman et al. 2006) and inherited erythromelalgia (Lee et al. 2007) are two autosomal
dominant pain conditions where point mutations in the SCN9A gene cause hyperpolarising
shifts in the voltage dependence of activation of the channel leading to increased neuronal
excitability. These mutations cause severe rectal and facial pain, and chronic burning
sensations in the hands and feet in the respective conditions.
Recent studies have shown that VGSC blockers displaying selectivity toward Nav1.8
can provide significant analgesia in rat models of neuropathic and inflammatory pain
(Ekberg et al. 2006; Jarvis et al. 2007). The /aO-conotoxin peptide MrVIB extracted from
cone snails reduced acute post incisional pain when injected into the footpad of male rats
prior to making the incision (Bulaj et al. 2006), and intrathecal MrVIB attenuated the
reduction in thermal and mechanical paw withdrawal thresholds following intra-plantar FCA
injection in male rats (Ekberg et al. 2006). The molecule A-803467 is a potent and selective
inhibitor of Nav1.8 channels that reduced both mechanical and thermal hypersensitivity in
rats subjected to a range of acute inflammatory insults (Jarvis et al. 2007).
Nav1.9 null mutant mice showed reduced sensitivity to the inflammatory mediators
FCA, prostaglandin E2 and carrageenan, but no change in pain behaviours in two models of
neuropathic pain (Priest et al. 2005), supporting the suggestion that the Nav1.9 isoform has a
role in pain sensations produced from inflamed tissues.
6.1.1 Aims
The studies described in this chapter were designed and performed with the aim to
better understand the role of Nav1.7, Nav1.8 and Nav1.9 in the maintenance of chronic pain
following inflammatory insult. Firstly, an immunohistochemistry study was designed to
establish if there are any long term changes in the expression of Nav1.7, Nav1.8 and Nav1.9
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in L3-L5 DRGs up to 28 days during the FCA-induced unilateral inflammatory joint pain
model (Wilson et al. 2006; Martindale et al. 2007). Moreover, by using the fluorescent
retrograde tracer FB, this study was able to examine expression levels in a specific sub-
population of cell bodies belonging only to the sensory neurons innervating the FCA-
injected knee joint (Salo and Theriault 1997; Ivanavicius et al. 2004; Fernihough et al. 2005).
In this way any subtle changes in channel expression could be directly attributed to the
sensory neurones innervating the inflamed joint. It is hypothesised that an up-regulation of
these sodium channels in the sensory afferent nerves innervating the knee joint could lead to
a neuronal hyperexcitability that manifests itself as a chronic joint pain.
The second aim was to investigate any behavioural analgesic effects of the sodium
channel blockers; ralfinamide (Veneroni et al. 2003; Cattabeni 2004; Stummann et al. 2005;
Yamane et al. 2007) and a compound synthesised at GlaxoSmithKline which is selective for
Nav1.8 at low doses, and is referred to as Compound A, when dosed directly into the FCA-
injected knee on days 14-18 of the same model of inflammatory pain. Injecting the
compounds directly into the knee joint space allowed the dose of drug present at the channels
to be accurately calculated. Any effects of the drug could be attributed to action on channels
at the site of inflammation in the periphery and not through any centrally mediated effects.
Three doses of each test drug were carefully selected to target the sodium channels present in
the sensory afferent nerves to block the transmission of signals in nociceptors without
blocking low threshold pressure and touch receptors or motor neurones.
6.2 Methods
Two studies investigating the role of sodium channels in FCA-induced chronic
inflammatory joint pain are described. Firstly IHC was performed at GlaxoSmithKline in
order to investigate Nav1.7, Nav1.8 and Nav1.9 sodium channel expression in L3-5 DRGs of
54 adult male Wistar rats (150-200g, Charles River, UK). Secondly a behavioural study was
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performed at The University of Edinburgh investigating the effect of sodium channel
blocking drugs administered directly into the knee joint in 56 adult male Wistar rats (150-
200g, Charles River, UK). The behavioural study was assisted throughout by Miss Fiona
Moultrie, an intercalated BSc Hons project student. All animals were housed four to a cage
in a 12 hour dark/light cycle and were given access to water and standard animal feed ad
libitum. All animals were allowed at least five days acclimatisation prior to behavioural
testing, followed by a week of habituation to the behavioural tests.
6.2.1 Design of IHC studies investigating sodium channel expression
6.2.1.1 Assessment of weight distribution
The distribution of a rat's body weight (WD) across their hind limbs was measured
using the incapacitance tester as described in section 2.2.1. Following the initial WD
assessment, all animals (n=54) received an injection of lOpl of 2% FB into the knee joint
under brief halothane anaesthesia (see section 2.4.1). Seven days after the injection of FB,
animals were divided into those which then received FCA (n=24) or control animals that
were anaesthetised but received no injection (n=30). Following the anaesthetic a single
control group of animals was killed to provide the day 0 tissues (n=6). FCA-treated rats were
then killed in groups on days 7, 14, 21 or 28 post-FCA (n=6) and at the same time points the
corresponding control groups (n=6) were also killed. Animals were killed using a rising
concentration of C02 followed by cervical dislocation.
6.2.1.2 Immunohistochemistry techniques
Ipsilateral dorsal root ganglia (DRGs) were removed from levels L3, F4 and F5 in
all study animals immediately after confirmation of death. They were embedded in optimum
cutting temperature (TissueTek, Canada) compound and snap frozen in isopentane cooled on
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dry ice. DRGs were carefully labelled, wrapped in tin foil and then stored at -80°C until they
were sectioned. Full details of the tissue processing and sectioning can be found in section
2.4.2. Every 10th section was counted, so that sections at a distance of 120pm apart were
counted to avoid counting the same cell body twice.
A pilot study using a range of concentrations of the sodium channel primary
antibodies Nav1.7, Nav1.8 and Nav1.9 was performed in order to establish the optimum
concentration required to achieve the best signal to background fluorescence. After the
working concentration of all three primary antibodies was decided, the main
immunohistochemical time-course study was performed. In all cases the optimum primary
antibody concentration was 1:200. Slides were prepared and treated with the specific sodium
channel primary antibody and secondary antibodies as described in section 2.4.3. Full details
of the primary and secondary antibodies used are given in section 2.4.5. Fluorescence in
DRGs was observed and quantified as described in section 2.4.7.
6.2.2 Ralfinamide and Compound A behaviour study design
All study animals (n=56) were given two days of behavioural habituation before the
study began. Behavioural tests comprised of measuring the WD of the animals and recording
the LWT of the animals to a knee joint squeeze using the PAM device as previously
described in section 2.2.1. and 2.2.2, and validated in chapter 5. The order in which the
behavioural measurements were made was designed in order to give the animals breaks
between measurements and prevent them becoming stressed by the procedures. Initially
three consecutive weight distribution readings were taken and then the animal was returned
to their cage. Five minutes later, the animal had alternate measurements of the FCA-injected
and contralateral limb assessed using PAM. This was repeated three times with a one minute
break in between each measurement. Finally the animal's knee joint diameter and body
weight were measured.
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On day 0 behavioural assessments were made and animals received an intra-articular
injection of 150/xg of FCA into the left (ipsilateral) knee joint under transient anaesthesia as
described in section 2.1.2. Subsequent behavioural tests were then made on days 1, 3, 7, 9
and 11 post-FCA. On day 11 animals were ranked in descending order based on their PAM
behavioural score for that day and randomised into 7 groups (n=8) to ensure an even spread
of sensitivity of animal in each dosing group. Blind drug dosing took place on days 14, 16
and 18 post-FCA. Rats were transiently anaesthetised (3% halothane in 02 at 1.5L.min"') and
lOOpl of drug or vehicle was injected into the knee joint space using a 25-gauge needle (BD
Microlance, UK). Behavioural assessments were performed one hour post-injection when the
animals had fully recovered from anaesthesia, and 24 hours later on non-dosing days (15 and
17 post-FCA). Further behavioural assessments were made on day 21 to observe any long
term effects of the drugs dosed. Animals were killed at the end of the study using a rising
concentration of C02 followed by cervical dislocation.
6.2.2.1 Drugs
Ralfinamide (made in house at GlaxoSmithKline, MW= 398.5), and Compound A
(made in house at GlaxoSmithKline, MW= 430.6), were dissolved in 2% DMSO (Fisher,
UK), 66% PEG400 (Sigma, UK) and 32% distilled water. lOOpl of drug was injected into the
knee joint cavity and was immediately diluted 1:1 by the lOOpl of fluid already present in the
arthritic knee (Barton 2007a). The final concentrations of the drug within the knee joint were
ralfinamide at lOpM, 30pM and lOOpM and Compound A at 200nM, 500nM and lOOOnM.
The doses of ralfinamide investigated were chosen based on previously published
data and information generated in house at GlaxoSmithKline (oral communications, Dr. A.J.
Reeve and Dr. P. Green). Patch clamp studies in dorsal root ganglion neurons held at -70mV
showed ralfinamide to have an IC50 of 55pM and 22pM at the TTX-resistant and an TTX-
sensitive sodium channels respectively (Stummann et al. 2005). Other studies revealed that
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ralfinamide had an IC50 of 22pM in human Nav1.8 channels held at -80mV (Dekker et al.
2005). A significant analgesic effect of the drug has been shown in behavioural studies, with
1 and 3mg.kg"' administered either intra-peritoneally or orally resulting in the attenuation of
the mechanical allodynia observed in the paw of FCA-treated rats (Veneroni et al. 2003).
These doses of 1 and 3mg.kg_1 given to a 250g rat with an estimated blood volume of 17.5ml
(7% of the body weight) were estimated to give concentrations of approximately 35pM and
105pM respectively.
Ideally a behavioural test (e.g., rotarod) investigating any motor effects or ataxia
caused by the drug would have been performed but due to licence restrictions this was not
possible. The doses of ralfinamide effective in the behavioural test described above did not
impair the gross motor function, and in vitro evidence suggests that ralfinamide causes a
frequency-dependent block selectively on nociceptive afferents (Veneroni et al. 2003).
Furthermore, data generated in house by GlaxoSmithKline showed that ralfinamide at a dose
of lOmg.kg"1 had no motor effect when tested on either a rotarod or in the LABORAS
apparatus (Jones and Roberts 1968; Quinn et al. 2003).
The doses selected for the Compound A were based on in-house data provided by
GlaxoSmithKline. An oral dose of 3mg.kg"' caused a significant analgesic effect in FCA-
induced joint pain. Furthermore, in vitro data indicated the compound is selective for Nav1.8
at 158nM, and both Nav1.8 and Nav1.3 at 500nM.
6.2.3 Statistical analysis
The value of cells expressing the sodium channel of interest were graphically
expressed as a group mean (± SEM) percentage of the FB population on days 7, 14, 21 and
28. Statistical analysis comparing the FCA injected group of animals with time matched
control groups was performed on each individual day using a Mann-Whitney test. A two-
way ANOVA was used to compare the FCA and time matched control groups at all time
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points over the whole study. Changes within the FCA or control groups over time were
compared using a Kruskal-Wallis ANOVA. In all cases a P value of <0.05 was considered
statistically significant.
Behavioural results were expressed as the group mean (± SEM) for the WD and the
LWT ratios. The statistical analysis used to compare differences within the same group over
time was the one-way ANOVA followed by a Dunn's post-hoc test. The test used to
compare different groups of animals, such as the dosing groups, over time was the two-way
ANOVA followed by Bonferroni's post-hoc test. In order to compare statistically the AUC
values calculated for each drug over the dosing period, a Kruskal-Wallis ANOVA was used
followed by Dunn's post-hoc test comparing the dosing groups back to vehicle. In all cases a
P value of <0.05 was considered statistically significant.
6.3 Results
6.3.1 IHC channel expression study results
6.3.1.1 Assessment of weight distribution
The injection of FB into the left knee joint did not change how the animals
distributed their body weight over their hind limbs. The mean (± SEM) WD value on day 0
before the injection was 1.01 ± 0.04 and was not significantly different from the mean WD
value on day 7, namely 0.94 ± 0.05 (F>0.05, Wilcoxon, n=54; Figure 6.1).
Injection of 150/xl of FCA into the left knee joint caused a decrease in the WD ratio
as animals shifted their stance and carried less weight on the injected limb. The day 7 mean
WD value prior to injection of FCA was 0.96 ± 0.03 and this fell significantly to 0.37 ± 0.03
by day 14 (P<0.05, Wilcoxon, n=24; Figure 6.1). The FCA-injected animals continued to
show a significantly lower group mean WD ratio at all time points post-FCA compared to
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the control animals (P<0.05, Kruskal-Wallis ANOVA, n=54). There was no significant
change in the WD ratio within the control animals at any time.
Time (Days post-FB)
Figure 6.1 Graph showing the changes in weight distribution of the 35 day study following injection
of FB (day 0) and FCA (day 7) into the left (ipsilateral) knee joint. FB caused no significant difference
in the mean weight distribution (P>0.05, comparing the day 0 ratio to the day 7 ratio, using a
Wilcoxon test, n=54). FCA injected into the ipsilateral knee seven days later caused a significant
reduction in the weight distribution ratio at all time point's post-FCA, as the rats shift their body, to
place less weight through the ipsilateral limb. * represents statistical significance (P<0.05) comparing
the WD ratio of the FCA injected animals to that of control using a Kruskal-Wallis ANOVA followed
by Dunn's post-hoc test.
6.3.1.2 Fast Blue fluorescence in DRG cell bodies
Intra-articular injection of FB into the knee joint resulted in certain individual cell
bodies fluorescing in the DRG (Figure 6.2). During this study 162 DRGs were harvested and
between 4 and 6 sections of each DRG were observed under the microscope. A total of 2463
FB fluorescing cell bodies were counted within these sections, with an average of 5 (min=0,
max=28) fluorescing cells being identified per individual ganglion. There was no significant
difference in the group mean number of FB positive cells counted in animals within the
FCA-injected group compared to the control group (,P>0.05, 28 ± 2 vs. 32 ± 2; Mann
Whitney). Of the 2463 FB positive cells counted, 44% were observed in L3, 38% in L4 and
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the remaining 18% in L5. Brightly fluorescing satellite cells surrounding FB-positive cell
bodies were observed throughout the study at each time point.
(a) FB
Figure 6.2 Representative photomicrographs showing FB fluorescence in FCA-injected L3-5 DRG
tissue 14 days post-FCA. (a) A small proportion of the total population of DRG cell bodies were FB
positive and are easily identifiable from the non-fluorescing cells, (b) A higher magnification
illustrates that surrounding the FB positive cell bodies are smaller satellite cells that are also brightly
fluorescing. Scale bar = 100pm.
Figure 6.3 Representative photomicrographs of two different DRG sections (a-c) and (d-f) taken
from animals 14 days post-FCA. Images captured show (a) and (d) the FB fluorescence, (b) and (e)
the Nav1.7 positive cells, (c) and (f) an overlay of the FB and Nav1.7 images. Arrows indicate cells
positive for both the FB and Nav1.7 channel. Note that the FB positive cells were not always
necessarily positive for the sodium channel and vice versa. By switching between filters without
moving the sections it was possible to count all the cells that were positive for both. Scale bar =
100pm, applies to each row.
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6.3.1.3 Fast Blue and Nav channel co-localisation
By flicking between the filters on the microscope to allow different excitation
frequencies of light to be shone on the sections, the fluorescence of both FB positive and
sodium channel positive cells bodies were observed within the same section (Figure 6.3a, b,
d and e). Absence of bleed through between filters was confirmed by the presence of three
types of cell, namely cells that were only positive for one of the sodium channels, cells that






Figure 6.4 Representative images of Nav1.7, Nav1.8 and Nav1.9 immunofluorescence in FCA-
injected ipsilateral DRG sections before administration of FCA and on days 14, 21 and 28 post-FCA.
It is not clear from simple visual inspection whether expression levels change over time, highlighting
the need for quantification. Scale bar = 100pm and applies to each column.
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6.3.1.4 Changes in Nav1.7 channel expression
The effect of FCA or control treatment on Nav1.7 expression in knee joint afferent
cell bodies was assessed on days 7, 14, 21 and 28, post-FCA (Figure 6.4). FCA caused an
increase in the percentage of Nav1.7 positive cells in the FB positive DRG population of L3-
L5 (Table 6.1). The mean group percentage (± SEM) of FCA animals was significantly
higher than control animals on days 14 and 28 post-FCA (F<0.05, Mann Whitney, control
vs. FCA; Figure 6.5a). In control animals no significant change was observed in the group
mean percentage at any time point over the 28 day period (P>0.05, Kruskal-Wallis
ANOVA). A total of 508 FB-positive cells were counted in the 5 control groups and 385 in
the 4 FCA groups. When all the time points for both FCA-treated and control animals were
considered together the mean percentage of Nav1.7 positive cells in FCA-injected animals
was significantly higher than that in all the control animals (P<0.01, FCA vs. control, 42.2%
± 1.7 vs. 32.3% ±2.3).
—-— Control (n=30) FCA-injected (n=24)
Day (post-FCA) Mean % SEM Mean % SEM
0 27.7 (28/102) 3.3 - -
7 35.8 (41/115) 6.1 35.5 (28/79) 3.9
14 32.3 (33/101) 3.4 t 45.9 (56/122) 2.7
21 36.0 (33/92) 3.1 42.9 (39/92) 3.1
28 25.4 (25/98) 4.0 t 47.8 (44/92) 3.9
Table 6.1 The group mean percentage of FB positive cells expressing the Navl-7 channel in L3-5
DRG of control and FCA-injected left knee joints. Numbers within the brackets indicate the number
of Navl-7 positive cells in the FB population (Nayl-7 / FB). Arrows indicate the time points at which
FCA caused an increase (P<0.05, Mann Whitney) in the percentage of FB cells that are Navl-7
positive when compared to control. The day zero values were taken as a basal reading from animals
prior to FCA or control treatment and therefore only one group (n=6) was required as the animals had
not yet been separated into treatment groups.
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6.3.1.5 Changes in Nav1.8 channel expression
Following FCA or no control the expression of Nav1.8 in FB positive cell bodies of
ipsilateral L3-L5 DRGs was assessed on days 7, 14, 21 and 28, post-FCA (Figure 6.4).
There was a significantly higher percentage of Nav1.8 expressing cells in the FCA-injected
group compared to control on days 14 and 28 (P<0.05, Mann Whitney, Table 6.2). No
significant change was observed in the group mean percentage of control animals at any time
point over the 28 day period (Figure 6.5b, F>0.05, Kruskal-Wallis ANOVA). A total of 417
FB positive cells were counted in the 5 control groups and 365 in the 4 FCA groups. The
mean percentage of all Nav1.8 positive cells at all time points in the FCA-injected set of
animals was significantly higher than that in the control groups (Mann Whitney, F<0.01,
49.8% ± 2.2 vs. 38.9% ±1.1, FCA vs. control).
—
— Control (n=30) FCA-injected (n=24)
Day (post-FCA) Mean % SEM Mean % SEM
0 37.3 (28/75) 4.4 - -
7 37.5 (50/133) 2.0 41.6(31/74) 4.8
14 38.0 (41/108) 2.3 t 55.0 (44/80) 2.6
21 39.9 (26/64) 2.8 48.4 (40/82) 4.4
28 40.8 (43/105) 2.0 t 53.2 (33/62) 4.7
Table 6.2 The group mean percentage of FB positive cells expressing the Nayl.8 channel in L3-5
DRG of control and FCA-injected left knee joints. Arrows indicate the time points at which FCA
caused an increase (P<0.05, Mann Whitney) in the percentage of FB cells that are Nav1.7 positive
when compared to control. The group mean percentages were calculated from counting the FB cells in
4-6 sections in each of the three DRG taken from the six animals in the group (n=6).
6.3.1.6 Changes in Nav1.9 channel expression
The effect of FCA or control treatment on Navl-9 expression in knee joint afferent
cell bodies of L3-L5 was assessed on days 7, 14, 21 and 28, post-FCA (Table 6.3). FCA-
injected animals have a significantly higher group mean percentage (± SEM) of Nav1.9
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positive cells expressed in the FB population compared to control animals at days 14, 21 and
28 (P< 0.05, Mann Whitney, Figure 6.5c). No significant change was observed in the group
mean percentage at any time point over the 28 day period in control animals (P>0.05,
Kruskal-Wallis ANOVA). A total of 479 FB positive cells were counted in the control
groups and 309 in the FCA groups. The mean percentage (± SEM) of Nav1.9 positive cells
in all the FCA-injected animals (45% ± 2.2) was significantly higher (PcO.OOl) than that in
all the control animals (24.7% ± 1.9) when every time point was taken into account.
^
—— Control (n=30) FCA-injected (n=24)
Day (post-FCA) Mean % SEM Mean % SEM
0 32.7 (23/70) 6.8 - -
7 24.9 (42/169) 3.1 39.2 (29/74) 4.7
14 22.7 (23/101) 3.7 t 46.4 (36/77) 3.3
21 26.2(15/57) 5.2 | 47.0 (47/100) 5.6
28 25.3 (21/82) 3.7 f 47.8 (34/71) 3.9
Table 6.3 The group mean percentage (± SEM) of FB positive cells expressing the Navl-9 channel in
L3-5 DRG of control and FCA-injected left knee joints. Arrows indicate the time points at which FCA
caused a significant increase (P<0.05, Mann Whitney) in the percentage of FB cells that are Navl-9
positive when compared to control. The group mean percentages were calculated from counting the
FB cells in 4-6 sections in each of the three DRG taken from the six animals in the group (n=6).
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Figure 6.5 Quantitative analysis showed that the percentage of: (a) Nav1.7, (b) Nayl-8 and (c) Nayl-9
immunofluorescent cells within the FB labelled DRG population are significantly upregulated in FCA
treated animals, as compared with control animals at various points during the FCA time-course
(Mann Whitney, * P< 0.05, ** P< 0.01, n=6). Note that at 7 days post-FCA there is no significant
difference in FCA treated animals and control animals with regards to all the Nav channels, and
further no significant difference at day 21 when looking at Navl-7 and Navl-8 channels.
6.3.2 Ralfinamide and Compound A behaviour study results
6.3.2.1 Body weight and diameter of the knee joint
FCA or the test drugs injected into the knee joint had no adverse affect on the
general health or motor function of the animals. Animals were anaesthetised four times
during the study, and on two occasions an animal suffered an adverse reaction and died
under anaesthesia. Where appropriate the data generated for these animals is included up to
the point at which they died. The mean weight of the animals prior to injection of FCA was
209 ± lg, a value that decreased insignificantly to 207 ± lg on the next day (P>0.05,
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Wilcoxon, n=56). Following this slight decrease, rats gained weight on a daily basis
throughout the study (Figure 6.6). There was no significant difference in the mean body
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Figure 6.6 Plot of the body weight against time showing the effect of FCA (150gg, intra-articular),
ralfinamide (lOOgl, lOpM and lOOpM) and Compound A (lOOgl, 200nM and lOOOnM) on the body
weight of the rats. There were no significant differences in the mean body weight between any of the
dosing groups (P>0.05, two-way ANOVA).
Inflammation induced by FCA resulted in the knee joint diameter ratio to decrease
significantly from 1.03 ± 0.01 prior to injection, to 0.72 ± 0.01, 24 hours after the injection
(P<0.05, Wilcoxon, n=56 Figure 6.7). This change in ratio resulted from the FCA-treated
joint diameter increasing significantly from 9.00 ± 0.03mm to 13.05 ± 0.1mm during this
time (P<0.05, paired t-test, n=56), whilst the contralateral limb remained unchanged. During
the ten day period from day 1 to day 11 post-FCA, the knee joint diameter ratio gradually
began to return towards the pre-injection value of 1, as the swelling in the ipsilateral knee
slowly began to resolve. On day 11 the joint diameter ratio of all the animals was 0.90 ±
0.01. This value was still significantly lower than the day 0 value, but was also significantly
higher than the day 1 value (.P<0.05, one-way ANOVA, n=56, Figure 6.7b). The knee joint
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diameter ratio did not significantly change after day 11, for the rest of the study (P>0.05,
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Figure 6.7 FCA caused the KD ratio to fall significantly from day 0 to day 1 (P<0.05, Wilcoxon,
n=56). (a) The KD ratio then increased daily from day 1 to day 11. (b) On day 11 the KD ratio was
still significantly lower than the day 0 value, but also significantly higher than the day 1 value
(P<0.05, one-way ANOVA, n=56). After day 11 the KD ratio did not significantly change during the
dosing period (day 14-18 post-FCA) and up till the conclusion of the study (P>0.05, two-way
ANOVA, n=56).
6.3.2.2 Assessment ofweight distribution on days 0-11 post-FCA
FCA caused a reduction in the weight distribution ratio on all days up to day 11 as
the rats altered their stance to place less weight through the FCA-treated left hind limb
(Figure 6.8a). The mean day 0 ratio fell from 0.97 ± 0.02, where animals carried an average
of 71 ± lg on their left limb and 73 ± lg on their right limb, to a day 1 value of 0.18 ± 0.02,
where animals only carried 20 ± lg on the FCA-treated limb and 111 ± 2g on the untreated
limb. The decrease in WD ratio from day 0 to day 1 was statistically significant and
remained so through to day 11 where the WD ratio was 0.25 ± 0.01 (P<0.05, one-way
ANOVA, n=56. Figure 6.8b). At no time from day 0 to day 11 was there any significant
difference between the mean WD ratio of animals that were subsequently to receive
ralfinamide, Compound A or vehicle on days 14-18 post-FCA.
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Figure 6.8 Graphs showing that (a) there was no significant difference in the mean group WD ratio of
animals in the vehicle, ralfinamide or Compound A dosing groups at any time on days 0-11, prior to
receiving treatment (P<0.05, two-way, ANOVA, n=56). (b) FCA into the left knee joint resulted in
the WD ratio to decrease significantly from the day 0 value on days 1 and 11 post injection (P<0.05,
one-way ANOVA, n=56).
6.3.2.3 Assessment of LWT on days 0-11 post-FCA
FCA reduced the basal LWT ratio on all test days up to day 11 as the injected limb
became more sensitive to the squeeze applied and the rats withdrew the limb at a lower force
(Figure 6.9a). The mean ratio on day 0 was 1.02 ± 0.01, with the withdrawal threshold of the
injected and non-injected limb being an average of 893 ± lOg and 884 ± 1 lg respectively.
Following FCA the mean ratio fell to 0.35 ± 0.02, with the withdrawal threshold of the
injected and non-injected limb being an average of 248 ± 7g and 716 ± 1 lg respectively. The
decrease in LWT ratio from day 0 to day 1 was significantly reduced and remained so until
day 11, when the ratio was 0.52 ± 0.01 (P<0.05, one-way ANOVA, n=56, Figure 6.9b). At
no time from day 0 to day 11 was there any significant difference between the mean LWT
ratio of animals that were to receive ralfinamide, Compound A or vehicle on days 14-18
post-FCA.
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Figure 6.9 Graphs showing (a) the plot of PAM LWT ratio against time following FCA injection,
there was no significant difference in the mean group PAM LWT ratio of animals in the vehicle,
ralfinamide or Compound A dosing groups at any time on days 0-11 (P<0.05, two-way, ANOVA,
n=56). (b) Injection of FCA into the left knee joint caused the PAM LWT ratio to decrease
significantly from the day 0 value on days 1 and 11 post injection (P<0.05, one-way ANOVA, n=56).
6.3.2.4 Assessment ofweight distribution on days 11-21 post-FCA
Following the establishment of an FCA-induced unilateral joint hypersensitivity,
animals were dosed directly into the knee joint under brief anaesthesia with either
ralfinamide (lOpM, 30pM or lOOpM), Compound A (200nM, 500nM or lOOOnM) or vehicle
(2% DMSO, 66% PEG400 and 32% dH20). Dosing had no significant effect on the group
WD ratio at any time point when compared to vehicle (P>0.05, two-way ANOVA, n=8;
Figure 6.10a and 6.10c). Despite there being no significant effect of the drugs compared to
vehicle, there did appear to be a trend that lOOpM of ralfinamide consistently caused an
increase in the WD ratio on the days it was dosed. This trend was also evident when
examining the calculated AUC values. Despite the dose-related increase in WD ratio AUC
values following ralfinamide, there was no significant difference in the AUC values of any
dose of Compound A when compared to vehicle (P>0.05, Kruskal-Wallis ANOVA, n=8,
Figure 6.10b). The range of doses of Compound A administered had no effect on the WD
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ratio AUC values, and were not significantly different when compared to vehicle (P>0.05,
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Figure 6.10 Graphs showing the effect of dosing (a) ralfinamide and (c) Compound A directly into
the knee joint on days 14, 16 and 18, on the WD ratio. There was no significant difference in the
group mean WD ratio of the three doses of either ralfinamide or Compound A at any time point
compared to vehicle (F>0.05, two-way ANOVA, n=8; Figure 6.10a and 6.10c). Calculating the AUC
for each group during the dosing period (14-18 post-FCA) allowed the cumulative effect of each drug
to be calculated. There was no significant difference in the AUC values calculated from the three
doses of either (b) ralfinamide or (d) Compound A compared to vehicle (P>0.05, Kruskal Wallis
ANOVA, n=8).
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6.3.2.5 Assessment of LWT on days 11-21 post-FCA
Neither Ralfinamide (10/xM, 3CtytM or lOO^M) nor Compound A (200nM, 500nM or
lOOOnM) had any significant effect on the group LWT ratio at any time point when
compared to vehicle (P>0.05, two-way ANOVA, n=8; Figure 6.11a and 6.11c). Despite an
absence of effect with the drugs relative to vehicle, there did appear to be a trend towards an
increase in LWT ratio in the group of animals receiving 100/xM of ralfinamide. This trend
was also observed when examining the AUC values calculated for each dose, as there
appears to be a dose-related increase in the LWT ratio AUC values. Despite this trend there
was no statistically significant difference in the AUC values of any dose of ralfinamide
administered, in comparison with the vehicle treated group (P>0.05, Kruskal-Wallis
ANOVA, n=8, Figure 6.11b). Compound A in the doses studied, had no effect on the LWT
ratio AUC values, and were not statistically different when compared to vehicle (P>0.05,
Kruskal-Wallis ANOVA, n=8, Figure 6.1 Id).
6.3.2.6 Further analysis of the response to 100pM ralfinamide
The animals dosed with 100/xM of ralfinamide showed a trend towards resolving the
FCA-induced joint hypersensitivity as evidenced by increases in both the WD and LWT ratio
values towards the normal value of 1. The weight distribution assessment of animals in this
group showed that on the dosing days 14, 16 and 18 the mean WD ratio was significantly
higher than the day 11 value (P<0.05, one-way ANOVA, n=8; Figure 6.12a). This was the
only group in the study that had group mean ratios on various days which were significantly
different from the day 11 ratios. Repeated intra-articular injections of 100/xM ralfinamide
resulted in the mean LWT ratios on days 15, 16 and 17 being statistically higher in
comparison to day 11 (P<0.05, one-way ANOVA, n=8; Figure 6.12b).
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Figure 6.11 Graphs showing the effect of (a) and (b) ralfinamide and (c) and (d) Compound A on the
group mean LWT ratio on days 11-21 when the various doses of drug were administered directly into
the knee joint on days 14, 16 and 18. There was no significant difference in the group mean LWT
ratio for any of the doses of either ralfinamide or Compound A at any time point compared to vehicle
(P>0.05, two-way ANOVA, n=8; Figure 6.11a and 6.11c). There was also no significant difference in
the AUC values of days 14, 16 and 18 for the three doses of ralfinamide (b) or Compound A (d) in
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Figure 6.12 Box and whiskers plot summarising the apparent reduction in joint hypersensitivity of
repeated intra-articular injections of lOOpM ralfinamide in (a) the WD ratio and (b) the LWT ratio.
Injections were on days 14, 16 and 18 (signified by the darker symbols) and behavioural assessments
were made 1 hour after the injection, (a) The WD ratio on days 14, 16 and 18 were significantly
higher than the day 11 WD ratio and (b) the LWT ratio on days 15, 16 and 17 were significantly
higher then the day 11 value (P<0.05, one-way ANOVA, n=8).
6.4 Discussion
6.4.1 Discussion of results from IHC studies
Expression levels of the VGSCs Nav1.7, Nav1.8 and Nav1.9 were studied in the cell
bodies of neurons which innervated the knee joint during the course of a well established
preclinical model of chronic joint pain (Donaldson et al. 1993). FCA injected into the intra¬
articular space of the knee joint produced a localised unilateral inflammation and established
a 'chronic' joint hypersensitivity which was maintained for up to 60 days post-FCA (Wilson
et al. 2006). The present study examined expression levels at weekly intervals up to 28 days
post-FCA during a period when the joint hypersensitivity was stable but the levels of
inflammation were reducing. The fluorescent retrograde tracer FB was successfully used to
show the DRG cell bodies of L3-L5 neurones which exclusively innervated the inflamed
knee joint (Salo and Theriault 1997). The results showed that there was an overall increase in
the expression of all three channels in the knee joint afferent population following injection
of FCA. More specifically, on days 14 and 28 post-FCA the percentage of all three channels
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in the FB population was significantly greater than that in control animals, with Navl-9 also
being significantly higher on day 21 post-FCA.
6.4.1.1 Nav1.7 expression following FCA-induced inflammation
In the present study FCA caused a significant increase in the number of Navl-7
positive neurones within the distinct FB population of L3-L5 ipsilateral DRG on days 14 and
28 post-FCA. Previously published reports in rats have shown that intra-plantar injection of
carrageenan increased channel mRNA and protein expression in L4/L5 DRG neurones,
measured four days after the injection (kanaka et al. 1998; Black et al. 2004). In a similar
model using an intra-plantar injection of FCA, the labelling of Navl-7 in L4-S1 DRG
neurones 24 hours post-FCA injection was significantly increased (Gould et al. 2004). A
study evaluating the expression of this channel in human teeth, removed due to serious pain,
revealed a dramatic increase in Nav1.7 in the nodes of Ranvier and at sites of demyelination
in the pulpal tissue, which the authors suggest may contribute to the development of dental
pain (Sorensen et al. 2003). The present study provides the first evidence that the
upregulation of Nav1.7 is maintained for at least 28 days following an inflammatory insult.
This suggests that Nav1.7 may not only play an important role in the establishment of
inflammatory pain, but could also be crucial for maintaining the chronic nature of the pain
even after the inflammation has been resolved (Strickland et al. 2007). The role of Nav1.7 in
experimental inflammatory pain is further strengthened by studies in mice where knocking
down or knocking out the channel in nociceptive DRG neurones substantially reduced
inflammatory pain behaviours and mechanical and thermal hypersensitivity associated with
inflammatory pain (Nassar et al. 2004; Yeomans et al. 2005). All these results corroborate
the recent clinical studies describing the importance of Nav1.7 in the lack of pain sensation
in the medical condition CIP where a mutation renders the channel dysfunctional (Cox et al.
2006; Ahmad et al. 2007; Goldberg et al. 2007). Conditions such as paroxysmal extreme
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pain disorder (Fertleman et al. 2006) and inherited erythromelalgia (Waxman and Dib-Hajj
2005; Lee et al. 2007) are caused by spot mutations in the channel which lead to a
hyperexcitability in the neurones the channels are expressed on and consequently increased
nociceptive afferent firing.
6.4.1.2 Nav1.8 expression following FCA-induced inflammation
A large body of research exists surrounding the role of Nav1.8 in both the initiation
and maintenance of chronic inflammatory pain (Ekberg and Adams 2006). Nav1.8
expression is rapidly upregulated in the early stages of inflammation following either a
single injection of FCA or repeated injections of PGE2, suggesting the channel plays a key
role in the initial induction of hypersensitivity (Gould et al. 2004; Villarreal et al. 2005).
Support for a role of Nav1.8 in the maintenance of inflammatory pain comes from studies
reporting that there is a significant increase in mRNA in DRG tissue four days after
carrageenan injection in the food-pad (Tanaka et al. 1998). Moreover, the increase in channel
expression is likely to be associated with increased distribution of the channels to peripheral
nerve terminals as FCA-induced inflammation results in an increase in the number of Nav1.8
channels observed in peripheral axons (Coggeshall et al. 2004). Studies in Nav1.8 null
mutant mice show a delayed hypersensitivity following inflammatory insult (Akopian et al.
1999) and Nav1.8 knockdown mice showed reduced pain behaviours following a peripheral
inflammatory insult (Khasar et al. 1998; Joshi et al. 2006). In the present study no
significant increase in Nav1.8 was observed at the earliest time point on day 7 post-FCA, but
there were significant increases in the expression of Nav1.8 on days 14 and 28 within
neurons which innervated the knee joint. This observation is in accord with the previously
published studies suggesting a role for the channel in maintaining a chronic hypersensitivity.
The channel may therefore play an important role in the immediate initiation in the
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hypersensitivity following the FCA, but the time points chosen in this study did not enable
us to gain any information about expression levels at 24 and 48 hours post-FCA.
6.4.1.3 Nav1.9 expression following FCA-induced inflammation
Results from the current study show that Nav1.9 is upregulated in knee joint afferent
DRG on days 14, 21 and 28 days post-FCA. Previous studies have also described an
upregulation in the mRNA and expression of the channel following FCA administration up
to one week after the insult (Tate et al. 1998; Amaya et al. 2006). Nav1.9 null mutant mice
show a reduced hypersensitivity to inflammatory pain induced by FCA, carrageenan,
formalin and prostaglandin E2 (Priest et al. 2005). Interestingly Black et al. (2004) reported
no change in the expression of Nav1.9 mRNA and protein in DRG four days after an intra-
plantar carrageenan injection in rats. Furthermore a decrease in the expression of the channel
on primary afferent nerves in the periphery 2 days after FCA-induced inflammation has been
described, with the authors concluding that Nav1.9 does not play a role in the peripheral
sensitisation that occurs during the early stages of inflammation (Coggeshall et al. 2004).
There appears to be conflicting evidence describing the expression of the Navl-9 channel in
the early stages of inflammatory pain (<day 7). Considering these previous studies and the
results presented here, where upregulation is observed in the first instance on day 14 post-
FCA (Strickland et al. 2007), it may be concluded that Nav1.9 does not play a role in the
establishment of the initial pain following an inflammatory insult, but does play a crucial
role in the maintenance of chronic pain.
6.4.1.4 Use of FB to highlight the knee joint afferent population
The use of fluorescent retrograde tracers for tracking peripheral nerves through to
their parent cell bodies is a well established technique (Kristensson 1970; Kuypers et al.
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1979; Kuypers and Huisman 1984). FB can be transported over long distances, showing
pronounced fluorescence in the cytoplasm of parent cells only 48 hours after injection
around the nerve terminals (Bentivoglio et al. 1980b). The use of fluorescent dyes in vivo to
identify knee joint afferent cell bodies in DRG tissue is well described (Hanesch and
Heppelmann 1995; Ivanavicius et al. 2004). In this study 82% of the cell bodies that were
counted were found in L3 and L4 DRG, a result that concurs with data obtained using the
retrograde tracer Fluoro-Gold where 88% were found in L3 and L4 DRG (Salo and Theriault
1997). There was no observable increase in the intensity of the fluorescence in cells of DRGs
taken from animals with longer survival times, a trend that has previously been reported
(Bentivoglio et al. 1980b). However it must be noted that in the present study the intensity of
the fluorescence was not quantified but merely qualitatively assessed by comparing slides at
different times after induction of joint hypersensitivity. A phenomenon that was observed in
the current study was the fluorescing of glial cells surrounding the retrogradely labelled cell
bodies. This has been previously reported as being due to the diffuse migration of dye from
the cell bodies into the adjoining satellite cells, and is thought to become more prominent the
longer the dye is present in the animal (Bentivoglio et al. 1980a; b). In certain circumstances
this might be of concern as it could potentially hinder the correct identification of positive
cells within the DRG. However due to the intensely bright fluorescence of the cytoplasm in
the present study it can be confidently assured, that only those neurones with retrogradely
labelled knee afferents were positively identified.
6.4.1.5 IHC summary
The significant increases in the expression of the VGSCs on days 14, 21 and 28
post-FCA observed in this study correlate with the presence of FCA-induced joint
hypersensitivity as measured by a reduction in the WD ratio. A previous study using the
same FCA-induced knee joint model of hypersensitivity showed significant increases in the
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levels of CGRP within all L3/L4 DRG neurones up to 35 days after intra-articular FCA
administration, correlating with a behavioural hypersensitivity of the joint (Staton et al.
2007). It would be interesting to determine whether this increase in CGRP expression takes
place solely in the knee joint afferent population, or whether the injection has global effects
within the whole DRG population. Similar studies profiling changes in other key channels
and receptors, such as the cannabinoids, opioids and the prostaglandins, which are known to
play a key role in inflammatory hypersensitivity, may provide further insight into the
multiple mechanisms involved in the establishment and maintenance of chronic
inflammation-induced pain.
In summary, a significant increase was observed in the channel expression levels of
the VGSCs; Nav1.7, Nav1.8 and Nav1.9 in a distinct group of ipsilateral L3-L5 DRG
neurones using a model of FCA-induced, chronic joint pain. The sensitisation of primary
afferent neurones in acute inflammatory pain has previously been reported to be due to
changes in the expression of several VGSC's, although the process clearly involves
considerably more than just the modulation of a single class of ion channels. Nevertheless, a
retrograde tracing technique was successfully used to demonstrate that Nav1.7 and Nav1.8
are upregulated in afferent neurones specifically innervating the site of chronic inflammatory
pain. Moreover, this study has increased our understanding of the neurobiology of
inflammatory pain by revealing an increased expression in Nav1.9 channels 14 days post-
FCA, highlighting a potential role of this channel in the maintenance of inflammatory
hypersensitivity.
6.4.2 Discussion of results from behavioural studies
In this study the effect of ralfinamide or Compound A on FCA-induced joint
hypersensitivity was assessed using the WD and LWT behavioural readouts. At first sight it
appeared that neither drug at any of the doses used had any analgesic effect on the joint
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hypersensitivity. Comparing the responses in the ralfinamide and Compound A groups with
that of the vehicle group showed no significant differences in either the WD or LWT ratio on
the individual days. Furthermore, there was no significant difference between the drug
groups and the vehicle group when the cumulative effect was investigated using the AUC
values calculated from the dosing period. The AUC values for the ralfinamide treated
animals were not statistically different to the vehicle group, but did appear to be biologically
significant with the increasing doses following a trend to cause an increase in both the WD
and LWT ratio. Further investigation revealed that with the highest dose of ralfinamide
investigated (lOOpM), there was a significant increase in both the WD and LWT ratios on
certain days during the dosing period when compared with the day 11 pre-treatment values.
This was the only group for either of the drugs to show an increase in the WD or LWT ratio
at any time point when compared to the day 11 value. The WD ratio readout for lOOpM
ralfinamide revealed significant increases in the group mean ratio on the dosing days of day
14, 16 and 18 when compared to the group mean ratio on day 11. LWT readouts revealed
significant differences between the mean ratios on days 15, 16 and 17 in comparison with
day 11 pre-treatment values. These effects were then absent on day 21. These findings
demonstrate that the dosing of compounds directly into the knee joint can provide an
effective analgesia as measured using two different behavioural readouts. More specifically,
the sodium channel blocker ralfinamide at a dose of 100/xM attenuated the FCA-induced
hypersensitivity during the dosing period.
6.4.2.1 Ralfinamide and Compound A
In a previous study employing the same model of FCA-induced knee joint
hypersensitivity as described (Wilson et al. 2006), no significant analgesic effect was
observed following oral dosing of ralfinamide at lOmg.kg"1 (in house, GlaxoSmithKline). In
a rat model of acute inflammatory pain evoked by FCA administered into the footpad (Butler
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et al. 1992), both oral and intra-peritoneal ralfinamide at doses of approximately 35pM and
105pM caused a significant, dose dependent, decrease in allodynia, measured using von Frey
filaments (Veneroni et al. 2003). Furthermore, patch clamp studies in rat DRG neurons held
at -70mV showed ralfinamide had an IC50 of 55pM and 22pM at the TTX-resistant and an
TTX-sensitive sodium channels respectively although the effects of the drug were more
pronounced on the TTX-resistant channels (Stummann et al. 2005). Other studies revealed
ralfinamide had an IC50 of 22pM in human Nav1.8 channels held at -80mV (Dekker et al.
2005). Data published after the completion of the current study shows that a dose of 25/xM in
the presence of 0.5/xM tetrodotoxin suppressed afferent hyperexcitability, with the mean
number of action potentials in capsaicin positive nociceptive DRG neurons being reduced
from 10.6 ± 1.8 to 2.6 ± 0.7 action potentials in every 600ms (Yamane et al. 2007). In view
of this evidence, the doses of 10/xM, 30pM and 100/xM selected for the present study were
reasonable, although it is perhaps no surprise that the lOpM dose did not cause any effect,
and in hindsight a dose of 300/rM may have provided a better indication of the analgesic
properties of the drug.
Relatively little is known about Compound A, with no data published to date. Data
generated at GlaxoSmithKline suggests that Compound A is only selective for Nav1.8 up to
158nM, and then both Nav1.8 and Nav1.3 up to 500nM (oral communication, Dr. Paula
Green, GSK). The doses of 200nM, 500nM and lOOOnM were chosen in order to try and
selectively target Nav1.8 using the lower doses, whilst investigating the compound as a
universal sodium channel blocker at the higher dose. The lack of analgesic effect of the drug
in any of the doses studied is surprising, as data generated from in vivo studies showed that
an oral dose of 3mg.kg_1 caused a significant analgesic effect in FCA-induced joint pain. It
could be that metabolites produced when the drug is given orally are responsible for its
analgesic action, and administration into the knee joint resulted in a different fate of the drug,
where these metabolites were not produced.
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A consideration to take into account is the fact that Compound A is highly insoluble
in either distilled water or saline. In order to get the compound into solution a vehicle
containing 2% DMSO was used. In vitro studies have shown that DMSO at 1-5% can alter
nerve conduction velocity and action potential propagation in ventricular tissue (Ogura et al.
1995), and topical application of 50% DMSO provides analgesia in human rheumatoid
arthritis (Abdullaeva and Shakimova 1989). The presence of 2% DMSO in the vehicle
during this study may account for the positive AUC value observed in the vehicle dosing
group (if the vehicle had no effect then the AUC value would be zero). This vehicle effect
makes it very difficult to achieve a statistically significant difference between the test drugs
and vehicle as described above. This being considered, the vehicle was prepared with the
lowest possible amount of organic solvent necessary in order to solubulise Compound A and
was administered directly into the knee joint, reducing the chances of observing any
centrally mediated side effects.
6.4.2.2 Differences in results obtained from the LWTand WD readouts
For both, WD and LWT, displaying the results as a ratio provided a clear method of
presenting the data as in both cases the un-injected limb acts as an internal control. In this
way any random day to day changes can be accounted for. Interestingly the analgesic effect
of lOOpM ralfinamide as measured using the WD ratio was only obtained on the dosing
days, whereas the analgesic effects measured using the LWT ratio were seen the day after
the dosing. This may be because injection into the knee joint caused superficial acute pain, as
a result of tissue damage. As the PAM LWT readout requires the knee joint to be squeezed,
the pain associated with the injection 1 hour previously may result in a falsely decreased
LWT, masking the analgesic effect of the ralfinamide on the underlying FCA-induced
chronic pain of the joint. In future studies the insertion of a needle into the un-injected limb
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could act as an internal control for this potential acute pain associated with the dosing
procedure.
6.4.2.3 Intra-articular administration of drugs
In this study, test drugs were administered directly into the FCA-injected knee joint.
This route is clinically relevant as drugs are often given into the knee joint of patients
suffering from OA or RA (Christophidis and Huskisson 1982; Stein et al. 1991; Stein et al.
1996a). Repeated intra-articular doses are not regularly used in the clinic due to the risk of
infection at the injection site. In the present study, on rare occasions leakage of a small
amount of drug solution was observed from the injection site. This was probably due to the
joint space in FCA-injected animals being slightly less than the estimated lOOpl (Barton
2007). It is possible that a residual amount of drug was retained in the joint following the
first dose that could affect the overall concentration of drug in the knee when the subsequent
doses were given. This could account for the unexpected differences in LWT ratio of the
lOOpM ralfinamide animals on the non-dosing days 15 and 17 compared to day 11.
Dosing directly into the knee joint required the animals to be briefly anaesthetised.
Taking into account the initial injection of FCA animals were anaesthetised four times and as
mentioned in the results above two animals died whilst under anaesthesia. The contribution
of the halothane anaesthetic towards any analgesic effect needs to be considered as in vitro
studies have demonstrated halothane can block TTX-resistant channels in the rat DRG
causing a shift in inactivation threshold (Scholz et al. 1998). However at the low
concentrations used during the temporary anaesthesia it is unlikely that halothane will
contribute to any decrease in joint hypersensitivity, especially as the behavioural tests took
place 1 hour after anaesthesia.
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6.4.2.4 Behavioural study summary
The results of this study demonstrate analgesia in a model of chronic inflammatory
joint pain can be achieved using the sodium channel blocker ralfinamide when a dose of
lOOpM is injected directly into the FCA-injected knee. Ralfinamide, which is thought to
predominantly act by blocking the TTX-resistant sodium channels Nav1.8 and Nav1.9,
caused a significant attenuation of the FCA-induced reduction in the WD and LWT ratios.
This suggests that there is afferent nerve discharge that is mediated, in part, by VGSCs
present in the peripheral nerves innervating the knee joint. An obvious next step would be to
investigate whether higher doses of ralfinamide would cause a more significant attenuation
of the FCA-induced joint hypersensitivity. Although rotarod studies from previously
published data suggested that the doses of ralfinamide and Compound A investigated would
not cause motor impairment, it would be wise to establish this in future studies, as injection
directly into the knee joint may have a more pronounced effect than systemic administration
of the drugs. The results obtained from the three doses of Compound A showed no
significant effect on either the WD or LWT ratios, but this can be attributed to the low doses
of drug chosen to achieve selective blockade of Nav1.8. Further studies with higher doses of
this compound may reveal an analgesic effect of the compound that was missed in this study
due to the low concentrations injected into the knee joint.
6.4.3 Sodium channel chapter summary
The results from the studies described in this chapter add to the wealth of literature
describing the roles, modulation and regulation of the VGSCs Nav1.7, Nav1.8 and Nav1.9 in
chronic pain associated with an inflammatory insult (for reviews see Amir et al. 2006;
Cummins et al. 2007). The increase in the expression of the channels in the rat knee joint
afferent cell body population in DRGs on days 14, 21 and 28 suggests that each channel may
play an independent role in the maintenance of inflammatory hypersensitivity in the long
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term by increasing neuronal hypersensitivity and spontaneous discharge. The sodium
channel blocker ralfinamide successfully attenuated the FCA-induced joint hypersensitivity
on day 14-18 post-FCA, a time point at which these channels were shown to be upregulated.
Sodium channels remain a promising and potentially viable target in the development of
novel peripherally acting analgesics for the treatment of chronic inflammatory pain. Given
the potentially lucrative market for novel pain therapies, drugs that are able to selectively
block these channels may provide analgesia with limited side effects. It remains to be seen
whether the recently synthesised Nav1.8 selective blockers MrVIB (Bulaj et al. 2006; Ekberg
et al. 2006) and A-803467 (Jarvis et al. 2007) will be effective in providing successful
patient analgesia.
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Chapter 7: General discussion
7.1 Development of PAM
7.1.1 Major findings
• The PAM device has been developed and validated as a novel behavioural tool for
assessing localised mechanical hypersensitivity of rodent knee joints.
• Results show that PAM can be used to obtain quantitative measurements of
mechanical hypersensitivity in the knee joint of rats and mice.
PAM detected the expected analgesic actions of prednisolone, morphine and
celecoxib.
• The LWT readouts obtained using the PAM device strongly correlated with results
obtained from the established weight distribution readout.
• In summary PAM provides a novel preclinical readout which is similar to assessments
made in the clinic using a dolorimeter (Langley et al. 1983).
7.1.2 Limitations of the PAM device
The use of PAM requires the animals to be repeatedly handled and have their
hypersensitive knees squeezed. In the present studies all efforts were made to reduce the
amount of stress caused to the animals by handling the animals regularly, habituating them to
the device and by making the assessments at the same time each day. Despite habituation
and conditioning, the practical use of PAM to elicit a limb withdrawal may be a stressful
experience for the animals, and analgesia is a well known consequence of activation of the
HPA axis in response to stress (Takahashi 1991). The present studies utilised the
contralateral limb as an internal control, as well as dosing with vehicle in order to prevent
false positive conclusion being drawn as a result of a stress-induced response.
A second limitation of the PAM device is that two operators are needed to make
measurements as one person holds the animal while a second operates the device. This is
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something that is unusual with regards to behavioural testing in pain studies as the
incapacitance tester, analgesymeter, Hargreaves thermal assessment and von Frey filaments
all require one operator only, and may therefore be considered a negative feature of the PAM
device.
7.1.3 Further investigations with PAM
PAM was designed so that it could be applied to the investigation of hypersensitivity
in different joints such as the ankle, or to areas of the body such as the paw which is
classically investigated using the Randall and Selitto analgesymeter (Randall and Selillo
1957), or von Frey filaments (von Frey 1894a; b; 1922). The device could now be used as an
assessment in preclinical drug discovery studies of inflammatory joint pain. In that respect,
PAM has the potential to facilitate the discovery and progression of novel analgesics into the
public domain.
A study in which telemetry devices which are capable of monitoring blood pressure
in the conscious animal (Kramer and Kinter 2003) were surgically implanted prior to
behavioural testing would show if the operation of PAM is stressful for the animals, even
after a habituation period. An increase in blood pressure is a general indication of
sympathetic nerve activity which can lead to activation of the HPA axis and result in a stress
response.
7.2 Opioid receptors on peripheral nociceptors
7.2.1 Major findings
• Results obtained from the behavioural experiments provide clear evidence that
functional opioid receptors are present on nociceptive afferents innervating the rat
knee joint at 14-18 days post-FCA.
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• EMI or morphine administered directly into the FCA-injected joint, under transient
anaesthesia, resulted in a reduction in the knee joint hypersensitivity as measured in
the conscious animal.
Furthermore, this reduction in hypersensitivity was evident in the behavioural
assessment performed half an hour after administration of EMI or morphine, and was
still significantly reduced compared to vehicle, four days after dosing.
• Nociceptive discharge from the MAN, evoked by noxious mechanical von Frey
filaments, was attenuated by EMI or morphine in terminally anaesthetised rats during
the 'chronic' phase of the joint hypersensitivity.
• This decrease in neural discharge was confirmed as being opioid-mediated, as the
opioid receptor antagonist naloxone blocked this attenuation of discharge.
• EMI caused no change in nociceptive discharge evoked by the von Frey filaments in
un-inflamed naive animals, suggesting the action of EMI is dependent on an
inflammatory induced change in the nociceptors.
7.2.2 Relationship to current understanding
Opioid receptors are present on predominantly small, unmyelinated, primary
afferents in naive rats (Fields et al. 1980; Coggeshall et al. 1997). Expression of p-opioid
receptors increased significantly in the ipsilateral DRG of rats 1-3 days after carrageenan-
induced hind-paw inflammation (Ji et al. 1995), yet no increase was seen over a similar time
period following FCA-induced hind-paw inflammation (Schafer et al. 1995). Inflammation
induced by intra-plantar FCA, enhanced axonal transport of opioid receptors to the
periphery, with an accumulation of the receptors observed in homogenized paw tissue
(Hassan et al. 1993; Zhang et al. 1998). The increase in opioid receptors observed at the site
of inflammation has been complemented by studies performed in rats, in which
inflammatory cells containing endogenous opioid peptides infiltrate the site of inflammation
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(Stein et al. 1990b). Studies in both mice and rats have focused on the acute phase (0-4 days)
of the inflammatory reaction, with strong evidence existing that highlights a peripheral
nociceptive action of opioids (Stein 1991).
A study investigating the more long term effects of systemically administered FCA,
used immunohistochemical labelling to report an increase in the expression of the p-opioid
receptors in DRG cell bodies at four weeks post-FCA, but not the dorsal horn leading the
authors to conclude that the receptors were being transported to the periphery (Ballet et al.
2003). In contradiction to this Li et al., (2005) reported a down regulation in p-opioid
receptor protein and gene expression one week after a monoarthritis was induced in the knee
joint using FCA. The results from my studies provide strong evidence that there are
functional opioid receptors associated with knee joint afferents during the chronic stage of
joint inflammation. This was demonstrated in studies where two different opioid agonists
were administered locally, and both were antinociceptive in the behavioural and
electrophysiological studies. Moreover, this antinociceptive effect was abolished by the
opioid receptor antagonist naloxone, proving that the effect was opioid-mediated.
7.2.3 Clinical implications
Preclinical models of human disease are used by the pharmaceutical industry as part
of the drug discovery process to facilitate the finding of novel pharmacological compounds
for use in the treatment of the symptoms associated with arthritis. Morphine administered
directly into the knee joint in RA sufferers reduces chronic joint pain associated with the
inflammatory disease (Stein et al. 1999); EMI or morphine, administered by the same route,
enabled rats to place more weight through their inflamed knee joint, a behavioural indication
that locally administered opioids provide analgesia in rats. These results build confidence in
the use of FCA-induced inflammatory joint pain as a preclinical model of inflammatory joint
pain because the data is comparable to that seen in the clinic.
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Chronic joint pain is often treated orally using a combination of two low dose
analgesics with different mechanisms of action, for example Ultracet containing the NSAID
paracetamol and the opioid tramadol (Emkey et al. 2004). This combination therapy allows
the level of pain relief to be maintained whilst minimising the side effects associated with the
higher doses of the individual drugs (Emkey et al. 2004; Miranda et al. 2007). It is possible
that EMI could be utilised in such a combination as results presented in this thesis show that
it is capable of attenuating the nociceptive signalling from knee joint afferents. Topical
application of the opioid lidocaine-prilocaine cream has been shown to be more effective
than i.v. morphine in treating post-operative pain associated with thoracostomy tube removal
(Valenzuela and Rosen 1999). EMI in a cream formulation, applied topically in the same
fashion as capsaicin cream (Deal et al. 1991), could also be explored as a convenient
palliative treatment for chronic joint pain. Experiments would have to be performed to
confirm that the drug is absorbed through the skin and into the joint capsule directly, rather
than via absorption into the blood stream of the highly vascularised joint, and subsequent
circulation to the joint capsule.
7.2.4 Limitations of the data
Despite several attempts with various different, type-specific, opioid receptor
antibodies, I was unable to establish an IHC protocol capable of generating fluorescent
staining with a clear signal to background ratio, when observing DRG sections under the
fluorescent microscope. This meant opioid receptor expression in the knee joint-specific
afferent cell bodies could not be investigated. The inclusion of opioid expression data would
have been invaluable in providing further evidence as to the changes in opioid receptors in
specific DRG during the course of the FCA-induced inflammation. An up-regulation would
imply that, increased amounts of opioid receptor are being transported into the periphery.
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This finding would, in part, help explain why nociceptive discharges are attenuated by EMI
or morphine in inflamed joint afferents, but not naive joints.
In the present studies the animals had to be anaesthetised, either terminally for
electrophysiology, or transiently when administering the opioids into the knee joint for the
behavioural work. It may be that pentobarbital used in the in vivo electrophysiology studies
modulated the opioid receptors and it would have been useful to conduct repeat experiments
using different anaesthetics such as urethane. In order to adhere to Home Office 3Rs, and to
remain within temporal and economic restraints of the experimental work, these experiments
were not performed. Pentobarbital was chosen as it has a short half life ensuring the level of
anaesthesia was more accurately controlled. Furthermore, conclusions drawn regarding the
effect of EMI and morphine were made after integrating the outcome of the
electrophysiological experiments and the behavioural studies. Every attempt was made to
ensure that these comparisons were fair by ensuring the same weight and strain of rats were
used and the time points at which tests were made were kept the same. However, different
anaesthetics were used for terminal and transient anaesthesia and the behavioural end-point
of weight distribution is a different stimulus to mechanically-evoked discharge. In the
electrophysiological experiments the C-fibres were the only type to be identified by
conduction velocities. Fibres that were not capsaicin sensitive but responded to noxious
mechanical stimulation were assumed to be A8-fibres, but without a conduction velocity this
could not be confirmed.
7.2.5 Further studies
Ideally the expression of the p, 8 and k opioid receptors would be quantified in knee
joint afferent DRG. Extensive but unsuccessful efforts were made at the time to perfect a
fluorescent staining protocol, and this challenge could be re-visited to provide valuable data
on receptor expression.
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The ability of the endogenous opioid peptide EM2 to reduce hyperalgesia in the
inflamed knee joint requires investigation, as studies were not performed due to time and
cost constraints during the project. Furthermore, the role of opioids in more advanced stages
of chronic joint hypersensitivity should be studied in alternative models of inflammation,
such as the antigen-induced arthritis model of OA (Buchner et al. 1995).
7.3 VGSCs
7.3.1 Major findings
• The present studies clearly demonstrated that expression of Nav1.7, Nav1.8 and
Nav1.9 in the FB labelled DRG population, were upregulated at various times during
the 28 day study (see Summary diagram 7.1).
The fluorescent retrograde tracer FB was successfully used to highlight a population of
afferent cell bodies within F3-5 DRG which innervated the knee joint.
• Results from behavioural studies revealed that intra-articular administration of the
sodium channel blocker ralfinamide (lOOpM) produced significant reductions in joint
hypersensitivity on the days it was dosed compared to pre-dose values, assessed using
both the incapacitance tester and the PAM device.
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Figure 7.1 Summary of how VGSC expression, opioid receptor signalling, and TRPV1 receptors
contribute to nociceptive discharge in nociceptive neurons following FCA-induced joint
inflammation. FB was injected into the knee joint and was retrogradely transported to DRG cell
bodies innervating the knee joint. Expression of Nav1.7, Nav1.8 and Nav1.9 were increased in FCA-
injected joints, whilst TRPV1 expression remained the same. Opioid peptides such as EMI and
morphine were administered into the knee joint where they activated opioid receptors expressed on
peripheral terminals. Inflammatory cells have also been implicated in providing analgesia at site of
tissue injury by releasing endogenous opioid peptides such as EMI. Coupling of the receptor to the
inhibitory G-protein resulted in a decrease in cyclic AMP, leading to a suppression of Na+ and Ca2+
currents, which in turn resulted in a decreased neuronal hyperexcitability.
FB = fast blue, | = increase in VGSC expression, - = no change in TRPV1 expression, OP = opioid
peptides, OR = opioid receptors and IC = inflammatory cells
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7.3.2 Relationship to current understanding
The present studies are in keeping with published papers reporting an increase in
expression of the Nav1.7, Nav1.8 and Nav1.9 channels in rat DRG tissue following
inflammatory insults (Black et al. 2004; Gould et al. 2004; Priest et al. 2005; Villarreal et al.
2005). The present results are the first to provide detail concerning changes in specific
channels during a rat model of FCA-induced chronic inflammatory joint pain up to 28 days
post-FCA (see chapter 6). Gould et al., (1998) investigated the changes in the expression
level of all the sodium channels in DRG tissue up to six months after FCA-induced
inflammation of the paw. Specific antibodies were used in present studies to investigate
individual sodium channel subtypes in knee joint specific cell bodies.
Knockdown of Nav1.7 in murine DRG decreased both acute and chronic pain
behaviours (Nassar et al. 2004; Yeomans et al. 2005), and intraplantar FCA resulted in an
increase in the levels of channel labelling in DRG 24 hours after the insult (Gould et al.
2004). It is therefore not surprising to find that Nav1.7 was up-regulated on days 14 and 28
post-FCA in the present study. Expression levels of Nav1.8 and Nav1.9 were also increased
on day 14-18 post-FCA. This is also in keeping with studies in rats where these subtypes
were upregulated in DRG following inflammatory insults in acute studies (Tanaka et al.
1998; Tate et al. 1998; Black et al. 2004; Coggeshall et al. 2004). The present results are the
first to demonstrate a role for these sodium channels in the maintenance of chronic
inflammatory pain after the inflammation has resolved. An increase in sodium channel
expression in nociceptive afferents will cause neural hyperexcitability and lead to an increase
in the spontaneous discharge that is associated with chronic pain.
7.4 General conclusions
The main finding of this thesis is that functional opioid receptors are present in joint
afferents innervating the knee joint 14-23 days after inducing joint inflammation with FCA.
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In behavioural studies, morphine or EMI administered directly into the knee significantly
attenuated the FCA-induced joint hypersensitivity. In addition, in vivo electrophysiology
recordings taken from the MAN showed that both morphine and EMI reduced neural
discharge evoked by von Frey filaments in FCA-injected knee joints. The attenuation of
nociceptive discharge was confirmed as being mediated through opioid receptors by
demonstrating that this reduction in action potential discharge was antagonised by naloxone.
The conclusions reached from the opioid work presented in this thesis suggest that
controlling the release of endogenous opioids at the sites of inflamed tissues, or restricting
exogenous opioids to the periphery, may provide excellent long term analgesia in chronic
inflammatory pain, whilst avoiding the common centrally mediated side effects.
A further finding is that the VGSC subtypes: Nav1.7, Nav1.8 and Nav1.9 contribute,
in part, to maintaining chronic neural hyperexcitability following an inflammatory insult. All
three channels were upregulated in the cell bodies of afferents innervating the knee joint 28
days after the initial inflammatory insult (see Figure 7.1). Behavioural tests showed that
there was a significant joint hypersensitivity on day 28 post-FCA, and in vivo
electrophysiology experiments showed that spontaneous neural discharge was increased in
FCA-injected animals compared to naive animals. These observations could be due, in part,
to the increased expression of the Nav1.7, Nav1.8 and Navl-9 on knee joint afferents in
FCA-injected animals on days 14 and 28 post-FCA. Investigations into whether ralfinamide
reduces this spontaneous activity observed in the in vivo electrophysiological recordings,
would confirm this role.
Additionally, IHC studies showed no difference in the levels of TRPV1 receptor
expression in knee joint afferent DRG cell bodies between naive and FCA-injected animals.
This data complements the in vivo electrophysiology finding that capsaicin-evoked neural
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A Pharmacological comparison of two different sensory readouts in a rat model of
chronic inflammatory joint pain
IT Strickland1, S J Medhurst2, A W Wilson2,1 Chessell2
'University of Edinburgh, Division of Neuroscience, Medical College, 1 George Square,
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The aim of this study was to compare two different methods of evaluating the
efficacy of known analgesics, currently available in the clinic, for the treatment of the
chronic pain associated with rheumatoid arthritis. The paw pressure withdrawal threshold
assay (Randall & Selitto, 1957) has long been used as a mechanical test of assessing
hypersensitivity in models of acute inflammatory pain (Anseloni et al., 2003). The recent
development of the weight bearing assay has seen the introduction of an alternative readout
providing an objective assessment of incident hypersensitivity (Clayton et al., 1997). Using a
rat model of chronic inflammatory joint pain (Donaldson et al., 1993), a monoarthritis was
induced by injecting 150f.il (lmg/ml) of Freund's complete adjuvant (FCA) into the intra¬
articular space of the knee joint. Injections were done under brief anaesthesia (3%
isofluorane with 02 at 1.51.min"'). A series of six, blind and randomised experiments (n=40,
for each experiment) were conducted assessing the analgesic potency of Rofecoxib (1,3 and
lOmg.kg"1), Etoricoxib (1,3 and lOmg.kg"1) and Ibuprofen (3, 10 and 30mg.kg"'), using both
the paw pressure withdrawal threshold and the weight bearing readouts. Drug or vehicle
(DMSO 1%, distilled water 33% and PEG40o 66%) were chronically dosed (p.o.) on days 13-
17 post FCA injection and the above readouts were used to assess the ability of the test drug
to reverse the induced hypersensitivity. The contralateral paw pressure withdrawal threshold
readout can be taken to negate any compound-induced motor deficits being falsely
concluded as analgesia. All data were transformed into an area under the curve (AUC) value,
for days 13-17 for each dosing group. Using Statistica V.6 the AUC data were statistically
analysed by an ANOVA followed by a Duncan's post-hoc test. A difference in groups was
only considered significant when P<0.05. The relationship between the AUC group means
were then assessed using Pearson's linear regression correlation analysis in order to produce
a correlation coefficient (where 1 = positive correlation, 0 = no correlation and -1 = negative
correlation) and an associated P value stating the statistical significance of the test. Results
revealed strong correlations between the two readouts (Rofecoxib r = -0.9949, Etoricoxib r =
-0.9834 and Ibuprofen r = - 0.9514) with both assays producing similar 50% effective dose
(ED50 values) for each drug. These results provide evidence that the weight bearing assay can
be used alongside the paw pressure withdrawal threshold assay to increase confidence in the
pre-clinical potency of novel analgesics and hopefully lead to improved clinical efficacy.
Clayton, NM; Oakley, I; Thompson, S; Wheeldon, A; Sargent, B; Bountra, C. (1997) BJP,
120, 219P.
Donaldson, LF; Seckl, JR & McQueen DS. (1993) JNM 49, 5-10.
Randall, LO; Selitto, JJ. (1957) A1PT. 111,409-419.
A novel behavioural readout for assessing hypersensitivity of knee joints in a murine
model of unilateral arthritis
I.T.Strickland1. N.J.Barton1, H.M.Brash1, D.S.McQueen1, A.J.Reeve2, A.W.Wilson2,
I.P.Chessell2
1 Division of Neuroscience, College ofMedicine and Veterinary Medicine, University of
Edinburgh, 1 George Square, Edinburgh, EH8 9JZ.
2
Neurology & Gastrointestinal CEDD, GlaxoSmithKline, Harlow,
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The aim of this study was to develop a new quantitative method for measuring
hypersensitivity of the knee (stifle) joint during a murine model of unilateral arthritis
(Gauldie et al,. 2004). The pressure application measurement device (PAM) is designed to
objectively assess a discrete localised hypersensitivity across the knee joint. The force
applied across a joint under test is measured by a force transducer fitted to the
experimenter's thumb (see Figure 1). A gradually increasing 'squeeze' force was applied
across the joint and by means of calibrated instrumentation the force in grams applied was
recorded. The test endpoint was when the animal withdrew its limb. Male C57BL6 mice
(n=24, 23-27g) were transiently anaesthetised (3% isofluorane with 02 at 1.51.min" ) and a
small incision was made over the knee joint to show the patella tendon, sham (n=8) animals
recovered with no further treatment. The remaining 16 animals were injected with Freund's
complete adjuvant (FCA; 20/xl, lOmg.ml"1) under the patella tendon into the intra-articular
space of the joint. Prior to surgery and for 21 days following PAM withdrawal threshold,
weight bearing (Clayton et al,. 1997), knee diameter and body weight were recorded. On day
10 the FCA injected animals were ranked and randomised into two matched groups (n=8)
and dosed (s.c.) on days 13-17 with either prednisolone (lmg.kg1) or vehicle (ethanol 5%,
PEG 45% and distilled water 50%). PAM data were transformed into an area under the curve
(AUC) value and analysed using a Mann-Whitney test, where p<0.05 was considered
significant. Results showed FCA injected animals had significantly lower withdrawal
thresholds than sham on day 3 (p= 0.0001), when compared to day 0, confirming the FCA
induced hypersensitivity. Over days 13-17 the prednisolone treated group had significantly
higher AUC values than the vehicle group (p= 0.0104), compared to day 10, due to a reversal
of hypersensitivity. PAM results correlated significantly with weight bearing data (r= 0.9,
Pearson's correlation). These results show that PAM is a robust tool which provides an easy
to use objective method for localised assessment of knee joint hypersensitivity in mice,
which correlates strongly with a previously accepted behavioural readout.
Clayton et al,. 1997 Br J Pharmacol 120:219P.
Gauldie et al,. 2004 J Neurosci Methods 139(2):281-291.
Figure 1. Pressure application measurement device (PAM)
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Intra-articular morphine is antinociceptive in a rat model of chronic joint
inflammation
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Intra-articular injection of morphine produces a long lasting analgesia in both
rheumatoid and osteoarthritis (Likar et al., 1997; Stein et al., 1999). Recent
electrophysiological data has provided evidence inconsistent with these clinical observations,
showing a loss of antinociception to the /x-opioid agonist endomorphin-1, in 7 day arthritic
animals (Li et al., 2005). The aim of this in vivo electrophysiological study was to
investigate the antinociception of morphine, in male Wistar rats (200-300g) induced with
arthritis by Freund's complete adjuvant (FCA) injected 14-28 days prior to the study (Wilson
et al., 2005), using the TRPV1 agonist capsaicin as an algogenic stimulus. Rats were
anaesthetised using pentobarbital (60mg/ml, O.lml/lOOg i.p. maintained by i.v. infusion of
7.8mg/hr) and neuronal recordings were taken from the medial articular afferents of the left
knee joint (Gauldie et al., 2001). Capsaicin (1/xg) was given every 45 mins as the test
protocol. Morphine (300/xg) or saline was then given after the second control application of
capsaicin. Drugs were injected close to the knee via an intra-arterial femoral catheter. A
Wilcoxon signed rank test was used to assess the statistical significance in any change in
firing frequency evoked by capsaicin before and after, either saline, or morphine. A Mann
Whitney test was used to show there was no significant difference in the firing frequency at
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Figure 1. The mean firing frequency ofknee joint afferents (spikes/second) in response to repeated capsaicin
(Ipg) doses. Control experiment (A. n=6) shows no significant change in the capsaicin evokedfiring. Morphine
(300pg) experiment (B. n=6) show a significant change in the firing frequency, 110 minutes after the morphine
when compared back to both controls.
The change in firing frequency from the 45 minute control application of capsaicin
compared to the final application was from 21.54spikes/sec to 20.86spikes/sec with saline, a
3% decrease, and from 14.55spikes/sec to 6.64spikes/sec with morphine, a 54% decrease.
Morphine significantly reduced nociceptive discharge evoked by capsaicin in arthritic
animals. This is in accord with the clinical data that intra-articular morphine is a potent
analgesic in inflammatory arthritis. Our results suggest that /x-opioid receptors are functional
in the later stages (days 14-28) of this model of arthritis. Further studies using the selective
/x-opioid agonist endomorphin-1 and the opioid antagonist naltrexone are needed to help
characterise the antinociceptive action of morphine and the receptors involved.
Gauldie, S.D. et al. (2001) Br J Pharmacol 132, 617-621
Li, Z. et al. (2005) Arthritis Rheum 56, 3210-3219
Likar, R. et al. (1997) Anesth Analg 84 1313-1317
Stein, A. et al. (1999) Pain 83 525-532
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Intra-articular morphine is antinociceptive
in a rat model of chronic joint inflammation
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Aim
The aim of this study was to investigate the peripheral antinociceptive effect of morphine on capsaicin induced firing of the medial articular
nerve (MAN), using electrophysiological techniques in a rodent model of chronic joint inflammation (Wilson et at., 2005).
Introduction
Intra-articular injection of morphine produces a long lasting analgesia in both rheumatoid- and osteo-arthritic human patients (Likar et a!.,
1997; Stein etal., 1999). Recent electrophysiological data from studies in rats has provided evidence inconsistent with these clinical
observations, showing a loss of antinociception to the p-opioid agonist endomorphin-1, in 7 day arthritic animals (Li et at., 2005).
Methods
Experiments were performed on 12 adult male wistar rats weighing 200-300g (Charles River, UK). Experiments were performed in
accordance with Home Office regulations and within UK animal welfare guidelines, and received Local Ethics Committee approval. A chronic
unilateral inflammation of the left knee joint was achieved by an intra-articular injection of 150pl of Freund's complete Adjuvant (FCA, Img.mM
heat killed Mycobacterium Tuberculosis suspended in mineral oil, Sigma). Animals were briefly anaesthetised using 3% isoflurane (02 at
1.5l.mirr1), and had the left knee shaved and cleaned. FCA was injected through the patella tendon into the joint space of the left knee. The
animals were allowed to recover from anaesthesia before being returned to cages layered with paper bedding for comfort.
Following the induction of chronic unilateral inflammation (14-28 days post injection) rats were anaesthetised using pentobarbital (60mg/ml,
0.1 ml/1 OOg i.p. maintained by i.v. infusion of 7.8mg/hr) and neuronal recordings were obtained from the medial articular nerves of the left knee
joint (Gauldie et al., 2001). Drugs were injected in 0.1ml saline close to the knee via a femoral catheter (i.a.) Capsaicin (1 pig i.a.) was injected
every 45 minutes as the test protocol. Morphine (300pg) or saline was injected i.a. after the second control application of capsaicin. A
Wilcoxon signed rank test was used to assess the statistical significance in any change in firing frequency evoked by capsaicin before and
after, either saline, or morphine. The null hypothesis was rejected at P<0.05.
Results
• Morphine significantly reduced the frequency of firing of the medial articular nerves in response to capsaicin,
compared to the initial control (P=0.001), attenuating the responses by 54% from 14.6 spikes/sec to 6.6 spikes/sec,
110 minutes post- drug administration (see Figure 1).
• This is in comparison to saline-injected animals, where the frequency of firing of the medial articular nerves in
response to capsaicin fell 3% from 21.5 spikes/sec to 20.9 spikes/sec (see Figure 1).
• There was no significant difference, at 0 minutes, in the firing frequency between the saline group (A) and the
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Figure 1. The mean firing frequency
(spikes/second) of knee joint
nociceptive afferents in response to
repeated doses of capsaicin (1pg).
Control experiment (A. n=6)
showed no significant change in
the capsaicin-evoked firing
Morphine (300pg) experimentsfB.
n=6) showed a significant change
in the firing frequency, 110 minutes
after the morphine, in comparison
with controls.
Time of capsaicin test (minutes)
Summary and Conclusions
• These results demonstrate that intra-articular morphine is a potent analgesic in this rodent model of
inflammatory arthritis.
• Our results indicate that opioid receptors are functional in advanced stages (days 14-28) of the model.
• Further studies using the selective p-opioid agonist endomorphin-1 and the opioid antagonist naltrexone
are needed to characterise the peripheral antinociceptive action of morphine and the receptors involved.
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Pressure application device (PAD) - A novel behavioural readout for assessing a
localised hypersensitivity of the knee joint in a murine model of unilateral arthritis
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Chronic joint pain has high incidence levels in the UK, but with current treatments
providing poor pain relief and commonly associated with undesirable side effects, there still
remains a great demand for the development of new, safer analgesics. The aim of this study
was to assess the novel Pressure application device (PAD) in a mouse model of unilateral
hypersensitivity, which mimics mild arthritis in man. PAD is the first mechanical tool
designed to assess objectively a discrete localised hypersensitivity directly across the knee
joint. We aimed to validate the device in order to improve the translation of novel analgesics
from in vivo models to man. A gradually increasing 'squeeze' force is applied across the
joint and by means of calibrated instrumentation the force in grams applied, up until the
animal withdraws its limb, is recorded. Male C57BL6 mice (n=16, 23-27g) were induced
with a mild unilateral inflammation of the left knee joint (Gauldie et al,. 2004), which
resulted in chronic joint hypersensitivity. PAD withdrawal thresholds were measured prior to
and for 21 days following induction of unilateral joint inflammation. On days 13-17 the
animals were dosed with the steroid; prednisolone (lmg.kg1), which is clinically effective in
the treatment of osteoarthritis. We found, that PAD accurately detected the initial joint
hypersensitivity and the subsequent analgesic action of prednisolone in mice. We conclude
that PAD is a robust device which provides an easy to use objective method for assessing
localised joint hypersensitivity, humanely, in laboratory animals. PAD is a new behavioural
tool which will facilitate the development and screening of novel analgesics for clinical use.
Gauldie et al,. 2004 J Neurosci Methods 139(2):281 -291
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in a murine model of unilateral hypersensitivity
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Aim
The aim of this study was to develop and validate a novel quantitative behavioural readout in a mouse model of unilateral hypersensitivity
(Gauldie et at,. 2004) which mimics mild arthritis in man. The Pressure application device (PAD), is the first mechanical tool designed to
objectively assess a localised hypersensitivity directly across the knee joint. We aimed to validate this device in order to improve the
translation of novel analgesics from in vivo models into man.
Introduction
Osteoarthritis (OA) and Rheumatoid arthritis (RA) are highly prevalent inflammatory conditions; with OA having an estimated incidence of
12.5% and RA 0.8% in the UK adult population (Bedson et at., 2005).With current treatments providing poor pain relief and commonly
associated with undesirable side effects, there still remains a great demand for the development of new, safer analgesics. Several behavioural
readouts are currently used to assess the hypersensitivity in the joints of arthritic rodents (Clayton et at.. 1997). However none of these are
able to assess a localised hypersensitivity directly across the arthritic joint.
Apparatus
PAD apparatus includes a base unit with display screen (Fig.1 A) and a
force transducer, with 5mm diameter application surface, mounted on a unit
worn on the experimenters thumb. Placing the force transducer on one side
of the joint and the forefinger on the opposite (Fig. 1B), a gradually increasing
'squeeze' was applied in a mediolateral plane across the mouse knee joint.
By means of the calibrated instrumentation the force in grams (gf) applied
was recorded (max = 500gf). The test endpoint was when the animal
withdrew its limb. On test days three recordings were taken per animal in
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Fig. 1. (A) PAD apparatus showing the base unit with force display screen and thumb worn force
transducer. (B) Example of how the gradually increasing 'squeeze' force is applied across a
joint. The transducer is placed on one side of the joint and the forefinger on the opposite.
Methods
Experiments were performed in accordance with Home Office
regulations and within UK animal welfare guidelines, and received Local
Ethics Committee approval. Male C57 black 6 mice (24, C57BL/6; Charles
River, UK; 23-28g) were used in the study. Mice were housed 8 to a cage
in a 12-h light/dark environment and were given free access to standard
animal feed and water for the duration of the study. All animals were
allowed three days acclimatisation before the experiment began and all
behavioural tests took place in the same room at the same time of day.
A chronic inflammatory joint pain was induced following day 0 baseline
PAD withdrawal threshold recordings. Mice were transiently anaesthetised
(3% isofluorane with 02 at 1,5l.min-1) and a small incision was made over
the knee joint to expose the patella tendon, sham (n=8) animals recovered
with no further treatment. The remaining 16 animals were injected with
Freund's complete adjuvant (FCA; 20pl, lOmg.ml"1) under the patella
tendon into the infra-articular space of the knee joint (Gauldie et at,. 2004).
On day 10 the FCA injected animals were ranked and randomised into
two matched groups (n=8 per group), based on their level of withdrawal
threshold (gf). The groups were dosed (s.c.) on days 13-17 blindly with
either prednisolone (1mg.kg_1) or vehicle (ethanol 5%, PEG 45% and
distilled water 50%) one hour before recordings were taken.
Data were transformed into an area under the curve (AUC) value during
the dosing period and analysed using a Mann-Whitney test, where P<0.05
was considered significant.
Results
1 2 3 4 6 6 7 8 9 10 11 12 13 14 16 16 17 18 19 20
Time (Days)
Fig. 2. Effect of prednisolone (n=8, s.c., Img.kg , filled circle) or vehicle (open circle) on the FCA induced
hypersensitivity (n=16, I.art., 20pl, all circles) over days 13-17 as measured by PAD. Untreated sham (n=8)
animals are represented by open triangles. Day 0 ratios of 1.0 are based on the day 0 group mean
withdrawal threshold values of 402gf, 400gf and 437gf.
• FCA injected animals had significantly lower withdrawal
thresholds than sham on day 3 (P< 0.01), compared to day 0,
confirming FCA induced a localised hypersensitivity which
was detected using PAD.
• During the treatment period (days 13-17) the prednisolone
treated group had significantly higher AUC values, compared
to day 10, than the vehicle group (P= 0.0104). This was due to
a prednisolone induced reversal of hypersensitivity.
Summary and Conclusions
• PAD is a robust instrument which provides an easy to use,
objective method for localised assessment of knee joint
hypersensitivity in mice. PAD will facilitate the screening and
development of novel analgesics for use in the clinic.
• A second PAD model is currently under development
designed and calibrated for measuring hypersensitivity in
rat knee joints.
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The expression of the sodium channel Nav1.9 has been shown to be altered in animal
models of neuropathic and acute inflammatory pain (Tate et al., 1998) and its role has been
implicated in the maintenance of inflammatory hypersensitivity (Priest et al., 2005). The aim
of this study was to profile changes in Nav1.9 expression over a 28 day time course in a rat
model of chronic inflammatory joint pain (Wilson et al., 2006). We used the fluorescent
retrograde tracer Fast Blue (FB) to highlight a discrete population of knee joint afferents
identifying a specific DRG neuronal profile.
Male Wistar rats (Charles River, n=54, 150-200g) were transiently anaesthetised
using 3% isoflurane in oxygen, and FB (10/xl, 20mg.mTI) was injected into the joint space of
the left knee. One week later test animals received an injection of Freund's Complete
Adjuvant (FCA; 150pl, lmg.ml"1) into the same joint to induce chronic inflammatory joint
hypersensitivity. Control animals received no FCA. Animals (FCA and control, n=6 per
group) were culled on days 7, 14, 21 and 28 post-FCA, and ipsilateral L3-L5 DRGs were
removed, immediately snap frozen and processed for fluorescent immunohistochemistry.
Serial 12/tm cryosections were cut, fixed in paraformaldehyde and labelled overnight with
Nav1.9 primary antibody (GSK in house, 1:200). Sites of antibody binding were revealed
using the secondary antibody; goat anti-rabbit-Alexa 488 (Molecular Probes, 1:200). In 5-7
sections of each DRG, the total number of FB positive cell bodies was counted, as was the
number of those FB positive cell bodies which also expressed Navl-9. The group mean co-
localisation percentage (± SEM) was calculated from the total counts of L3-L5 for each
animal (see Figure 1).
At days 14, 21 and 28 there was a significant increase in the percentage of Nav1.9
positive knee joint afferent cell bodies innervating the hypersensitive joints (Mann Whitney,
P<0.05 vs. control). These results provide further evidence that Navl-9 channels may play a
role in maintaining neuronal hyperexcitability in chronic inflammatory joint pain.
□ Control Animals M FCA injected animals
Study
Control
Time post FCA injection (days)
Figure 1. Percentage ofNayl.9 positive knee joint ajferent cell bodies in control and FCA-induced
knee joint hypersensitive animals over a 28 day time course study (n=6 per group, * = P<0.05, ** =
P<0.01, Mann Whitney test)
Priest et al., 2005 Proc.Natl.Acad.Sci.U.S.A 102, 9382-9387.
Tate et al., 1998 Nat Neurosci 1, 653-655.
Wilson et al., 2006 Eur J Pain 10, 537-549.
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Introduction
The expression of the sodium channel Nav1.9 has
been shown to be altered in animal models of
neuropathic and acute inflammatory pain (Tate et al.,
1998) and its role has been implicated in the
maintenance of inflammatory hypersensitivity (Priest
et al., 2005). These TTX-resistant sodium channels
are expressed in the dorsal root ganglion (DRG)
where they can be transported centrally, or to the
periphery to regulate neuronal hyperexcitability.
In the present study we used a Freund's complete
adjuvant (FCA) insult to establish chronic
inflammatory hypersensitivity of the knee joint
(Wilson et al., 2006). By using the retrograde tracer
fast blue (FB) we identified a distinct population of
cell bodies of knee joint afferent nerves (Hanesch et
al., 1995) and subsequently investigated Nav1.9
receptor expression levels in this specific neuronal




All experiments were performed using adult
male Wistar rats (Charles River, UK; n=54)
weighing between 150-200g. Prior to FB injection,
and throughout the study, hind limb weight
distribution was measured using the Linton
Incapacitance tester (Wilson et al., 2006).
For intra-articular knee joint injections of FB
and FCA, animals were transiently anaesthetised
using 3% isoflurane in oxygen, the left (ipsilateral)
knee joint was shaved and cleaned and 10pt of
FB (20mg.m|-1, tiling Plastics, Germany) or 150pl
of FCA (1 mg.ml'1, Sigma, UK) was injected
under the patella tendon into the joint space of
the left knee. Animals recovered from
anaesthesia before being returned to their cage.
On day minus 7, all animals (n=54) received an
initial injection of FB. 7 days later (day 0), test
animals (n=24) received a further injection of
FCA, whilst control animals (n=30) received no
further treatment. Animals were killed (FCA and
control, n=6 per group) on days 7, 14, 21 and 28
post FCA. Ipsilateral L3-L5 DRGs were removed
and embedded in optimum cutting temperature
(TissueTek, Canada) compound and snap frozen
in isopentane cooled on dry ice. DRGs were
stored at -80°C until they were sectioned.
Fluorescent Immunohistochemistry
Serial 12pm cryosections were cut, fixed in
paraformaldehyde and labelled overnight with
Nav1.9 primary antibody (GSK in house, 1:200).
Sites of antibody binding were revealed using the
secondary antibody; goat anti-rabbit-Alexa 488
(Molecular Probes, 1:200).
Analysis
In 5-7 sections of each DRG, the total number
of FB positive cell bodies was counted, followed
by the number of those FB positive cell bodies
also expressing Nav1.9. The group mean co-
localisation percentage (± SEM) was calculated
from the total counts of L3-L5 for each animal.
x-
Results
1. FCA induced a significant hypersensitivity
up to 28 days post injection
Injection of fast blue on day minus 7 had no effect as
assessed using the weight distribution ratio (see Figure
1-)
Figure
FCA injection (day 0)
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Fig. 1. Time course study behavioural data - intra-articular
injection of FCA caused a significant hypersensitivity at all
timepoints (n=54, Mean ±SEM, ANOVA followed by
Bonferroni's post-hoc comparisons, "* = P<0.001).
2. Fast Blue acts as a retrograde tracer,




Fig. 2. Sample photomicrograph showing the selective
fluorescence of fast blue positive knee joint afferent soma.
Following intra-articular injection of 10pil of 2% fast
blue, afferents retrogradely transport the dye back to
their somata located in the DRG. Using fluorescent
microscopy these fast blue-positive cells are clearly
visible, highlighting the cell bodies of nerves innervating
the knee joint.
3. The majority of knee joint afferents have






Fig. 3. Distribution of fast blue-positive cell bodies in L3- L5
DRGs.
A total of 788 fast blue-positive cell bodies was
counted from L3-L5 ipsilateral DRGs. Of these cells
84% were found in L3 and L4. These results are in
accordance with previously published data (Salo et al
1997), where 88% of knee joint afferent cell bodies
were found in L3 and L4 when looking at L1-L5 rat
DRGs
4. Nav1.9 receptor expression increases 14,




Naive 7 14 21 28
Time (Days post-FCA)
Fig. 4. FCA caused an increase in the percentage ofNav1.$
receptor expressing knee joint afferent cell bodies at 14, 21
and 28 days post FCA (Mean ±SEM, Mann Whitney FCA
vs. control, * = P<0.05 and " = P<0.01).
Figure 5.
Fig. 5. Example photomicrographs ofNav1.9 staining in a.
FCA and b. control DRG sections at day 21. Scale bar
represents 100pm
Conclusions
• FCA causes behavioural hypersensitivity that
is established by day 7 and maintained at day 28
post-injection. This behavioural hypersensitivity
is mirrored by an increase in Nav1.9 receptor
expression in cell bodies of knee joint afferents
over this time period.
• The increased receptor expression is likely to
lead to a shift in the resting membrane potential
closer to the activation threshold and increase
neuronal excitability.
• These results provide further evidence that
Nav1.9 channels play a role in the maintenance of
neuronal hyperexcitability in chronic
inflammatory joint pain.
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Peripherally administered endomorphin-1 attenuates nociceptive discharge evoked by
noxious mechanical stimulation in a rat model of chronic inflammatory joint
hypersensitivity
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Endomorphin-1 (EM-1) is an endogenous tetrapeptide with high selectivity and
affinity for the p-opioid receptor (Zadina et al., 1997). EM-1 has similar functional
properties to morphine and has been shown to inhibit nociceptive activity in primary
afferents during noxious mechanical hyper-rotation of acutely inflamed knee joints (Li et al.,
2005). The aim of this in vivo electrophysiology study was to determine whether EM-1
could attenuate mechanical joint hypersensitivity 14-23 days after induction of an
inflammation in the knee joint (Donaldson et al., 1993).
Unilateral knee joint arthritis was induced in the left joint of adult male Wistar rats
(n=15, 150-200g) by a 150/xl intra-articular injection of Freund's complete adjuvant (FCA;
lmg.mr' Mycobacterium tuberculosis, Sigma, UK). Rats were transiently anaesthetised
using 3% isoflurane in oxygen and FCA was injected into the knee joint space. On days 14-
23 animals were anaesthetised by an i.p. injection of pentobarbital sodium (60mg.ml"' at
lOpl.kg"'), maintained throughout the experiments by an i.v. infusion of pentobarbital
(7.8mg.hr"'). Extracellular neuronal recordings were made from the medial articular nerve
(MAN) of the ipsilateral knee joint (Gauldie et al., 2001). The MAN was mechanically
stimulated using von Frey filaments of lg, 7g and 21g at a fixed position within the receptive
field on the exposed surface of the knee joint. Filaments were tested in ascending order for a
period of 10s with a break of 10s in between each stimulation. Applications of the hairs were
repeated every 20mins. The effect of each individual filament was measured as the change in
the action potential frequency (impulses.s"'), during the test period compared to that of the
preceding ten seconds. Five tests were performed before and after dosing with EM-1 (100pg,
n=5), naloxone (500pg) and EM-1 (100pg, n=5) and saline vehicle (n=5). Drugs were
administered in a volume of lOOpl close to the knee via a femoral arterial cannula. The mean
(± SEM) normalised frequency of firing was calculated for each individual filament, with the
highest frequency within each experiment being designated 100%. Data were analysed using
a one-way analysis of variance (ANOVA, Kruskal Wallis) where E<0.05 was considered
statistically significant.
Results showed that EM-1 significantly inhibited firing of the MAN evoked by the
7g and 21g von Frey filaments. The mean discharge evoked by the 7g filament fell
significantly from 6.7 ±1.6 impulses.s"1 to 1.3 ± 0.3 impulses.s"1 (P<0.05, 46 ± 5% to 10 ±
2%) and the firing frequency evoked by the 21g filament fell significantly from 9.7 ± 2
impulses.s"' to 2.2 ± 0.4 impulses.s"' (P<0.05, 70.8 ± 5% to 24 ± 5%). This significant
inhibition was reduced when naloxone was administered before the EM-1. The vehicle had
no significant effect on the frequency of firing evoked by any of the filaments tested.
These results suggest that jU-opioid receptors are present and functional in the periphery on
the MAN during the advanced stages (days 14-23) of this model of chronic inflammatory
joint hypersensitivity. This is further evidence that peripherally acting opioids could play an
important role in managing chronic pain in the clinic, without the unwanted side effects of
the centrally acting opioid morphine.
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Gauldie, S. et al., (2001) Br J Pharmacol 132, 617-21
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Peripherally administered endomorphin-1 attenuates nociceptive
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1. Aims of the study
An in vivo electrophysiology study was undertaken to investigate the
effect of endomorphin-1 (EM1) on the neural activity of nociceptors in the
rat medial articular nerve (MAN), as assessed by the response to noxious
mechanical stimulation 14-23 days after the induction of an inflammation
in the knee joint.
2. Introduction
EM1 is an endogenous tetrapeptide with a high selectivity and affinity
for the p-opioid receptor (MOR). EM1 has been shown to exhibit
analgesic properties similar to morphine (Zadina et al., 1997).
Experimental inflammation of the rat knee joint, induced by Freund's
complete adjuvant (FCA), is a model of human inflammatory arthritis and
has been used to investigate the mechanisms involved in the
establishment of chronic pain (Donaldson et al., 1993). Moreover the
model has been utilised as a pre-clinical screen tor novel analgesics in a
drug discovery environment.
EM1 has been shown to inhibit nociceptive activity in primary afferent
fibres of the MAN in response to noxious hyper-rotation of the FCA-
inflamed knee joint. This effect is present in naive animals and animals
tested at an acute stage of the model (48hrs post-FCA), however the
effect is absent in animals tested 7 days into the model, leading the
authors to conclude that MOR are down-regulated during chronic
inflammation (Li et al., 2005).
Intra-articular injection of morphine is known to produce a long lasting
analgesia in humans suffering from inflammatory arthritis in the knee
(Likar et al., 1997). With this in mind the present study was performed in
order to investigate whether functional MOR are present in the knee joint
primary afferents during a more chronic phase of the FCA-induced rat
model of joint inflammation than has previously been studied.
3. Methods
Unilateral arthritis was induced in the left knee joint of adult male
Wistar rats (n=15, 150-200g, Charles River) by an intra-articular injection
of 150pl of FCA (Img.mh1 Mycobacterium tuberculosis, Sigma). Rats
were transiently anaesthetised using 3% isoflurane in oxygen and FCA
was injected into the knee joint space. On days 14-23 animals were
anaesthetised by an i.p. injection of pentobarbital sodium (60mg.mH at
10pl.kg-1), maintained throughout the experiments by an i.v. infusion of
pentobarbital (7.8mg.hr1). Extracellular neuronal recordings were made
from the MAN of the left knee (Gauldie et al., 2001).
The MAN was mechanically stimulated using von Frey filaments of 1,
7 and 21g at a fixed position within the receptive field of the MAN, on the
exposed surface of the knee joint. Filaments were tested in ascending
order for a period of 10s with a break of 10s between successive stimuli.
Tests were conducted every 20mins, with five tests being performed
before and after dosing with either vehicle (saline, n=5), EM1 alone
(100pg, n=5), or EM1 (1 OOpig, n=5) following pre-treatment with 500pg
naloxone (see Figure 1). Drugs were administered in a volume of 100pl
close to the knee via an arterial femoral cannula.
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Figure 1. Schematic of the test protocol showing the times of mechanical stimulation
(red arrows) and the time when the drugs were delivered (blue arrow). Pre-treatment
with naloxone (500ug) occurred 3 minutes before the EM1 was administered.
The effect of each individual filament was measured as the change in
the action potential frequency (impulses.s-1) during the test period
compared to that of the preceding ten seconds. The mean (± SEM) neural
discharge was calculated for each individual filament. Data were analysed
using a one-way analysis of variance (ANOVA, Kruskal Wallis) where
P<0.05 was considered statistically significant.
4. Results
EM1 inhibited firing of the MAN evoked by the 1, 7 and 21g von Frey
filaments. The mean neural discharge fell from 0.6 ± 1.6 to 0.09 ± 0.03
impulses.s"1 evoked by the 1g filament, 3.3 ± 0.6 to 0.64 ± 0.2 impulses.s'1
evoked by the 7g filament and 4.8 ± 0.7 to 1.1 ± 0.2 impulses.s-1 evoked by
the 21g filament, when comparing pre-drug values to post-drug values. All
the reductions in neural firing were significant (* represents P<0.05, ***
represents P<0.001, Kruskal Wallis ANOVA). This significant inhibition was
not observed when naloxone was administered 180s before EM1. The
vehicle (saline) had no effect on the frequency of firing evoked by any of
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Figure 2. Graphs showing the mean
neural discharge (impulses.sr1) of
MAN primary afferents in response
to mechanical von Frey filament
stimulation of 1, 7 and 21g before
and after administration of (a) saline
(n-5, fibres=14), (b) EM1 (100pg,
n=5 fibres=11) and (c) EM1 and
naloxone (100pg and 500/jg, n=4





• These results suggest that MOR are present and functional in
primary afferent nerves during the advanced stages (days 14-23) of
the FCA-induced model of chronic inflammatory joint hypersensitivity.
• The potent antinociceptive effect of the MOR agonist EM1, occurs
through an opioid receptor mediated mechanism, as the
antinociceptive effect is blocked by pre-treatment with the opioid
receptor antagonist naloxone.
• This study provides further evidence that peripherally acting
opioids play an important role in managing chronic pain in the clinic,
without the unwanted side effects of the centrally acting opioid
morphine.
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Abstract
Chronic joint pain affects physical well being and can lead to severe psychological and social problems, therefore successful long-term manage¬
ment is highly sought-after. No current behavioural measures of pain used in pre-clinical models mimic the clinical dolorimeter, which provides
an objective measure of joint hypersensitivity. In this study we aim to use a novel behavioural readout alongside an established measure to mimic
the multifactorial measurements taken in the clinic. Using the pressure application measurement (PAM) device a gradually increasing squeeze was
applied across the knee joint of rats until the animal gave an indication of pain or discomfort. PAM and the incapacitance tester were used to detect
joint hypersensitivity in a well-established rodent model of adjuvant-induced arthritis. Subsequently, the analgesic effects of prednisolone (1, 3
or lOmgkg-1), morphine (3mgkg~l) and celecoxib (15mgkg_1) were assessed. Both PAM and the incapacitance tester detected a reversal of
hypersensitivity 1 h post-drug administration. Furthermore, the two readouts were highly correlated, and power analysis indicated that PAM was
highly reproducible. In conclusion, PAM provides a novel, accurate behavioural tool for detecting a primary mechanical hypersensitivity in a rat
model of chronic inflammatory joint pain.
© 2007 Elsevier B.V. All rights reserved.
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1. Introduction
Osteoarthritis (OA) and rheumatoid arthritis (RA) are preva¬
lent diseases, with estimated incidences of 12.5% (Bedson
et al., 2005) and 0.8% (Symmons, 2005) in the UK adult
population, respectively. Arthritis is associated with chronic,
debilitating pain in the joints. Pain is the most common symptom
of patients seeking medical consultation (Loeser and Melzack,
1999). Chronic joint pain not only affects physical well being,
for instance impairing the ability to work, but can also lead to
severe psychological and social problems as a result of sleep dis¬
turbance, anxiety and depression (Ashburn and Staats, 1999).
Successful long-term management is therefore highly sought-
after.
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Rodent models of chronic inflammatory joint hypersensitiv¬
ity have been developed (Chillingworth and Donaldson, 2003;
Donaldson et al., 1993; Gauldieet al., 2004; Wilson et al., 2006)
to help elucidate the underlying pathophysiology involved in
arthritic conditions by identifying specific key modulators or
receptors involved in the pain process. These models are com¬
monly used as pre-clinical screens for novel analgesics, with
the aim to improve the treatment of chronic joint pain in the
clinic. In order to do this successfully it is essential that results
from pre-clinical models correlate well with observed changes
in the clinic to facilitate the translation of novel treatments into
successful patient pain management.
To date, several behavioural readouts have been used to assess
joint hypersensitivity in animal models, using thermal, mechan¬
ical, or electrical sensory stimuli (for review see Le Bars et
al., 2001). Only the weight distribution readout obtained using
an incapacitance tester (Clayton et al., 1997) has so far been
considered as a fair measurement of the persistent chronic hyper-
0165-0270/$ - see front matter © 2007 Elsevier B.V. All rights reserved,
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sensitivity observed in patients. The incapacitance tester is able
to provide an objective, non-evoked assessment of "incident"
pain by measuring the average weight placed on each hind
limb. Naive rodents distribute their weight equally between both
hind limbs under normal conditions (Kobayashi et al., 2003).
However, following induction of joint inflammation, animals
redistribute their weight in order to put less weight through the
affected joint.
Whilst this readout has gone a long way to correlate with the
clinical observation of 'pain on standing' it is only one mea¬
surement of complex pain. In the clinic, patients are scored by a
variety of readouts or tasks, often being subjected to firm squeez¬
ing of affected joints (Ritchie et al., 1968). For instance, using
the pressure dolorimeter (Langley et al., 1983), a localised quan¬
titative measure of hypersensitivity directly around the affected
joint can be measured. Using this device, a gradually increas¬
ing pressure is applied perpendicularly across the joint until the
patient indicates tenderness orpain, atwhich point a 'sensitivity'
score is recorded. Clinicians are able to summate a number of
quantitative evaluations to assess a patient's level of pain or dis¬
comfort. In this study we aim to use a novel behavioural readout
alongside an already established readout, with a view to bring¬
ing together two quantitative animal evaluations to mimic the
multifactorial measurements taken in the clinic.
Here we describe a novel behavioural readout, for use with
rats, utilising similarprinciples to the clinical pressure dolorime¬
ter. The pressure application measurement (PAM) device is
designed to apply a gradually increasing squeeze pressure
directly across the kneejoint of rats until the animal gives an indi¬
cation of pain or discomfort. At this point a quantitative value of
the force applied is recorded, giving a similar 'sensitivity' score.
The aim of this study was to determine if PAM was able to
detect a Freund's complete adjuvant (FCA)-induced hypersen¬
sitivity in the knee joints of rats, and subsequently ifPAM could
detect a reversal of this hypersensitivity using analgesics known
to be effective in the clinic. A dose-response study using pred¬
nisolone (Pyne et al., 2004), and further studies using morphine
(Caldwell et al., 2002), and celecoxib (Schnitzer et al., 2005),
were performed to investigate the reproducibility and sensitivity
(a)
of PAM, whilst comparing the device with the already estab¬
lished weight distribution readout. Thus enabling an additional,
clinically relevant pain readout to be applied pre-clinically aid¬
ing the translation of novel analgesics from animal to man.
2. Materials and methods
Experiments were performed in accordance with Home
Office regulations and within UK animal welfare guidelines, and
received Local Ethics Committee approval. Adult male Wistar
rats (Charles River, UK; initial weight range 137-284 g) were
used in the study. Animals were housed four to a cage in a 12 h
light/dark environment and were given free access to standard
animal feed and water for the duration of the study. All ani¬
mals were allowed 6 days acclimatisation before the experiment
began and all behavioural tests took place in the same room at
the same time of day. Animals were weighed on each test day
to monitor their general health.
2.1. Behavioural assessment
2.1.1. PAM-knee joint withdrawal threshold measurement
PAM consists of a force transducer mounted on a unit fitted
to the operator's thumb (see Fig. 1). The thumb unit is connected
to a recording base unit containing the control panel and digital
readout display. The apparatus has a force transducer with a
range of 0-1500 g (Honeywell, Farnell, UK) and the diameter
of the circular contact is 8 mm; giving the device a surface area
of 50.3 mm2.
Animals were lightly, but securely held and the operator
placed the thumb unit on one side of the animal's knee joint
and the forefinger on the other. A gradually increasing squeeze
force was applied across the joint at a rate of approximately
300 grams per second ensuring the maximum test duration was
5 s. By means of calibrated instrumentation the force in grams
applied was displayed on the digital screen and recorded. The
test endpoint was when the animal withdrew its limb or showed
any behavioural signs of discomfort or distress, such as freezing
of whisker movement or wriggling. As the animals were lightly
Fig. 1. Presentation of the pressure application measurement (PAM) device, (a) The portable control unit with digital display and thumb attachment; (b) PAM in use
measuring the limb withdrawal threshold (LWT) of a rat.
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held with their hind limbs suspended, any movements to pull or
twist out of the operator's fingers were obvious. Any motion to
attempt to withdraw from the device was transferred from the
rat limb to the operator's fingers and forearm, and was taken as
an indication of the test end point. On very rare occasions the
first sign of distress was shown as the animal vocalising prior
to limb withdrawal, and on these occasions this was taken as
the test end point. The peak gram force (gf) applied immedi¬
ately prior to limb withdrawal was recorded by the base unit,
and this value was designated the limb withdrawal threshold
(LWT). Three measurements of both the ipsilateral and con¬
tralateral limbs were made at 1 min intervals during which the
animals were returned to their respective cages. The mean LWTs
were calculated.
2.1.2. Incapacitance tester—weight distribution
The weight distribution between the animal's hind limbs was
measured using the incapacitance tester (Linton Instruments,
UK). The apparatus consists of two force transducers capable
of measuring the body weight that the animal places on each
hind limb. Animals were placed on the incapacitance tester with
their hind paws centred on the two force transducers; the average
body weight distribution in grams was calculated over a period
of three seconds. Weight placed through the ipsilateral limb was
expressed as a ratio of theweight placed through the contralateral
limb, with a ratio of 1.0 resulting from equal weight distribution
across both hind limbs. Each animal had three recordings taken
per test day and the mean weight distribution ratio was calculated
for each group.
2.1.3. Knee joint diameter
The knee joint diameters (left and right) were measured
just below the level of the patella using hand-held digital
micro-callipers (Mitutoyo, Japan; accuracy ±0.1 mm), used as
a measure of swelling during the study.
2.2. Arthritis induction
Rats were transiently anaesthetised with 3% halothane in
oxygen. FCA (1 mgml-1; Sigma, UK) was injected at a volume
of 150 p.1 into the joint space of the left knee through the patella
tendon using a sterile 25-gauge needle (B&D Microlance, UK).
Control animals were anaesthetised but received no injection.
The animals were allowed to recover from anaesthesia before
being returned to cages.
2.3. Study design and drug treatment
A pilot study was carried out to determine whether PAM
could detect a window of hypersensitivity following intra¬
articular FCA in comparison with sham animals. The study also
compared values for PAM with those obtained in the same ani¬
mals using the incapacitance tester. Baseline values for body
weight, weight distribution, PAM LWT and knee joint diam¬
eters were measured on day 0, prior to induction of the joint
inflammation, and were repeated two to three times per week
until day 28. No habituation to the PAM device was conducted.
Secondly, a drug-treatment study was carried out, to inves¬
tigate whether PAM was able to detect reversal of this joint
hypersensitivity and how this differed with three types of drug,
an opioid, a steroid and a non-steroidal anti-inflammatory drug
(NSAID). In order to perform a thorough pharmacological
investigation in this study, whilst using the minimum number
of animals, a dose-response relationship to prednisolone was
examined and single top doses of an opioid and an NSAID
were also investigated. A pre-study behavioural assessment was
introduced to habituate the animals to the device. Baseline val¬
ues for body weight, weight distribution, PAM LWT and knee
joint diameters were measured on day 0, prior to induction of
the joint inflammation. Measurements were made two to three
times per week until day 10, when animals were randomly
assigned into treatment groups. Drugs were administered sub-
cutaneously (s.c.) in a volume of 2 ml kg-1 between days 14
and 18. Prednisolone (1, 3 or lOmgkg-1) was dosed once per
day; whereas morphine (3mgkg-1), celecoxib (15mgkg_1)
and vehicle (ethanol 5%, PEG 45% and distilled water 50%)
were given twice a day. The dose range of prednisolone used
was decided from published results from the lab (Gauldie et al.,
2004), and single doses ofmorphine and celecoxib were decided
from other studies giving strong positive reversals of hyper¬
sensitivity (Wilson et al., 2006). One hour after blind dosing,
behavioural assessments were made following a strict protocol
in order to give animals a rest period between the weight distribu¬
tion and the PAM measurements. Briefly, animals were weighed
and had their weight distribution assessed by making three
consecutive readings before being returned to their cage. Ten
minutes later animals had the sensitivity of both the ipsilateral
and contralateral joints assessed using PAM. Three consecutive
readings were taken, with a 1 min interval between each mea¬
surement, where the animal was returned to the cage. Finally the
knee joint diameters were measured. Further behavioural assess¬
ments were carried out once the dosing period was complete, on
days 21, 24 and 28.
2.4. Data analysis
Prior to analysis, an area under the curve (AUC) summary
of each animal's repeatedly measured responses during the
dosing period was calculated. These AUC values were then anal¬
ysed using a one-way analysis of variance (ANOVA) approach.
Measurements taken over several days were analysed using a
repeated measures ANOVA. In both cases, individual groups
were compared using planned comparisons on the predicted
means. Differences between ipsilateral and contralateral sides
were analysed using paired /-tests. In all cases the null hypoth¬
esis was rejected at P<0.05. The data were log transformed
where appropriate to stabilize the variance. Data are expressed
as observed mean ± standard error of the mean (SEM). Statisti¬
cal analyses were carried out using Statistica version 6 (Statsoft,
Tulsa, OK, USA).
Two different power analyses were carried out on the drug
study to investigate the reliability and confidence levels obtained
from the two different readouts in the framework of this exper¬
imental design. In the first, perhaps more standard power
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analysis, the numberof animals required to reach a certain power
obtained from an observed drug effect was assessed. For this
analysis, calculations were based on an effect size equivalent to
the observed difference between vehicle and the highest dose of
prednisolone.
In the second analysis, the effect of varying the numberof ani¬
mals used, or the numbers of measurements made, on the power
of the experiment was assessed. By calculating the animal and
measurement variance components, for the weight distribution
and PAM LWT responses separately, we investigated the effect
of varying replication of both animals and the measurements on
the statistical power of the treatment comparisons.
3. Results
In both studies, intra-articular injection of FCA had no
adverse effects on the animal's general health as evidenced by
the fact that they continued to feed and gain weight normally
throughout the study. There were no significant differences in
body weights between any of the FCA-injected and sham ani¬
mals at any time point (data not shown).
In both studies there were no significant differences between
the mean PAM LWTs or knee joint diameters of the ipsi-
lateral and contralateral limbs and no significant differences
between treatment groups, prior to FCA injection on day 0
OP >0.05).
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Fig. 2. (a) The ipsilateral PAM LWTs in gram force and (b) ratio of weight
distribution between the hind limbs of sham (n = 8) and FCA-injected (n = 8)
rats over a 28-day pilot study. PAM detected a large window of hypersensitivity,
similar and comparable to that observed with the incapacitance tester. Statistical
significance (PcO.05) is represented by *; statistical analysis carried out to
compare the two groups at each time point using a repeated measures ANOVA.
3.1.1. Pressure application measurement (PAM)
Prior to induction of joint inflammation (on day 0), the aver¬
age ipsilateral LWT was 710 ±41 gf (n = 16) and the average
contralateral LWT reading was 790 ± 39 gf (n = 16). Following
injection of FCA, the average ipsilateral LWT of the treatment
group decreased by 57% to 316 ± 45 gf (n = 8), by day 1. This
was significantly lower than both the day 0 value (P < 0.05) and
the sham group at the same time point (P< 0.001; see Fig. 2a).
Despite receiving no further treatment the ipsilateral LWT of
sham animals increased significantly by 57% to 1028±48gf
(n = 8, P<0.05) on day 1. The average ipsilateral LWT ofFCA-
injected rats were significantly lower than sham and contralateral
joints (P<0.05) over the full 28-day time course studied.
3.1.2. Incapacitance tester—weight distribution
The average ratio of weight distribution between ipsilat¬
eral and contralateral limbs in rats was 0.96 ±0.03 (n=16)
on day 0. The ratio of weight distribution between the hind
limbs for FCA injected rats decreased by 70% to 0.29 ± 0.05
(n = 8, see Fig. 2b). This was significantly less than sham ani¬
mals (Z5 < 0.05), which had a ratio of 1.05 ±0.02 (« = 8) at this
time point. The ratio remained significantly reduced in FCA-
injected animals compared with the sham group up to and
including day 28 (P < 0.001). There were no significant changes
observed in the sham group at any time point in this behavioural
readout.
3.1.3. Joint inflammation
Basal measurements of joint diameter were 9.92 ± 0.08 mm
for ipsilateral knees (n = 16), and 9.85 ± 0.12 mm for contralat¬
eral knees (w=16). On day 1, the average ipsilateral knee
joint diameter of FCA-injected animals was 13.11 ±0.06 mm
(« = 8), compared with 10.12 ±0.1 mm (n = 8) in control ani¬
mals. The swelling remained significant compared with sham
animals on days 2, 5, 7 and 9 post-FCA (P< 0.001), how¬
ever, thereafter the values returned towards basal levels, and
no further significant differences were observed (data not
shown).
3.2. Behavioural evaluation of the effect ofa dose range of
prednisolone, and single doses ofmorphine and celecoxib
on the FCA-induced hypersensitivity
3.2.1. Pressure application measurement (PAM)
Measurements were made on days 0, 2, 4, 7 and 10,
to determine that a window of hypersensitivity was present
prior to drug treatment regimes. On each of these days the
ipsilateral PAM LWTs of all FCA-injected animals (n = 47)
were significantly less than those of the sham group (n = 8,
P< 0.0001). On day 10, arthritic rats were randomly assigned
into one of six treatment groups; celecoxib 15 mgkg "1
(« = 8), morphine 3 mg kg'"1 (n = 8) or prednisolone 1 (n = 7),
3 (« = 8), or 10mgkg-1 (n- 8). AUC values were calcu-
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Fig. 3. The (a) ipsilateral PAM LWTs and (c) weight distribution ratios of vehicle and prednisolone treated arthritic rats and the corresponding graphs of AUC values
for the two readouts during the dosing period (b and d). The drug-dosing period was between days 14 and 18 as indicated by the box on the graphs. The incapacitance
tester was able to detect the dose-dependant reduction in hypersensitivity evoked by FCA in groups treated with 1, 3 and lOmgkg-1 prednisolone. PAM did not
show a three-point dose-response, instead the 1 and3mgkg_l doses gave similar responses, whereas the lOmgkg-1 gave a greater reversal. Statistical analysis was
carried out to compare the AUC values for the drug-treated group compared with vehicle; "Statistical significance (P< 0.05), determined by an ANOVA.
lated for each individual animal to observe any drug induced
analgesia over the 5-day dosing period. AUC values were
calculated using each animal's day 10 value as a base¬
line to observe changes from day 14 through to day 18.
Results showed that PAM detected a significant analgesic
effect of all drugs administered (P< 0.0001 for morphine,
celecoxib and prednisolone lOmgkg-1, and P<0.05 for
prednisolone 1 and 3 mgkg-1, compared with vehicle, see
Figs. 3a and 4a).
Further PAM LWT measurements were taken after the ces¬
sation of drug-treatment, on days 21, 24 and 28. In all groups
any analgesic effect of the compound previously administered
was abolished, with there being no significant difference to the
vehicle-treated group.
3.2.2. Incapacitance tester—weight distribution
Measurements were made on days 0, 2, 4, 7 and 10, to
determine a window of hypersensitivity was present prior to
drug treatment regimes. On each of these days the weight
distribution ratio of all FCA-injected animals (n = 47) was
significantly less than those of sham (n = 8, P< 0.0001).
AUC values were calculated for the dosing period and
showed that the FCA-induced hypersensitivity was signifi¬
cantly reversed by celecoxib 15 mgkg-1 (n = 8), morphine
3 mgkg-1 (n = 8) and prednisolone at 3 (n = 8) and lOmgkg-1
(n = 8) (P < 0.05, compared with vehicle), but not by 1 mg kg-1
(n = 7) prednisolone (see Figs. 3 and 4c). The weight dis¬
tribution ratio AUC values also revealed a dose related
reversal of hypersensitivity using the incapacitance tester (see
Fig. 3d).
Further measurements made on days 21, 24 and 28, revealed
that the incapacitance tester detected no lasting reversal ofhyper¬
sensitivity following the cessation of drug administration with
there being no significant difference between each drug group
and vehicle (P>0.05).
3.2.3. Joint inflammation
Subcutaneous dosing of 3 mgkg-1 morphine or 15 mgkg-1
celecoxib had no effect on FCA-induced joint swelling. How¬
ever, prednisolone at 1, 3 and lOmgkg-1 all significantly
reduced the average ipsilateral knee joint diameter, (P < 0.05,
compared with vehicle) during the dosing period (data not
shown).
3.2.4. Correlation ofthe PAM with weight distribution
In order to determine the strength of the correlation between
the results obtained from the two readouts, a Spearman's linear
regression analysis was carried out. The mean PAM ipsilat¬
eral LWT for each group was plotted against the mean ratio
of weight distribution of the same group, with results from all
experimental days included. A strong correlation between the
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Fig. 4. The (a) ipsilateral PAM LWTs and (c) weight distribution ratios of vehicle-, morphine- and celecoxib-treated arthritic rats; and the corresponding graphs of
AUC values for the two readouts during the dosing period (b and d). The drug-dosing period was between days 14 and 18 as indicated by the box on the graphs.
PAM was able to detect the analgesic action of both drugs compared with vehicle. Statistical analysis was carried out to compare the AUC values for the drug-treated
group to that of vehicle-treated animals using an ANOVA; 'Statistical significance (P<0.05).
results obtained from the two different readouts was observed
(see Fig. 5a; Spearman r = 0.91; P<0.0001).
3.2.5. Power analysis of rat drug study
The first power analysis performed (Fig. 5b) was calcu¬
lated from the effect size equivalent to the observed difference
between vehicle and the highest dose of prednisolone. Graphi¬
cal results clearly show that in the structure of this experimental
design, where each animal has three measurements taken for
each readout, that a higher statistical power was achieved from
the PAM readout compared with the weight distribution read¬
out. In this experimental design if six animals per group were
used for investigating a hypothesised drug effect equal to the
observed effect, we could expect to achieve approximately 97%
power using the PAM readout, but only 70% power with the
weight distribution readout.
In a second power analysis (data not shown) results revealed
that the statistical power could be greatly increased in the PAM
readout, by increasing the number of measurements taken per
animal from three to five, however increasing the number of
animals used from 8 to 10 showed no real benefit. This was in
contrast to the weight distribution readout, where increasing the
number of animals from 8 to 10 greatly improved the power, but
increasing the number of measurements showed no real bene¬
fit. This highlights the benefit of investigating the experimental
design. For PAM we can actually increase the statistical power
of an experiment by increasing the number of measurements
while reducing the number of animals.
4. Discussion
This study has demonstrated the use of a novel behavioural
tool for assessing joint pain in a rat model of experimental
chronic joint inflammation. The results of these studies indi¬
cate that PAM provides a reliable, quantitative measurement
of localised, FCA-induced mechanical hypersensitivity in the
knee joint of rats. PAM was also able to detect the analgesic
action of prednisolone, morphine and celecoxib. Furthermore, a
strong correlation between the weight distribution readout and
the PAM measurements were made, illustrating that PAM is a
simple behavioural test that will be a valuable addition to current
measures for assessing hypersensitivity in the joint.
Clinically, joint pain is assessed either subjectively using
the Ritchie articular index or objectively using a dolorimeter
(Langley et al., 1983; Ritchie et al., 1968). The Ritchie articu¬
lar index allocates one of four grades of tenderness in patients'
joints: "not tender" (0), "tender" (1), "tender and winced" (2)
and "tender, winced and withdrew" (3). Previous studies car¬
ried out in this laboratory used a similar subjective scale of joint
hypersensitivity (Gauldie et al., 2004). However, a quantitative
measure, which mimics the pressure dolorimeter, would con¬
siderably improve assessments of experimental joint pain by
providing an objective measure. The dolorimeter uses a grad¬
ually increasing force, applied in a perpendicular plane across
the joint margin, to assess localised hypersensitivity of a human
joint. The dolorimeter can be used on different joint types and
has been adopted in clinical studies assessing osteoarthritis
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Fig. 5. (a) The correlation between the absolute ipsilateral LWTs (measured by
PAM) and the ratio of the weight distribution between the hind limbs (measured
by the incapacitance tester) in rats. There was a strong correlation between the
two readouts (Spearman linear correlation factor, r=0.91, P < 0.0001). (b) Anal¬
ysis of the sample sizes required from the PAM and weight distribution (WD)
readouts in triplicate measurements to reach certain statistical power levels.
Results are calculated from an effect size equivalent to the observed difference
between the vehicle group and the 10mg kg"1 prednisolone group and results
are based upon the observed variability in the study.
(Ottillinger et al., 2001) of the knee as well as the pain associated
with fibromyalgia (Gracely et al., 2003). Currently, no objective
measure of joint hypersensitivity is used to assess experimental
arthritic joint pain in laboratory rodents. To that end, PAM was
developed to align pre-clinical measures to those used clinically
and help the translation of animal studies to human conditions.
Calibrated forceps have been used as a means of mechanical
stimulation during electrophysiological recording (Gracely et
al., 2003; Li and Neugebauer, 2004; Neugebauer and Li, 2002),
or to measure knee joint or paw pain in experimental inflam¬
mation and primary hyperalgesia induced in deep tissues by
inflammation (Han et al., 2005; Luis-Delgado et al., 2006; Yu
et al., 2002). The latter involved direct application of the for¬
ceps to muscle or to the knee joint of rats (Cui et al., 1999;
Skyba et al., 2005). However, although the technique is reported
to be an easy to use, reliable method of assessing nociceptive
withdrawal thresholds, they also show a steady increase in paw
withdrawal threshold over a 9-day period that was highly corre¬
lated to an increase in weight gain over this time (Luis-Delgado
et al., 2006). The authors suggest that the modification of pain
sensitivity was due to increased size of the paw. This problem
does not arise with PAM, as no change in pain threshold occurred
over a 3-week period, despite the animals gaining weight in each
study. In the pilot study a significant increase in LWT was noted
in ipsilateral joints of naive rats and contralateral joints of all
animals. This increase was due to the absence of initial induc¬
tion measurements prior to the start of the study. Subsequently, a
pre-study behavioural assessment was carried out prior to study¬
ing the effect of chosen gold standard analgesics, removing this
initial anomalous result.
The authors in these studies reported several problems with
the forcep style of device, including variation caused by the
operator due to finger placement on the forceps, and inaccurate
values of withdrawal thresholds, as the calibrated reading given
is a function of the force applied by the experimenter and the
resistance offered by the joint. PAM is calibrated directly across
the force transducer and directly records the precise force placed
across the knee joint, up until the point of joint withdrawal. As
PAM uses a single force transducer worn on the experimenters
thumb, the amount of operator variation will only occur in the
placement of the transducer on the knee joint of the animal being
tested. However this is only a minor issue as the large surface
areas of the PAM thumb attachment removes potential inaccu¬
racy in focusing on an exact point on the joint, which happens in
the case of small forcep tips. A further advantage of PAM is the
ability to change the size of the pressure application surface and
the force range of the transducer, allowing the device to be used
in several species as well as the possibility of assessing other
joints and paws.
In this study, PAM proved to be an easy to use device, which
allowed rapid, reproducible measurements, using triplicate mea¬
surements at each time point taken. The absence of a significant
difference between the ipsilateral and contralateral LWT in naive
animals, together with the low variability, indicated that PAM
could use the contralateral joint as an internal control, an idea
originally proposed by Randall and Selitto (1957).
Typical withdrawal thresholds for naive rats were approxi¬
mately 1000 gf. These values are considerably higher than those
seen in the paw using calibrated forceps or the Randall and
Selitto device (Baamonde et al., 2004; Cook and Moore, 2006;
Luis-Delgado et al., 2006; Randall and Selitto, 1957; Walker et
al., 2003) which is probably due to the difference in the size and
gross anatomy of the paw and the knee joint, in addition, the
surface area over which the pressure is applied differs between
the different devices. Pressure exerted onto the skin may activate
nociceptive afferents in several tissues, depending on the surface
area of the object used. Contact with a punctuate object such as a
needle may exclusively activate nerve endings in the skin, in par¬
ticular C fibres. Because deformation of the skin can be achieved
with very small forces (Garell et al., 1996; Garnsworthy et al.,
1988; Khalsa et al., 1997), these stimuli have little effect on
afferents innervating deeper tissues. In contrast, a preferential
activation of deep afferents is possible if pressure is exerted
on a larger area of skin and the contact surface is rounded or
padded (Treede et al., 2002). According to experiments using
topical local anaesthesia, the contribution of cutaneous afferents
to pain evoked by blunt pressure is minor (Kosek et al., 1995).
This evidence adds support to the use of PAM as a measure
of nociceptive activity in deeper tissues such as the joint itself,
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rather than overlying skin. This is in contrast to von Frey hairs,
which as a punctuate stimulus, activate skin afferents rather than
those innervating the joint capsule and surrounding tissues.
Neugebauer and Li (2002) report that pressure stimuli
>50 gmm-2 applied to the kneejoint with calibrated forceps was
noxious, as it consistently evoked hind limb withdrawal reflexes
in awake rats. When values in our study were transformed into
an approximate pressure the noxious LWT was ~20gfmm-2.
However, the data from PAM is not routinely presented as a force
per unit area (pressure), as it cannot be assumed that the entire
surface of the disc is in contact with the joint, furthermore in
inflamed joints the deformation of the joint onto the disc is dif¬
ferent to that in naive animals. PAM measurements are therefore
more accurately expressed as a force, in grams.
PAM was able to detect FCA-induced hypersensitivity,
observed as a decrease in LWTs of around 60% compared
with the basal levels in normal joints. This hypersensitivity was
timematched to the significant inflammation observed following
FCA injection. The ability ofPAM to detect FCA-evoked hyper¬
sensitivity provides an excellent experimental model in which to
test the analgesic properties of novel compounds over a period
of stable inflammation between days 14 and 18 post-FCA.
Prednisolone, a standard positive control in drug screening
(Pyne et al., 2004), was studied over a 5-day period to check
whether the drug would lead to a resolution of FCA-induced
hypersensitivity as a correlate to the hyperalgesia we would
expect to see in man. PAM detected prednisolone analgesia,
over the 5 days of dosing, which was abolished after dosing
ceased. PAM also showed significant reversal ofevoked mechan¬
ical hypersensitivity in arthritic rats treated with the opioid
morphine and the cyclooxygenase-2 inhibitor, celecoxib, which
was comparable to that seen in the weight distribution readout.
Dose-related reduction of hypersensitivity to prednisolone was
not observed using PAM whereas a dose related analgesia was
observed using the incapacitance tester. When using weight dis¬
tribution, the global effects of each drug on the whole animal are
determined, whereas the PAM device is measuring a localised
effect at the knee joint. This may explain why the PAM results
observed were not dose related, as the doses were sub-threshold
for a dose-response curve to be observed as measured by the
PAM device.
When results are examined strong correlations are seen
between the two behavioural assessments. These results suggest
that both techniques have the ability to detect a joint hypersensi¬
tivity, which can be attenuated using gold-standard analgesics.
PAM has the added advantage of assessing the hypersensitivity
of the joint at the site of the inflammation, in a similar fashion
to the clinical dolorimeter (Langley et al., 1983).
The 3R's play a large part in the planning of in vivo studies,
where the aim is always to reduce the number of animals used, or
refine the techniques involved. In this study we have shown that
PAM measurements can be collected alongside the usual weight
distribution recordings, increasing the information from a sin¬
gle set of animals. The power analysis performed on this study
has shown that PAM has a higher statistical power as a tool for
measuring the efficacy of drugs used to reverse the FCA-induced
hypersensitivity than the weight distribution readout. The power
curves suggest that if PAM were used as a stand-alone readout
in future studies then the number of animals per group could
be reduced from eight to six, without compromising the statis¬
tical power of the study. Potentially PAM could be used to help
reduce the number of animal's required in future joint hyper¬
sensitivity studies, but we are aware that these plots are based
on the variability calculated from a single study. Replication of
these results in further studies would increase the confidence in
the conclusions drawn in this article.
In conclusion, the present study shows that PAM provides a
novel, accurate behavioural tool for detecting a localised primary
mechanical hypersensitivity in a rat model of chronic inflamma¬
tory joint pain. PAM is the first tool designed to measure both
primary and secondary hypersensitivity objectively. It can be
used in various experimental pain models and could be extended
for use in other species. Results from these studies suggest PAM
will aid the screening of novel analgesics designed to improve
chronic inflammatory pain.
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Abstract
Voltage-gated sodium channels play an essential role in regulating the excitability of nociceptive primary afferent neurones. In par¬
ticular the tetrodotoxin-sensitive (TTX-S) Navl-7 and the tetrodotoxin-resistant (TTX-R) Nav1.8 and Nav1.9 channels have been
suggested to play a role in inflammatory pain. Previous work has revealed acute administration of inflammatory mediators, such
as Freund's complete adjuvant (FCA) or carrageenan caused an upregulation in the levels of Nav1.7 and Nav1.8 protein in DRG
(dorsal root ganglia) tissue up to 4 days post-insult. In the present study, the expression of Nav1.7, Nav1.8 and Nav1.9 was examined
over a 28 day timecourse during a rat model of FCA-induced chronic inflammatory joint pain. Using the retrograde tracer Fast Blue
(FB) and specific Nav1.7, Nav1.8 and Nav1.9 sodium channel antibodies, immunohistochemical staining techniques were used to
study sodium channel expression in a distinct population of L3-L5 knee joint afferent DRGs. In the ganglia, counts were made of
positively labelled cells in the FB population. The results demonstrate that, following FCA injection, Nayl-9 expression is upregu-
lated at days 14, 21 and 28 post-FCA, with Navl .7 and Navl .8 showing increased channel expression at days 14 and 28. These obser¬
vations are accompanied by a unilateral joint hypersensitivity in the FCA-injected knee indicated by a behavioural shift in weight
distribution measured using an incapacitance tester. The increased presence of these channels suggests that Nav1.7, Nav1.8 and
Nav1.9 play a role, at least in part, in the maintenance of chronic inflammatory pain several weeks after the initial insult.
© 2007 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Ltd. All
rights reserved.
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1. Introduction
Chronic inflammatory joint pain results, in part, from
primary afferent fibres innervating the joint becoming
sensitised through a series of complex peripheral mech-
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anisms (Coggeshall et al., 1983; Hildebrand et al., 1991;
Schaible and Grubb, 1993; Kidd and Urban, 2001).
Voltage-gated sodium channels (VGSC's) are funda¬
mental in regulating the excitability of neurones and sig¬
nificant changes in the expression of these channels can
produce abnormal spontaneous firing patterns which
can lead to chronic pain (Waxman et al., 1999; Lai
et al., 2004).
A number of experimental models of inflammatory
pain in the rat have revealed changes in the expression
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of various subtypes of VGSC within the dorsal root gan¬
glia (DRG) during acute inflammation (Okuse et al.,
1997; Tanaka et al., 1998; Black et al., 2004; Coggeshall
et al., 2004; Gould et al., 2004; Villarreal et al., 2005). Of
the nine sodium channel cx-subunits (Goldin et al., 2000),
a great deal of research has focused on the role that the
tetrodotoxin-sensitive (TTX-S) Navl-7 and the tetrodo-
toxin-resistant (TTX-R) Nav1.8 and Nav1.9 isoforms,
which are predominantly expressed in peripheral damage
sensing neurones, play in inflammatory pain (Nassar
et al., 2004; Priest et al., 2005; Ekberg et al., 2006). The
expression of these channels in particular has been
shown to be highly dynamic in models of both neuro¬
pathic and inflammatory pain and the modulation of
these channels in DRG tissue may present a therapeutic
opportunity for the selective manipulation of primary
sensory neurons. Reports describe an increased expres¬
sion ofNav1.7 and Nayl-8 in rat DRG neurones in mod¬
els of chronic neuropathic and inflammatory pain (Amir
et al., 2006; Ekberg and Adams, 2006), leading to
enhanced neuronal excitability, whilst null mutant mice
demonstrate attenuated response to inflammation-
induced hypersensitivity and noxious stimuli (Akopian
et al., 1999). The role of Nav1.9 is less well understood,
Priest et al. (2005) report no change in Nav1.9 expression
in DRGs in a mouse model of acute pain, but a potential
role for the channel in the maintenance of chronic
inflammatory pain has been suggested (Dib-Hajj et al.,
1998; Tate et al., 1998; Fjell et al., 1999).
In the present study, we have examined the expression
of Nav1.7, Nav1.8 and Nav1.9 in ipsilateral L3-L5
DRGs at various time points throughout a model of
FCA-induced, unilateral chronic inflammatory joint
pain (Wilson et al., 2006; Martindale et al., in press).
In order to focus the study on channel expression within
the knee joint primary afferent population, the fluores¬
cent retrograde tracer Fast Blue (FB) was injected
through the intact skin and patellar ligament into the
centre of the knee joint cavity (Kuypers and Huisman,
1984; Hanesch and Heppelmann, 1995). FB revealed
the identity of cell bodies of neurones which innervate
the knee joint, highlighting a specific neuronal sub-pop¬
ulation of the DRG (Salo and Theriault, 1997; Ivanavi-
cius et al., 2004; Hwang et al., 2005). DRG were
stained using primary antibodies specific to Nav1.7,
Nav1.8 and Nav1.9 and counts ofpositively labelled cells
within the FB population were made.
2. Methods
2.1. Animals
Experiments were performed in accordance with
Home Office regulations and UK animal welfare guide¬
lines and received Focal Ethics Committee approval. All
experiments were performed using adult male Wistar
rats weighing between 150 and 200 g upon arrival
(Charles River, UK; n = 54). Animals were housed 4
to a cage in a 12 h dark/light cycle and were given access
to water and standard animal feed ad libitum. All ani¬
mals were allowed at least five days acclimatisation prior
to behavioural testing.
2.2. Behavioural studies
An evaluation of how the animals distribute their
weight across the hind limbs was measured using the rat
incapacitance tester (Finton Instruments, UK). The appa¬
ratus comprises two force transducers mounted side by
side, capable ofmeasuring the force placed through them
over a set period of time. Animals were placed with each
hind limb centred on a transducer platform and the force
exerted on each transducer wasmeasured over a 3 s period
(Clayton et al., 1997; Wilson et al., 2006). The weight car¬
ried by the injected limb was divided by that carried by the
un-injected limb giving a weight distribution (WD) ratio.
A ratio of 1.0 results from the animal distributing its
weight equally across both hind limbs. Each animal was
measured three times on each test day and the mean
weight distribution ratio (±SEM) was calculated for each
group. Statistical analysis was carried out using a Krus-
kal-Wallis one way analysis of variance (ANOYA) fol¬
lowed by Dunn's post-hoc comparisons. P values less
than 0.05 were considered statistically significant.
2.3. Retrograde labelling of dorsal root ganglia
In order to identify the cell bodies of afferent nerves
innervating the knee joint, Fast Blue (FB, Illing Plastics,
Germany) was used as a retrograde tracer to label artic¬
ular DRGs (Hanesch and Heppelmann, 1995; Salo and
Theriault, 1997; Catre and Salo, 1999; Ivanavicius et al.,
2004). All rats (n = 54) were transiently anaesthetised
using 3% isoflurane in oxygen and had their left (ipsilat¬
eral) knee joint shaved and cleaned using a dilute Hibi-
scrub solution. Using a 30-gauge needle (BD Microfine,
USA) attached to a 100 pi Hamilton syringe; 10 pi of 2%
FB was injected through the patella tendon into the joint
space of the left knee. Animals were allowed to recover
from anaesthesia before being returned to their cage,
which was layered with soft paper bedding. Trial injec¬
tions were performed on cadavers prior to the study to
ensure that 10 pi of FB could be injected into the knee
joint cavity without visible leakage, minimising the
chance that afferent cell bodies surrounding the knee
would be falsely labelled.
2.4. Induction of chronic inflammatory hypersensitivity
All rats were transiently anaesthetised using 3% iso¬
flurane in oxygen and had their left knee shaved and
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cleaned using a dilute Hibiscrub solution. Rats in the
Freund's Complete Adjuvant (FCA) groups (n = 24)
were then injected with 150 pi of FCA (lmgmF1
Mycobacterium tuberculosis, Sigma, UK) through the
patella tendon into the knee joint space using a 30-gauge
needle (BD Microfine, USA). Control animals (n = 30)
were untreated. Animals were allowed to recover from
anaesthesia before being returned to their cage.
2.5. Study design
All animals (77 = 54) were behaviourally assessed to
determine the WD in naive rats on day 0 prior to FB
injection. Following the injection of the retrograde tra¬
cer, animals were further assessed for any change in
WD at selected times over a 35 day period. On day 7
post-FB, animals were treated with FCA to induce a
chronic inflammatory hypersensitivity, with control ani¬
mals remaining untreated. Following behavioural
assessments animals were killed in groups (77 = 6) on
days 7, 14, 21 and 28 post-FCA along with the corre¬
sponding time matched controls, and a single group of
animals on day 0, using a rising concentration of C02
followed by cervical dislocation. Ipsilateral dorsal root
ganglia (DRGs) were removed from levels L3, L4 and
L5 and embedded in optimum cutting temperature (Tis-
sueTek, Canada) compound and snap frozen in isopen-
tane cooled on dry ice (77 = 6 per group). DRG were
then stored at —80 °C until they were sectioned.
2.6. Fluorescent immunohistochemistry
DRGs were sectioned using a Leica CM3050S cryo-
stat. Sections were cut (12 pm) and thaw-mounted in
series on 10 slides (Superfrost Plus Gold, Menzel-Gla-
ser, Germany) with each slide containing 5-8 sections
at different levels throughout the DRG. Sections were
fixed in 4% paraformaldehyde (30 min), washed with
phosphate buffer solution (PBS; 2x5 min), and non¬
specific binding was blocked using a solution of 10%
normal goat serum, 10% bovine serum albumin and
80% PBS (60 min). Sections were then labelled overnight
(4 °C) with affinity isolated rabbit immunoglobulins
raised against unique synthetic peptides immunogens
corresponding to the sodium channels Nav1.7
(K241,1:200), Nav1.8 (K106,1:200), and Nav1.9
(K186,1:200). These specific alpha sodium channel sub¬
type antibodies (GlaxoSmithKline, Harlow, UK) were
all developed to cross-react with both human and rat
antigens (Amaya et al., 2000; Coward et al., 2001a,b).
Additional sections were incubated as described above,
but with the omission of the specific primary antibody
to act as negative controls. The following day, sections
were washed in PBS (3x5 min) and sites of antibody
labelling were revealed using the secondary antibody
Alexa-488 goat anti rabbit (1:200, A11094, Molecular
Probes, UK; 120 min at 37 °C). Sections were washed
in PBS (3x5 min) and coverslipped using Citifluor solid
mounting kit (CFPVOH and AF100, Citifluor, UK).
2.7. Data acquisition and analysis
For each antibody FCA-injected animals at days 7,
14, 21 and 28 post-FCA and their corresponding time
matched control animals were investigated. Each group
contained six animals from which ipsilateral L3-L5
DRGs were collected from each animal. Fluorescence
in DRGs was observed using a Leica DMR microscope.
Sections were initially observed under an excitation fre¬
quency of 380nm to reveal and count the total number
of FB positive cells in 6-8 sections from each DRG. Set¬
ting the microscope filter to excite the sections at 488nm
then enabled the sodium channel fluorescing cells to be
visualised. By switching the filters between the two differ¬
ent excitation wavelengths the total number of double-
labelled cells were identified and counted. From the total
FB count and the double labelled count, the mean animal
co-localisation percentage (± SEM) of sodium channel
positive cells within the FB positive sub-population
was calculated at each time point. Only cells with visible
nuclei were counted in order to avoid counting positive
cells more than once. All analyses were carried out with
the observer blind to the groupings and representative
photomicrographs were captured throughout. Statistical
analyses were carried out using Mann Whitney tests ±
SEM, with statistically significant differences between
groups confirmed as P values less than 0.05.
3. Results
3.1. Behavioural assessment of hypersensitivity
Intra-articular injection of FB alone had no effect on
the mean weight distribution ratio (pre-injection vs. day
7 post-injection, (77 = 54) 7 days post-injection, and at all
time points throughout the control groups (Fig. 1).
Injection of FCA resulted in the mean weight distribu¬
tion ratio (± SEM) significantly decreasing from the
pre-injection value of 0.96 ± 0.03 to a day seven post-
FCA value of 0.37 ± 0.03 (Mann Whitney, n = 54,
P< 0.001). FCA animals had a significantly lower
weight distribution ratio at all time points post-injection
when compared to control (ANOVA, n = 54,
P< 0.001). There was no significant difference within
the control groups at any time point.
3.2. Fast Blue fluorescence
Following the intra-articular injection of FB the fluo¬
rescent tracer was retrogradely transported by knee joint
primary afferent nerves into their cell bodies in the
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Fig. 1. A time course study (n = 54) of the weight distribution changes
following injection of FB and FCA. Intra-articular injection of FB into
the left knee joint caused no significant difference in the mean weight
distribution (pre-injection vs. day 7 post-injection, n — 54). Intra¬
articular injection of FCA into the same knee seven days later caused a
significant reduction in the weight distribution across the hind limbs at
all time points post-FCA, as the rats place less weight through the
ipsilateral limb. Kruskal-Wallis ANOVA followed by Dunn's post-hoc
(■""PC 0.001; FCA vs. control, n = 6; day 14 = 1.07 ±0.08 vs.
0.35 ±0.10 and day 35 = 1.07 ±0.06 vs. 0.47 ±0.03).
DRG. This resulted in an average of 7 (min = 0,
max = 28) FB positive fluorescent cells being identified
per individual ganglion (Fig. 2). These cells were thus
identified as afferents from the knee joint.
A total number of 2463 FB positive cell bodies were
counted during the study. There was no significant differ¬
ence in the mean number (± SEM) of FB positive cells
counted in FCA or control animals at each time point
per group (82 ± 5 vs. 92 ± 6; Mann Whitney). Of the
2463 FB positive cells counted, 44% were found in L3,
38% in L4 and the remaining 18% in L5. Brightly fluores¬
cent satellite cells surrounding FB-positive cell bodies
were observed throughout the study at each time point.
3.3. Fast Blue and Nav channel co-localisation
Fluorescent immunohistochemistry enabled both the
sodium channel positive cells (green. Fig. 3b and e)
and the FB population of cells (blue, Fig. 3a and d) to
(a) FB
be determined in the same sections. Absence of bleed-
through between fluorescent filters was confirmed by
the presence of three types of cell, namely cells that were
only positive for one of the sodium channels, cells that
were only positive for FB, and cells that were positive
for one of the sodium channels and also for FB
(Fig. 3c and f).
3.3.1. Changes in Nav1.7 channel expression
The effect of FCA on Nav1.7 expression in the FB
positive L3-L5 ipsilateral DRG cell body population
was assessed on days 7, 14, 21 and 28 post-FCA
(Fig. 4). FCA caused a significant increase in the mean
group percentage (± SEM) of Navl-7 positive cells at
days 14 and 28 increasing from 32.4% ± 3.4 to 45.9% ±
2.7 and 25.0% ± 5.2 to 43.5% ± 3.8, respectively
(P < 0.05, Mann Whitney, control vs. FCA; Fig. 5b
and d). In control animals no significant change was
observed in the group mean percentage at any time point
over the 28 day period. A total of 406 FB-positive cells
were counted in all control groups and 385 in all FCA
groups. When all the time points of both FCA-injected
and control animals were considered together, the mean
percentage of Nav1.7 positive cells in FCA-injected ani¬
mals was significantly higher (P < 0.01, 42.2% ± 1.7 vs.
32.3% ± 2.3) than that in all the control animals.
3.3.2. Changes in Navl.H channel expression
Following administration of FCA the expression of
Nav1.8 in FB positive cell bodies of ipsilateral L3-L5
DRGs was assessed on days 7, 14, 21 and 28 post-
FCA (Fig. 4). Following injection of FCA there was a
significant increase in the group mean percentage of
Navl -8 positive cells at days 14 and 28, increasing from
38% ± 2.3 to 54.6% ± 2.6 and 40.8% ±2.1 to 53.6% ±
4.7 respectively (P<0.05, EC 0.01, control vs. FCA;
Fig. 5a and d). In control animals no significant change
was observed in the group mean percentage at any time
point over the 28 day period. A total of 419 FB positive
cells were counted in all control groups and 391 in all
FCA groups. The mean percentage of all Navl-8 posi-
(b) FB
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Fig. 2. Representative photomicrographs of FB fluorescence in ipsilateral L3-5 DRG tissue, (a) Note that only a small proportion of the total
population ofDRG cell bodies fluoresce and are easily identifiable from the non-fluorescing cells. Using a higher magnification (b) it can be seen that
there are smaller satellite cells surrounding the fluorescing cells that are also brightly fluorescing. Scale bar = 100 pm.
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Fig. 3. Two rows of representative photomicrographs of two different sections (a-c and d-f). Images captured show (a and b) the FB fluorescence, (b
and e) the Nav1.7 positive cells and (c and f) an overlay of the FB and Nayl.7 images. Arrows indicate cells positive for both the FB and Nav1.7
channel. Note that the FB positive cells (a and d) are not always necessarily positive for the sodium channel and visa versa. By switching between
filters without moving the sections it is possible to count all the cells that are positive for both. Scale bar =100 pm.
tive cells at all time points in the FCA-injected set of ani¬
mals (49.8% ±2.2) was significantly higher (P< 0.001)
than that in the control groups (38.9% ± 1.1).
3.3.3. Changes in Nav1.9 channel expression
Following administration of FCA, Nav1.9 expression
within the FB positive population of L3-L5 ipsilateral
DRGs was quantified on days 7, 14, 21 and 28 post-
FCA (Fig. 4). Injection of FCA resulted in a significant
increase in the group mean percentage (± SEM) of
Nay 1.9 positive cells at days 14, 21 and 28 increasing
from 22.7% ±3.1 to 46.4% ±3.3, 26.2% ± 5.2 to
47.0% ± 5.6 and 25.4% ± 3.7 to 47.8% ± 3.9 respectively
(/><0.05, P<0.01, control vs. FCA, Mann Whitney;
Fig. 5a-c). No significant change was observed in the
group mean percentage at any time point over the 28
day period in control animals. A total of 415 FB positive
cells were counted in the control groups and 309 in the
FCA groups. The mean percentage (± SEM) of
Nav1.9 positive cells in all the FCA-injected animals
(45% ± 2.2) was significantly higher (7° < 0.001) than
that in all the control animals (24.7% ± 1.9) when every
time point was taken into account.
4. Discussion
The levels of the VGSCs Nav1.7,Nav1.8 and Nav1.9
increase during the course of a well established preclin¬
ical model of chronic joint pain. Injection of FCA into
the intra-articular space of the knee joint produces a
localised inflammation leading to the establishment of
a chronic joint hypersensitivity that is maintained up
to 90 days post-FCA as previously described (Wilson
et al., 2006). The current study examined time points
up to 28 days, when there is a stable ongoing hypersen¬
sitivity with reduced levels of inflammation, symptom¬
atic of chronic inflammatory-induced pain. We utilised
the fluorescent dye FB to study channel expression in
L3-L5 ipsilateral DRGs of neurones exclusively inner¬
vating the inflamed knee joint (Salo and Theriault,
1997). All of the animals used in this study had joint
hypersensitivity measured using the weight distribution
behavioural readout (Clayton et al., 1997; Barton
et al., 2007).
This study is the first to use a retrograde tracer to
demonstrate significant changes in the expression of
VGSCs in specific L3 L5 DRG neurones innervating
the rat knee joint, following intra-articular injection of
FCA into the same knee. Previously published studies
have highlighted changes in Nav1.7, Nav1.8 or Nav1.9
channel expression in rat DRG tissue following injection
of FCA or carrageenan into the hind paw (Black et al.,
2004; Nassar et al., 2004). However, these studies not
only differ in the location and type of adjuvant injected,
but also in the time course being studied, with expres¬
sion levels typically investigated between one to four
days post-insult (Tanaka et al., 1998; Gould et al.,
1999; Black et al., 2004; Nassar et al., 2004). One study
investigated the long-term effects of FCA on sodium
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Fig. 4. Representative images of Nav1.7, Navl-8 and Nayl-9 immunofluorescence in FCA-injected ipsilateral DRG sections before administration
of FCA and on days 14, 21 and 28 post-FCA. Note, that as only relatively few cell bodies in each image are FB positive (typically 2-5 per section) the
VGSC immunofluorescence in all DRG cell bodies has been shown to demonstrate the subtle increases in channel expression during the time course.
After administration ofFCA it can be seen that Nav1.7, Nav1.8 andNav1.9 channel expression has increased on days 14 and 28 post-FCA, although
it is less clear from simple visual inspection whether Nayl.7 and Navl-9 expression is increased on day 21 post-FCA, highlighting the need for a
quantitative count. Scale bar =100 pm.
channel immunoreactivity in DRG, but used a pan
sodium channel antibody that was unable to distinguish
between the different channel isoforms (Gould et al.,
1998). These results revealed a rapid increase in sodium
channel expression 24 h post-FCA to levels that were
maintained for at least 2 months, suggesting sodium
channels play a critical role in the establishment and
maintenance of chronic inflammatory pain.
Relatively few studies have investigated the role of
Nav1.7 in inflammatory hypersensitivity, but those that
have report increases in channel mRNA and protein in
L4/L5 DRG neurones four days after intra-plantar
injection of carrageenan (Black et al., 2004), and L4-
S1 DRG neurones 24 h post-FCA injection (Gould
et al., 2004). Mutations in Nav1.7 have recently been
shown to occur in humans suffering from the painful
inherited disease erythermalgia (Waxman and Dib-Hajj,
2005), further suggesting the channel has the functional
ability to play an important role in afferent pain signal¬
ling. In the present study intra-articular injection of
FCA caused a significant increase in the number of
Nayl.7 positive neurones within the distinct FB popula¬
tion of L3-L5 ipsilateral DRG on days 14 and 28 post-
FCA. This is the first evidence that Nav1.7 is upregu-
lated in chronic models of inflammation and may indeed
contribute to the maintenance of the FCA-induced joint
hypersensitivity, which is sustained for weeks after the
initial insult.
A much larger body of research exists surrounding
the role of Nav1.8 in the initiation and maintenance of
chronic inflammatory pain (Amir et al., 2006; Ekberg
and Adams, 2006). Nav1.8 expression is rapidly upregu-
lated in the early stages of inflammation following either
a single injection of FCA or repeated injections of
PGE2, suggesting the channel plays a key role in the ini¬
tial induction of hypersensitivity (Gould et al., 2004; Vil-
larreal et al., 2005). Support for a role of Nav1.8 in the
maintenance of inflammatory pain comes from studies
reporting that there is a significant increase in mRNA
in DRG tissue 4 days after carrageenan injection
(Tanaka et al., 1998). Moreover, the increase in channel
expression is likely to be associated with increased distri-
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Fig. 5. Quantitative analysis showed that the percentage of: (a) Nav1.7, (b) Nav1.8 and (c) Nayl-9 immunofluorescent cells within the FB labelled
DRG population are significantly upregulated in FCA treated animals, as compared with control animals at various points during the FCA
timecourse ('P< 0.05, "PC 0.01, FCA vs. control). Note that at 7 days post-FCA there is no significant difference in FCA treated animals and
control animals with regards to all the Nay channels, and further no significant difference at day 21 when looking at Nav1.7 and Nayl.8 channels.
bution of the channels to peripheral nerve terminals as
FCA-induced inflammation results in an increase in
the amount of Nav1.8 channels observed in peripheral
axons (Coggeshall et al., 2004). In the present study
no significant increase in Nav1.8 was observed at the
earliest time point, but there were significant increases
in the expression of Nav1.8 within knee joint afferent
neurones on days 14 and 28, in accord with the previ¬
ously published studies suggesting a role for the channel
in maintaining a chronic hypersensitivity.
Information on the role of Nav1.9 in inflammation-
induced hypersensitivity is relatively scarce, with Black
et al. (2004) reporting no change in the expression of
Nav1.9 mRNA and protein in DRG four days after
an intra-plantar carrageenan injection. However injec¬
tion of FCA into the hind paw has been shown to
increase DRG levels of Nav1.9 mRNA twofold, 7 days
post-injection (Tate et al., 1998). Results from this pres¬
ent study show a significant increase in Nav1.9 channel
expression on days 14, 21 and 28 post-FCA. Although
Nav1.9 channel expression does not change in the early
stages of inflammatory pain, and is therefore not impli¬
cated in the establishment of the hypersensitivity, we
conclude its upregulation at later time points highlight
a possible role for the channel in the maintenance of a
chronic inflammatory pain.
The use of fluorescent retrograde tracers for track¬
ing peripheral nerves through to their parent cell
bodies is a well established technique (Kristensson,
1970; Kuypers et al., 1979; Kuypers and Huisman,
1984). Fast Blue can be transported over long dis¬
tances, showing pronounced fluorescence in the cyto¬
plasm of parent cells only 48 h after injection around
the nerve terminals (Bentivoglio et al., 1980b). The
use of fluorescent dyes in vivo to identify knee joint
afferent cell bodies in DRG tissue is well described
(Hanesch and Heppelmann, 1995; Ivanavicius et al.,
2004). In this study 82% of the knee joint afferent cell
bodies were found in L3 and L4 (data not shown), a
result that concurs with previously published data
(Salo and Theriault, 1997) using the retrograde tracer
Fluoro-Gold where 88% of knee joint cell afferents
were found in L3 and L4. There was no observable
increase in the intensity of the fluorescence in cells of
DRGs taken from animals with longer survival times,
a trend that has previously been reported (Bentivoglio
et al., 1980b). A phenomenon that was observed in the
current study was the fluorescing of glial cells sur¬
rounding the retrogradely labelled cell bodies. This
has been previously reported as being due to the diffuse
migration of dye from the cell bodies into the adjoining
satellite cells, and is thought to become more promi¬
nent the longer the dye is present in the animal (Bentiv¬
oglio et al., 1980a,b). In certain circumstances this
might be of concern as it could potentially hinder the
correct identification of positive cells within the
DRG. However due to the intensely bright fluorescence
of the cytoplasm in the present study we are confident,
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that only those neurones with rctrogradely labelled
knee aflferents were positively identified.
The significant increases in the expression of the
VGSCs on days 14, 21 and 28 post-FCA observed in this
study correlates with the presence of an FCA-induccd
joint hypersensitivity. A previous study using the same
FCA model revealed significant increases in the levels
of CGRP within all L3/L4 DRG neurones up to 35 days
after intra-articular FCA administration, correlating
with a behavioural hypersensitivity of that joint (Staton
et al., 2007). It would be interesting to determine if this
increase in CGRP expression takes place solely in the
knee joint afferent population, or whether the injection
has global effects within the DRG due to cross-talk
between adjacent cells. Similar studies profiling changes
in other key channels and receptors, such as the cannab-
inoids, opioids and the prostaglandins, which are known
to play a key role in inflammatory hypersensitivity, may
provide further insight into the multiple mechanisms
involved in the establishment and maintenance of
chronic inflammation-induced pain.
In summary, we have demonstrated a significant
increase in the channel expression levels of the VGSCs;
Nav1.7, Nav1.8 and Nav1.9 in a distinct group of ipsi-
lateral L3-L5 DRG neurones during a model of FCA-
induced, chronic joint pain. The sensitisation of primary
afferent neurones in acute inflammatory pain has previ¬
ously been reported to be due to changes in the expres¬
sion of several VGSC's, although the process clearly
involves considerably more than the modulation of just
a single class of ion channels. Nevertheless, we success¬
fully utilised a retrograde tracing technique to demon¬
strate that NavT7 and Nav1.8 are upregulated in
afferent neurones specifically innervating the site of
chronic inflammatory pain. Moreover, this study has
increased our understanding of the neurobiology of
inflammatory pain by revealing an increased expression
in Nayl.9 channels 14 days post-FCA highlighting a
potential role of this channel in the maintenance of
inflammatory hypersensitivity.
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